Development of a Cationic Mucic Acid Polymer-Based Nanoparticle siRNA Delivery System by Pan, Dorothy Weichi
Development of a Cationic Mucic 
Acid Polymer-Based Nanoparticle 
siRNA Delivery System 
Thesis by 
Dorothy Weichi Pan 
 
In Partial Fulfillment of the Requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
CALIFORNIA INSTITUTE OF TECHNOLOGY 
Pasadena, California 
 
2016 
(Defended May 5, 2016)
 ii
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2016 
Dorothy Weichi Pan 
ORCID: 0000-0003-4066-7750 
All rights reserved. 
 iii
ACKNOWLEDGEMENTS 
There are numerous people to whom I am grateful who have made my thesis 
research possible and enriched my experience at Caltech.  
First of all, I would like to thank my advisor, Professor Mark E. Davis, for his 
mentorship during my PhD. He makes himself available to his students, especially when 
they have puzzling data and questions. For an MD/PhD student aspiring to bridge the space 
between the laboratory and the clinic, his wealth of experience in translational medicine, 
business, and entrepreneurship after having brought two therapeutics to clinical trials was a 
valuable resource. I’d also like to thank Professor Jim Heath, the chair of my committee, 
for his leadership with Caltech’s NanoSystems Biology Cancer Center, as well as my other 
committee members Professor Judy Campbell and Professor Dave Tirrell for their insights 
into proposing and planning projects.  
Executing a project that starts with chemical synthesis takes testing to the in vitro 
and all the way to the in vivo stage requires many instruments and facilities, as well as the 
expertise for a broad range of subjects. Dr. Yen Yun at City of Hope kindly provided 
pharmaceutical antibodies that I used as targeting agents for my project. I’d like to thank 
Dave Vandervelde in the liquid NMR facility for suggesting useful methods and aiding me 
in the analysis of my polymers. Mona Shahgholi in the mass spectrometry facility trained 
on a couple instruments that allowed me to obtain the masses of crucial material. I also 
worked extensively with Alasdair McDowell doing cryo-transmission electron microscopy 
to confirm the size of my nanoparticles. Andres Collazo trained me and helped 
troubleshoot problems with confocal microscopy. Suresh Gupta, the computer guru in the 
chemical engineering department, was able to save me a lot of time trying to fix the many 
 iv
computers operating instruments in our lab which crashed during my time performing 
experiments. The staff at the animal facility was also critical to performing mouse 
experiments, especially vet tech Gwen Williams for her thorough knowledge of procedures 
and intuition for mouse behavior, and veterinarian Dr. Karen Lencioni for her advice on 
caring for mice with tumors. Alyssa Maskell, Lorena Sandoval, and John Papsys provided 
animal husbandry for which I am appreciative.  
I would also like to thank the members of my lab for being wonderful colleagues. 
Han Han, Leonard Medrano, Yashodan Bhawe, and especially Devin Wiley and Jonathan 
Zuckerman, provided a lot of mentorship when I was getting my project started. Ben Boal 
worked in the chemistry hood across from me and was a source of advice in synthetic 
procedures. My MD/PhD colleague Andrew Clark, as well as Emily Wyatt and Dana 
Levine, are always willing to discuss ideas and experiments. I had the privilege of 
mentoring undergraduate Kristin Anderson for two summers, as well as Jan Winkler from 
ETH and Merle Bischoff from Aachen for their master’s theses, and I gained a lot of 
insight by helping them propose and guide them through their projects.  
Agnes Tong in the chemistry graduate program office was a valuable resource with 
all things related to requirements, paperwork, and much more. Martha Hepworth was also 
helpful with a lot of secretarial tasks. Roland Rapanot is a rock star administrator for the 
USC-Caltech MD/PhD program and facilitates the organization of the MD/PhD journal 
club where I first met my advisor Mark Davis and learned about the types of projects 
worked on in his lab. I’d also like to thank the former and current program directors Drs. 
Robert Chow and Steve Mittelman for their dedication to training and mentoring physician-
scientists.  
 v
Outside the lab, I was very involved in many activities at Caltech. The Catalina 
Community Associates and the Resident Associates have been an amazing team to work 
with in building and fostering a residential community. I’d like to thank Felicia Hunt and 
Larissa Charnsangavej for their support of residential life, and my RA and CCA colleagues 
Beau Pritchett, Swarnima Manohar, Corey Reeves, Christine Morrison, Emily Wyatt, 
Daniel Brooks, Camille McAvoy, and many other CCA’s for their contributions, 
teamwork, and friendship. The Caltech Y is also a place that fosters a sense of adventure 
and service for the Caltech community. As a member of the outdoors committee, I’d like to 
thank the staff at the Y, Athena Castro, Portia Harris, Liz Jackman, and especially Greg 
Fletcher, for their support of all our student-led trips. Becky Schwantes, Jeremy Sandler, 
Casey Handmer, Howard Hui, William Frankland, Andrew Robbins, Joan Ballester, and 
Zoltan Tuza have been wonderful friends with whom I have led countless hikes and trips so 
that less experienced students could safely participate in adventures. Isaac Fees, Rebecca 
Rojansky, and I also led a Y hike where Rebecca (also an MD/PhD) and I had to deal with 
some altitude and medical issues that put our clinical reasoning to use in the wilderness! 
Having been a musician for about 80% of my life, I was glad to be able to play the 
flute and piccolo with the Caltech-Occidental Symphony Orchestra and in chamber music 
groups. The orchestra conductor Allen Gross chose a variety of major symphonic repertoire 
with flute and piccolo parts that were both fun and challenging for us to play. It was 
amazing to make music with a fantastic flutist and friend, Megan Newcombe, and getting a 
review from Delores Bing after a concert that the flute section is the best section in the 
orchestra. Megan and I were joined by Jeffrey Thompson, Jill Craven, and Jeremy Yager in 
the trombone section for dinner before orchestra rehearsal every week, and had 
 vi
conversations about music as well as careers – interviews, postdocs, and jobs – as they are 
all a step ahead of me in life after being a student. Concertmaster Sean Symon kept me 
company in another sound-proof practice room late at night in the music house. Zachary 
Erickson pestered me about the concerto competition until I finally decided to learn the 
Nielsen Flute Concerto and even got to play it with the orchestra. My flute teacher, Gary 
Woodward, is perhaps the most patient coach ever with an infinite number of ways to think 
about music and technical tricks up his sleeve. Hye-Sung Choe was a wonderful coach for 
my first chamber group at Caltech with Colin McKinney, Michael Zhang, and Jennifer Zhu 
playing Saint-Saens. Michael Kreiner has been a lot of fun to work with as bassoonist and 
coach for multiple of my chamber groups, including with Kelly Kim, Charles Cao, Jamie 
Rankin, and Aidan Chatwin-Davies. Aidan Chatwin-Davies was first a musical colleague, 
then a friend who also enjoyed hikes, but our relationship has become something more, and 
I appreciate him for supporting my hectic lifestyle.  
Lastly, I’d like to thank my family for telling me I was crazy to do an MD/PhD but 
letting me do it and supporting me along the way anyways. My sister, Tiffany Pan, started 
medical school at USC during my PhD and is now ahead of me in medical school, holding 
true to her assertion that she would never do an MD/PhD even when she had a chance to 
apply into the program. However, her stories about her sick patients when she comes home 
from the hospital reaffirms to me the need for more research and discovery especially in the 
fields of neurology and oncology, and I have much to look forward to as I head back into 
the clinical portion of my training.  
 
 vii
ABSTRACT 
Cancer chemotherapy has advanced from highly toxic drugs to more targeted 
treatments in the last 70 years. Chapter 1 opens with an introduction to targeted therapy for 
cancer. The benefits of using a nanoparticle to deliver therapeutics are discussed. We move 
on to siRNA in particular, and why it would be advantageous as a therapy. Specific to 
siRNA delivery are some challenges, such as nuclease degradation, quick clearance from 
circulation, needing to enter cells, and getting to the cytosol. We propose the development 
of a nanoparticle delivery system to tackle these challenges so that siRNA can be effective. 
Chapter 2 of this thesis discusses the synthesis and analysis of a cationic mucic acid 
polymer (cMAP) which condenses siRNA to form a nanoparticle. Various methods to add 
polyethylene glycol (PEG) for stabilizing the nanoparticle in physiologic solutions, 
including using a boronic acid binding to diols on mucic acid, forming a copolymer of 
cMAP with PEG, and creating a triblock with mPEG on both ends of cMAP. The goal of 
these various pegylation strategies was to increase the circulation time of the siRNA 
nanoparticle in the bloodstream to allow more of the nanoparticle to reach tumor tissue by 
the enhanced permeation and retention effect. We found that the triblock mPEG-cMAP-
PEGm polymer condensed siRNA to form very stable 30-40 nm particles that circulated for 
the longest time – almost 10% of the formulation remained in the bloodstream of mice 1 h 
after intravenous injection.  
Chapter 3 explores the use of an antibody as a targeting agent for nanoparticles. 
Some antibodies of the IgG1 subtype are able to recruit natural killer cells that effect 
antibody dependent cellular cytotoxicity (ADCC) to kill the targeted cell to which the 
antibody is bound. There is evidence that the ADCC effect remains in antibody-drug 
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conjugates, so we wanted to know whether the ADCC effect is preserved when the 
antibody is bound to a nanoparticle, which is a much larger and complex entity. We utilized 
antibodies against epidermal growth factor receptor with similar binding and 
pharmacokinetics, cetuximab and panitumumab, which differ in that cetuximab is an IgG1 
and panitumumab is an IgG2 (which does not cause ADCC). Although a natural killer cell 
culture model showed that gold nanoparticles with a full antibody targeting agent can elicit 
target cell lysis, we found that this effect was not preserved in vivo. Whether this is due to 
the antibody not being accessible to immune cells or whether the natural killer cells are 
inactivated in a tumor xenograft remains unknown. It is possible that using a full antibody 
still has value if there are immune functions which are altered in a complex in vivo 
environment that are intact in an in vitro system, so the value of using a full antibody as a 
targeting agent versus using an antibody fragment or a protein such as transferrin is still 
open to further exploration.  
In chapter 4, nanoparticle targeting and endosomal escape are further discussed 
with respect to the cMAP nanoparticle system. A diboronic acid entity, which gives an 
order of magnitude greater binding (than boronic acid) to cMAP due to the vicinal diols in 
mucic acid, was synthesized, attached to 5kD or 10kD PEG, and conjugated to either 
transferrin or cetuximab. A histidine was incorporated into the triblock polymer between 
cMAP and the PEG blocks to allow for siRNA endosomal escape. Nanoparticle size 
remained 30-40 nm with a slightly negative ca. -3 mV zeta potential with the triblock 
polymer containing histidine and when targeting agents were added. Greater mRNA 
knockdown was seen with the endosomal escape mechanism than without. The 
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nanoparticle formulations were able to knock down the targeted mRNA in vitro. Mixed 
effects suggesting function were seen in vivo.  
Chapter 5 summarizes the project and provides an outlook on siRNA delivery as 
well as targeted combination therapies for the future of personalized medicine in cancer 
treatment. 
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C h a p t e r  1  
Introduction 
Targeted therapeutics for cancer 
 Cancer is currently the second leading cause of death in the United States.1 With 8 
million cancer-related deaths in 2012, malignancies are also one of the major causes of 
death and disability worldwide.2 The most common types of cancer diagnosed as well as 
leading to death are those arising from sites in the lung, breast, prostate, and colon, as 
shown in Figure I.1.1 In addition to the human burden caused by cancer, the financial costs 
are considerable. In 2009, an estimated $286 billion in medical costs and in lost 
productivity was caused by new cancer diagnoses, with 94% of that amount being incurred 
in developed countries such as the United States.3 This price tag may be due to the use of 
newer therapies for cancer, which are more specific against the cancer and enable the 
patient to have a better quality of life that allows them to carry on most of their usual 
activities. 
 
Figure I.1: Cancer incidence and death by site. From Stricker and Kumar in Robbins Basic 
Pathology, 8th Edition. 
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  Although many toxic chemotherapeutics such as methotrexate and cisplatin are 
still part of many chemotherapy regimens, cancer treatment has advanced in the last 70 
years from highly toxic drugs with many adverse effects to more specific therapies that 
cause fewer side effects. Some of the first toxic compounds used against leukemia were 
derivatives of nitrogen mustard and anti-folates.4,5 Many of these chemotherapeutics used 
for cancer treatment target cell replication. Because cancer cells generally proliferate more 
rapidly than other cell types in the body, these types of chemotherapeutics have a larger 
impact on the malignant cells. However, because some cells in the body, such as blood 
cells, epithelial cells lining the gastrointestinal (GI) tract and skin or hair, need to be 
replenished fairly frequently, there can be severe adverse effects resulting from 
chemotherapeutics, such as anemia, nausea, vomiting, diarrhea, sores, and hair loss.  
The first targeted therapy developed was Gleevec, or imatinib, which inhibits the 
tyrosine kinase domain fused by bcr-abl resulting from the Philadelphia chromosome 9;22 
translocation.6 Since then, numerous targeted therapies have been developed, many of 
which target tyrosine kinases – tyrosine kinase inhibitors (TKIs). For example, erlotinib 
and gefitinib are inhibitors of the intracellular tyrosine kinase domain in the epidermal 
growth factor receptor (EGFR) often overexpressed or mutated in non-small cell lung 
cancer (NSCLC), colorectal cancer, and head and neck cancers.7-10  
In addition to TKIs, antibodies against the extracellular domain of EGFR, such as 
Erbitux (cetuximab) and Vectibix (panitumumab) have been developed to inhibit EGFR 
signaling in NSCLC, colorectal, and head and neck cancer, though cetuximab is currently 
only FDA approved for colorectal and head and neck cancer and panitumumab for 
colorectal cancer.11-12 Genentech’s blockbuster drug, Herceptin (trastuzumab), is also an 
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antibody which is directed against human epidermal growth factor receptor 2 (Her2).13 
Her2 is often overexpressed in up to 30% of breast cancers and some types of gastric 
cancer.14,15 In all cases, eventually the malignant cells mutate and become resistant to the 
targeted therapy.12,16-18 Therefore, newer targeted therapies are developed in an effort to 
overcome therapy resistance, and many of these targeted therapies are used in combination 
with other targeted therapies or chemotherapy, such as cetuximab with irinotecan, 
fluorouracil, and leucovorin (FOLFIRI) in metastatic colorectal cancer.9,19-21  
The idea to combine a targeted antibody therapeutic with a chemotherapeutic as a 
single drug resulted in antibody-drug conjugates (ADCs). ADCs link a cytotoxic drug to an 
antibody to better target the chemotherapeutic agent to the appropriate cells. They were 
developed to enhance the potency of the antibody after resistance to trastuzumab 
developed, as well as create a sort of combination therapy with multiple modes of action in 
a single formulation.22 Trastuzumab conjugated to the cytotoxic microtubule disruptor 
emtansine (DM1) shown in Figure I.2, Kadcyla (T-DM1) is an example of an FDA 
approved ADC, with many more in development at Genentech and other pharmaceutical 
companies.23-24 Although T-DM1 initially is effective against transtuzumab-resistant 
cancers, resistance to the ADC eventually develops and combinations with other 
therapeutics are used in an attempt to rescue its function.22-27   
 
Figure I.2: Trastuzumab conjugated to a DM (T-DM1) is an example of an antibody drug 
conjugate that is FDA approved. From Junttila, et al. Breast Cancer Res. Treat. 2011, 128, 
347-356. 
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Perhaps it is cancer’s ability to outsmart each new therapy and the myriad side 
effects that these therapies cause that cancer has been dubbed “the emperor of all 
maladies.”28 TKIs, antibodies, and ADCs have been shown to be effective and less toxic 
than the cytotoxic chemotherapeutic agents, but some adverse effects remain. For example, 
TKIs and antibodies against EGFR can cause skin rashes and GI toxicity because EGFR is 
highly expressed in epithelial tissues. ADCs such as T-DM1 is also able to cause many of 
the side effects associated with cytotoxic chemotherapy, though it is obviously less toxic 
than emtansine alone, which is not tolerated by patients at all.22 In an effort to develop a 
therapeutic that is more potent against malignant cells but less toxic to the patient, 
nanoparticles with more design complexity and flexibility show promise to enable multiple 
therapeutic modes of action with high drug-loading capacity while having minimal 
penetration to normal tissue.  
Nanoparticle Therapies 
The earliest nanoparticle therapeutics sought to reduce the toxicity of cytotoxic 
chemotherapeutics by encapsulating the drug in a liposome (doxorubicin, Doxil) or coating 
it with albumin (paclitaxel, Abraxane).29,30 Although the development of nanoparticles 
(shown in Figure I.3) has a history of more than forty years, only a few of these early 
nanoparticle formulations have been FDA approved and are on the market as shown in 
Table I.1. A much larger number of nanoparticles therapies are in various stages of clinical 
trials.30-32  
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Figure I.3: Timeline of nanoparticle development. Doxil, Abraxane, and Genexol-PM (in 
Korea) are approved for cancer therapy. CRLX101, CALAA-01, and BIND-014 are in 
clinical trials for cancer therapy. Adapted from Kamaly, et al. Chem. Soc. Rev. 2012, 41, 
2971-3010. 
Despite the few nanoparticles that have been FDA approved, nanoparticles show 
efficacy and substantially decrease the toxicity of the chemotherapeutic agents that they 
have been formulated to deliver. For example, CRLX101, a cyclodextrin-PEG polymer 
containing camptothecin that forms a 30 nm diameter nanoparticle, has been shown to have 
few adverse effects compared to other camptothecin-containing drugs not in nanoparticle 
form (shown in Figure I.4). Adverse effects are seen in less than 40% of patients, with very 
few of the serious grade 3-4 adverse effects seen. It has been shown to preferentially 
localize in tumor tissue in gastric cancer without being present in adjacent normal gastric 
tissue.33  
This passive targeting of nanoparticles to tumor tissue is due to what is named the 
enhanced permeation and retention (EPR) effect illustrated in Figure I.5. This phenomenon 
has origins in both blood vessel and lymphatic differences between tumor tissue and 
normal tissue. Blood vessels in tumor tissue are leaky and allow nanoparticles less than 
around 200 nm to pass through, unlike in normal tissue where they have tight junctions that 
prevent nanoparticle passage. Additionally, poor lymphatic drainage in tumor tissue 
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contributes to the accumulation of nanoparticles.34 Passive targeting of nanoparticles by the 
EPR effect contributes to the enhanced safety profile of nanoparticle therapeutics, and 
enables the use of drug combinations with the nanoparticle-encapsulated drug that would 
otherwise be too toxic for the patient.  
In addition to the improved safety profile of nanoparticle therapeutics, nanoparticles 
are able to encapsulate hydrophobic drugs that are not normally soluble in aqueous solution 
and protect a sensitive drug from being degraded before reaching the tumor.34 Polymers 
can have high loading capacity of drug onto the polymer which forms the nanoparticle. The 
nanoparticles also can be targeted to particular cells within a tumor or to enhance cellular 
uptake of the therapeutic. If the targeting agent for the nanoparticle is also an effective 
therapeutic such as an antibody, then a nanoparticle with multiple mechanisms of action is 
created.  
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Table I.1: Nanoparticle delivery systems for cancer therapy on the market and in clinical 
development. From Egusquiaguirre, et al. Clin. Transl. Oncol. 2012, 14, 83-93. 
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Figure I.4: Adverse effects of camptothecin-containing drugs and CRLX101, a 
nanoparticle which contains camptothecin. From Cerulean Pharma Inc., United States 
Securities and Exchange Commission Annual Report  
(http://www.sec.gov/Archives/edgar/data/1401914/000156459016014403/ceru-
10k_20151231.htm) 
 
Figure I.5: The enhanced permeation and retention (EPR) effect of nanoparticles 
accumulating in tumor tissues due to leaky blood vessels and poor lymphatic drainage. 
From Peer, et al. Nature Nanotechnology 2007, 2, 751-760. 
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siRNA Delivery: Advantages and Challenges 
Nanoparticle-based delivery of macromolecular agents as a therapeutic commenced 
with the discovery of RNA interference (RNAi) by Fire and Mello in 1998.35 Small 
interfering RNA (siRNA) is a short double stranded RNA ca. 21 base pairs. It is able to 
very specifically cleave the messenger RNA (mRNA) complementary to it using the RNAi 
induced silencing complex (RISC) in the cytosol to silence an overexpressed or mutated 
gene, as shown in Figure I.6. siRNA sequences are now being developed with very high 
potency, so that the concentration required for silencing 50% of the mRNA is in the single 
digit picomolar scale. Because siRNA is catalytic, once it has reached the cell cytosol it 
will remain for a prolonged period of time subject to cell division rate.36 RNAi has the 
promise of being able to silence any gene, including for intracellular proteins, such as 
KRAS, which have been considered “undruggable.”37 Once a nanoparticle siRNA delivery 
system is developed, it is able to deliver any siRNA sequence, including multiple siRNA 
sequences in the same particle for combined silencing of multiple genes fueling the cancer 
cell’s growth. Silencing of multiple genes using multiple siRNA sequences in the same 
delivery system has been shown both in preclinical studies and clinical trials.38,39  
Delivering siRNA can be challenging. siRNA needs to be protected from being 
degraded by nucleases present in the bloodstream as well from recognition by toll-like 
receptors (TLR’s) which would activate the immune system.40 This can be achieved by 
using a delivery system that protects the siRNA from being accessed by nucleases and 
immune components. siRNA also has a very short circulation time in the bloodstream, with 
rapid renal clearance.41-46 Even with polycationic siRNA delivery systems, such as 
CALAA-01, circulation time is short and the nanoparticles are disassembled at the 
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glomerular basement membrane in the kidney.42-46 Furthermore, the siRNA needs to be 
internalized into cells, where it is endocytosed into an endosome. Then the siRNA needs 
escape from the endosome and reach the cytosol to bind to RISC and perform its functions, 
as shown in Figure I.7. 
siRNA
mRNA
cleaved mRNA
RISC
siRNA
Extracellular Space
Cytosol
 
Figure I.6: siRNA mechanism of action                
Cytosol
Extracellular Space
H+
H+
H+
Endocytosis
Endosomal
Escape
Mechanism
 
Figure I.7: siRNA nanoparticle endocytosis into an endosome necessitates an endosomal 
escape mechanism for siRNA to reach the cytosol where it can bind to RISC and perform 
its functions. 
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Despite the challenges that siRNA delivery faces, a number of nanoparticles 
containing siRNA for cancer therapy (Table I.2), as well as several other applications 
(Table I.3), have reached the clinic and shown to be effective, though there has yet one to 
be approved to date.47-51 Furthermore, these siRNA-containing nanoparticles show fairly 
good safety profile.41,48,52   
 
Table I.2: Nanoparticles containing siRNA for cancer treatment in clinical trials. From 
Zuckerman and Davis, Nature Review Drug Discovery 2015, 14, 843-856. 
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Table I.3: siRNA for non-cancer therapy applications that have reached the clinic. From 
Draz, et al. Thernostics 2014, 4, 872-892. 
Thesis Organization 
This thesis presents a nanoparticle siRNA delivery system based upon a cationic 
mucic acid polymer that attempts to overcome the challenges facing siRNA therapy for 
cancer treatment. These challenges, as mentioned earlier, include protecting the siRNA 
with the delivery system, increasing the siRNA nanoparticle circulation time, getting 
siRNA into cells, and allowing the siRNA to escape from the endosome to the cytosol for 
function.  
Chapter 2 details the development of a cationic mucic acid polymer siRNA delivery 
system to achieve a long circulation time. Chapter 3 explores using targeting agents to 
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allow nanoparticle internalization: some antibodies have multiple functions which include 
an immune-mediated antibody-dependent cellular cytotoxicity (ADCC) effect, and we 
wanted to see whether this function is preserved when the antibody is attached to a 
nanoparticle to evaluate the value of using an antibody to target the nanoparticle with an 
added ADCC effect over using a protein or peptide without these immune effects to target 
the nanoparticle. Chapter 4 discusses achieving internalization of the cationic mucic acid 
polymer-based nanoparticle and endosomal escape. Finally, chapter 5 concludes with an 
outlook on the future of nanoparticle therapeutics and targeted cancer treatment.  
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C h a p t e r  2  
Cationic mucic acid polymer-based siRNA delivery systems 
This chapter has been published as: 
Pan, D.W. and Davis, M.E. Cationic mucic acid polymer-based siRNA delivery systems. 
Bioconjugate Chem. 2015, 26, 1791-1803. doi : 10.1021/acs.bioconjchem.5b00324  
 
Abstract 
Nanoparticle (NP) delivery systems for small interfering RNA (siRNA) that have 
good systemic circulation and high nucleic acid content are highly desired for translation 
into clinical use. Here, a family of cationic mucic acid-containing polymers is synthesized 
and shown to assemble with siRNA to form NPs. A cationic mucic acid polymer (cMAP) 
containing alternating mucic acid and charged monomers is synthesized. When combined 
with siRNA, cMAP forms NPs that require steric stabilization by polyethylene glycol 
(PEG) that is attached to the NP surface via a 5-nitrophenylboronic acid linkage (5-
nitrophenylboronic acid-PEGm (5-nPBA-PEGm)) to diols on mucic acid in the cMAP in 
order to inhibit aggregation in biological fluids. As an alternative, the cMAP is covalently 
conjugated with PEG via two methods. First, a copolymer is prepared with alternating 
cMAP-PEG units that can form loops of the PEG on the surface of the formulated siRNA-
containing NPs. Second, an mPEG-cMAP-PEGm triblock polymer is synthesized that 
could lead to a PEG brush configuration on the surface of the formulated siRNA-containing 
NPs. The copolymer and triblock polymer are able to form stable siRNA-containing NPs 
without and with the addition of 5-nPBA-PEGm. Five formulations: (i) the cMAP with 5-
nPBA-PEGm, (ii) cMAP-PEG copolymer both (a) with and (b) without 5-nPBA-PEGm, 
and (iii) mPEG-cMAP-PEGm triblock polymer both (a) with and (b) without 5-nPBA-
  
19
PEGm, are used to produce NPs in the 30-40 nm size range, and their circulation times 
evaluated in mice using tail vein injections. The mPEG-cMAP-PEGm triblock polymer 
provides the siRNA-containing NP with the longest circulation time (5-10% of the 
formulation remains in circulation at 60 min post-dosing), even when a portion of the 
excess cationic components used in the formulation are filtered away prior to injection. A 
NP formulation using the mPEG-cMAP-PEGm triblock polymer that is free of excess 
components could contain as much as ca. 30wt% siRNA.    
INTRODUCTION 
Therapeutics that use RNA interference (RNAi) as their mechanism of action have 
great promise for the treatment of human disease. For example, siRNA has attractive 
features for use as a therapeutic, including: (i) the ability to target essentially any gene 
(thus, all targets are in principle druggable), (ii) potent, single-digit, picomolar IC50’s 
(concentration required for 50% inhibition) for mRNA inhibition in well-designed siRNAs, 
(iii) chemical modifications and sequence designs that can minimize off-target effects and 
immune stimulation without compromising potency and target specificity, and (iv) a 
catalytic RNAi mechanism of action, resulting in extended siRNA inhibition of mRNA 
target expression.  Although a major obstacle to the translation of siRNA into an effective 
and efficient therapeutic is the delivery of the nucleic acid to the target, siRNA-based 
experimental therapeutics have reached the clinic.1 
Therapeutics investigated for cancer treatment are primarily administered 
systemically and use some type of synthetic compounds (positively charged lipids or 
polymers) in their formulations to deliver siRNA.2 A number of these formulations are now 
called nanoparticles (NPs). CALAA-01 was the first siRNA-based therapeutic to reach the 
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clinic for the treatment of cancer.3-5 This targeted NP contains a cyclodextrin-based 
polycation (CDP) that assembles with siRNA via electrostatic interactions between positive 
charges on the polymer and negative charges on the siRNA backbone. CALAA-01 was 
able to deliver siRNA to solid tumors in patients and release functional siRNA that 
inhibited the target using an RNAi mechanism (the first example in a human).4,5 While 
CALAA-01 revealed several positive attributes, one of its shortcomings is that it has a very 
limited circulation time. The fast clearance of CALAA-01 that is observed in animals 
(mice, rats, dogs, and non-human primates) is also observed in humans.5 We have 
investigated the origin of this short circulation time, and have shown that CALAA-01 
disassembles at the glomerular basement membrane (GBM) in the kidney.6 We speculated 
that this clearance mechanism may affect any NP formulation that is primarily assembled 
through electrostatic interactions between cationic delivery components and anionic nucleic 
acids.6 Other siRNA delivery systems that use either cationic polymers or lipids have 
shown similar short circulation times and renal clearance.7-10  
A number of the current polymeric and liposomal systems used to deliver siRNA in 
vivo contain excess cationic components in their formulations (positive to negative charge 
ratios are commonly greater than 1), in addition to a large amount of material, e.g., 
polyethylene glycol (PEG), used to sterically stabilize the formed NPs. Excess cationic 
components can have unwanted side effects in vivo, causing adverse reactions such as 
platelet aggregation, complement activation, and inflammatory reactions.9,11-14  
The development of a polymer system for siRNA delivery that both increases the 
circulation time of siRNA-containing NPs and decreases the amount of non-siRNA 
components within the formulation would be advantageous. Here, we present efforts to 
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address this need. We have created a family of cationic mucic acid-based polymers 
(cMAP) for siRNA delivery in vivo. This polymer delivery system has some features 
analogous to the CDP system, since the latter system did function in humans.4,5 The 
cationic polymer developed here uses a simpler sugar, mucic acid, than the cyclodextrin, 
and enables an alternative strategy for surface functionalization. Instead of NP surface 
functionalization via inclusion complex formation (CDP) with adamantane (AD), the 
cMAP contains vicinal diols that are binding sites for boronic acids which can be used to 
PEGylate and target the cMAP-based NPs. (NPs formed with mucic acid containing 
polymers for the delivery of small molecule drugs have incorporated targeting agents via 
this method of assembly.15,16) The basic cMAP was also further reacted with functionalized 
PEG into linear block copolymers. Reaction at the end-groups of cMAP with either a di-
activated, carboxylic acid-PEG or an activated, carboxylic acid-PEG-methoxy (PEGm) 
leads to two possible copolymers: a cMAP-PEG copolymer or an mPEG-cMAP-PEGm 
triblock polymer. The cMAP-PEG copolymer can assemble with siRNA to form PEG 
loops on the surface to stabilize the NP, while the mPEG-cMAP-PEGm triblock can form a 
PEG brush configuration on the NP surface. The latter triblock approach has been explored 
previously with CDP and plasmid DNA (pDNA), and that triblock polymer did not have 
the ability to encapsulate the pDNA.17 It has been shown that polymers that encapsulate 
pDNA may not be good at condensing siRNA and vice versa.18,19 Here, we demonstrate 
that the mPEG-cMAP-PEGm triblock polymer is able to form siRNA-containing NPs 
(which can have ca. 30 wt% of the formulation being siRNA) with increased circulation 
times in mice. Additionally, the NPs can be easily assembled directly in phosphate buffered 
saline (PBS) without any additional 5-nPBA-PEGm to stabilize the NPs. 
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RESULTS AND DISCUSSIONS 
cMAP Synthesis, NMR Characterization, and End-Group Determination. A cationic 
mucic acid polymer (cMAP) was synthesized by using the series of reactions schematically 
illustrated in Scheme II.1. The mucic acid and the intermediate reaction products leading to 
the preparation of mucic acid ethylenediamine were fully characterized (Supporting 
Information: Figures II.S1-II.S7, Structure II.S1, and Table II.S1). The condensation 
reaction between mucic acid ethylenediamine and DMS yielded the cMAP material. 
Because DMS can hydrolyze at conditions like those used for the polymerization, we 
investigated the reaction pathway for this reaction and the products formed (Supporting 
Information: Table II.S2, Structures II.S2-II.S4, Figures II.S8-II.S13). This information 
assisted in the characterization of the cMAP product.   
NMR analysis of cMAP (Supporting Information: Structure II.S5, Figures II.S14-
II.S20, and Tables II.S3-II.S7) enabled the assignment of all resonances to the various 
carbon and hydrogen environments in the polymer. Of importance was the identification 
of the end group composition of cMAP, as these functionalities are utilized in subsequent 
reactions with functionalized PEG to form cMAP-PEG copolymers or mPEG-cMAP-
PEGm triblock polymers.  
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Scheme II.1. Synthesis of cationic Mucic Acid Polymer (cMAP). 
 
The cMAP end groups include methoxy of a methoxy ester, amine, and small 
amounts of carboxylic acid (Figure II.1). 1H NMR analysis of cMAP shows the presence 
of a characteristic sharp methoxy peak at 3.55 ppm (Figure II.2), and this assignment is 
supported by 1H-13C HSQC NMR measurements (Supporting Information: Figure 
II.S16). The methoxy group originates from the loss of ammonia from the imidate group 
of the DMS through hydrolysis (Supporting Information: Table II.S2, Structures II.S2-
II.S4, Figures II.S8-II.S13), and had been previously reported.20 The methylene group 
adjacent to the methoxy can be observed as a triplet at 2.25 ppm in the 1H NMR spectrum 
(Figure II.2). The amine end group that originates from the mucic acid ethylenediamine 
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cannot be directly observed with 1H NMR. However, analysis of the NMR spectrum of 
the monomer (Supporting Information: Figure II.S4-5) and the HMBC NMR spectrum of 
cMAP (Supporting Information: Figure II.S18) enabled assignment of the triplet at 2.85 
ppm to be from a methylene group adjacent to the amine functional group. Additionally, 
a TNBSA assay for primary amines was positive, thus confirming that the cMAP has a 
terminal primary amine as an end group. Lastly, there was a small amount of carboxylic 
acid as an end group that arises from complete hydrolysis of the methyl ester or as an 
impurity in the starting DMS. The methylene group adjacent to the carboxylic acid is 
observed as a small triplet at 2.00 ppm in the 1H NMR spectrum (Figure II.2). The ratios 
of these end groups in a batch of cMAP can be determined by comparing the integrations 
of the triplets at 2.85 (amine), 2.25 (methoxy), and 2.00 (carboxylate) ppm, and are 
shown for 8 batches in Supplementary Information, Table II.S8. The average values for 
the % amine, % methoxy, and % carboxylate are 49%, 42%, and 9%, respectively.  
 
 
 
Figure II.1. End groups of cMAP. Polymers can have one amine and one methoxy (top), 
both amine (middle), or both methoxy (bottom) end groups. A small amount of carboxylic 
acid is also observed and would be generated from hydrolysis of one end of DMS.  
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Figure II.2. 1H NMR (600 MHz) of cMAP showing resonances from the methoxy group 
and methylene groups adjacent to the end group functionalities.  
 
cMAP-PEG Copolymer and mPEG-cMAP-PEGm Triblock. cMAP was reacted with 
activated carboxylic acid end groups on PEG, such as succinimidyl propionic acid ester 
(SPA) or succinimidyl valeric acid ester (SVA). cMAP reacted with di-SPA-PEG or 
mPEG-SVA generated copolymers or triblock polymers, respectively, with PEG lengths of 
2, 3.4, or 5 kD (NMR data from these polymers are provided in the Supporting 
Information: Figures II.S21-II.S27). 
 
Scheme II.2: Synthesis of cMAP-PEG copolymer. 
 
Because a significant amount of diamine terminated polymer chains exist in the 
cMAP mixture, reaction with di-SPA-PEG (Scheme II.2) resulted in cMAP-PEG 
copolymers with large size distributions (copolymers ranged from a diblock cMAP-PEG 
copolymer just slightly larger than 10 kD, to a cMAP-PEG-cMAP triblock polymer 
terminated by a methyl ester or carboxylic acid on the cMAPs, to a long polymer of over 
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100 kD; size distributions reported in Supporting Information: Table II.S9-10 are from the 
polymer yields obtained by fractionating the crude polymer through sequentially smaller 
molecular weight cutoff centrifugal spin filters). Because a polymer with such a large 
molecular weight could pose substantial toxicity in vivo, in an effort to synthesize a well-
defined polymer with a reasonable length, the cMAP-PEG-cMAP triblock polymer species 
was isolated from the copolymer using this fractionation method. Other triblock polymers 
of this repeat structure of a cationic polymer flanking a PEG or PLA polymer has been 
explored previously for gene and iron oxide-carbon nanotube delivery.21-23  
Reacting cMAP with mPEG-SVA limited the structure of the resulting product to 
the mPEG-cMAP-PEGm triblock polymer (Scheme II.3) (NMR characterizations provided 
in Supporting Information: Figures II.S28-II.S33). Some cMAP-PEGm diblock polymer 
was also present and separated from the desired triblock by fractionation.   
 
Scheme II.3: Synthesis of mPEG-cMAP-PEGm triblock polymer. 
 
Molecular Weights of Polymers by GPC. Gel permeation chromatography was used to 
characterize the molecular weight of cMAP. Though the elution time of the polymer can be 
correlated to its size, with new cationic polymers there are no ideal size standards for 
calibration. Therefore, we determined the absolute molecular weight of the polymers using 
a multi-angle light scattering detector. The advantage of this method is its dependence only 
on the polymer’s scattering ability and its concentration; it does not require a standard for 
comparison. The differential refractive index with respect to concentration, dn/dc, of cMAP 
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was determined (Table II.1) and used to measure molecular weight. The average molecular 
weight of 9 batches of cMAP was around 6 kD with a polydispersity index (PDI) of less 
than 1.1 (Table II.1). The results from the individual batches can be found in Supporting 
Information: Table II.S11. Using a similar method, the 5k cMAP-PEG copolymer had a 
larger size distribution with a PDI of 1.4, and an Mw of 42 kD and Mn of 29 kD (Table 
II.1). The 5k mPEG-cMAP-PEGm triblock was about 21 kD with a PDI of less than 1.1 
(Table II.1). Additionally, results for the 3.4 kD PEG cMAP-PEG copolymer and the 2 kD 
PEG mPEG-cMAP-PEGm triblock, as well as the cMAP-PEG-cMAP triblocks derived 
from fractionating the cMAP-PEG copolymer are all reported in Supporting Information: 
Table II.S12.   
Polymer dn/dc (mL/g) Mn (kD) Mw (kD) PDI 
(Mw/Mn) 
cMAP (9 batches ± std. error) 0.1806 ± 
0.0002 
6.30 ± 
0.40 
6.76 ± 0.40 1.08 ± 0.01 
cMAP-PEG5k copolymer (2 
batches ± 
 std. error) 
0.1660 ± 
0.0003 
28.72 ± 
4.55 
41.49 ± 
14.65 
1.40 ± 0.29 
mPEG5k-cMAP-PEG5km (3 
batches ± 
 std. error) 
0.1420 ± 
0.0004 
20.98 ± 
0.67 
21.95 ± 
0.67 
1.05 ± 0.02 
Table II.1.  Molecular weights of cMAP-based polymers.  
 
siRNA Encapsulation by cMAP-based Polymers. The ability of cMAP, cMAP-PEG 
copolymer, and mPEG-cMAP-PEGm triblock polymer to encapsulate siRNA was 
confirmed using both a RiboGreen assay and a gel retardation assay. cMAP is able to 
encapsulate siRNA at a charge ratio (+/-) of 1+/-, and the cMAP-PEG5k copolymer and the 
mPEG5k-cMAP-PEG5km triblock both are able to fully encapsulate siRNA by a charge 
ratio of 3 or 2, respectively, using the fluorescent RiboGreen assay (Figure II.3). Similar 
siRNA encapsulation data is reported for copolymers and triblock polymers of the other 
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PEG lengths in Supporting Information: Figures II.S42-II.S43. The results of the 
RiboGreen assay are perhaps more sensitive, but comparable to those from a gel retardation 
assay (shown for cMAP and cMAP-PEG copolymer in Supporting Information: Figures 
II.S39-II.S41).  
 
Figure II.3. Percentage of siRNA encapsulated by cMAP, cMAP-PEG5k copolymer, and 
mPEG5k-cMAP-PEG5km triblock polymer using the RiboGreen assay. 
 
Nanoparticle Formulations and Properties.  
Formulations. 5-nitrophenyl boronic acid-PEGm (5-nPBA-PEGm), synthesized as shown 
in Scheme II.4, contains a boronic acid group that allows one end of this 5kD PEG to bind 
to vicinal diol groups on mucic acid15,16 in cMAP at a pH above 6.8 to provide steric 
stabilization of the siRNA-containing NPs, as illustrated in Scheme II.5. The various NP 
formulations using cMAP, cMAP-PEG copolymer, and mPEG-cMAP-PEGm triblock 
polymer with or without extra 5-nPBA-PEGm are shown in Scheme II.6. A NP prepared 
by mixing cMAP and siRNA at a 3+/- charge ratio without the addition of 5-nPBA-PEGm, 
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while stable in water, is unstable in PBS (one 5-nPBA-PEGm per diol added to the 
formulation, Supporting Information: Figure II.S44).  
 
Scheme II.4. Synthesis of 5-nitrophenylboronic acid-PEGm. 
 
 
 
Scheme II.5. pH dependence of 5-nitrophenylboronic acid-PEGm which forms the boronic 
acid ester with vicinal diols on cMAP at a physiological pH of around 7.4, but which will 
dissociate at acidic pH.  
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Scheme II.6. Diagram showing the various NPs with siRNA that were formed: cMAP (I, 
not stable and not injected), cMAP + 5-nPBA-PEGm (A), cMAP-PEG copolymer (B), 
cMAP-PEG copolymer + 5-nPBA-PEGm (C), mPEG-cMAP-PEGm triblock (D), and 
mPEG-cMAP-PEGm triblock + 5-nPBA-PEGm (E). (Note: Illustration is not drawn to 
scale or stoichiometry and doesn’t reflect how particles are formulated – e.g. in PEGylated 
formulations the PEG is added to the polymer first, before the siRNA is added). 
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In contrast to cMAP alone, cMAP-PEG copolymer and mPEG-cMAP-PEGm 
triblock polymer are able to form stable particles without additional 5-nPBA-PEGm. 
However, the pure cMAP-PEG-cMAP triblock polymer isolated from the cMAP-PEG 
copolymer was not able to form stable siRNA-containing NPs without added 5-nPBA-
PEGm, perhaps because it does not contain enough PEG to fully shield and sterically 
stabilize the NP (Supporting Information: Table II.S13 and Figures II.S45-II.S47).  
Although the cMAP-PEG copolymer and mPEG-cMAP-PEGm triblock polymer 
form stable NPs in PBS, formulations with additional 5-nPBA-PEGm were also prepared 
to test whether the extra PEG offered greater steric stability to the NPs when tested in vivo. 
The amount of PEG bound to the NPs is approximately 20% (Table II.2). The polymeric 
components of the NP were mixed together with an equal volume of siRNA to form NPs at 
concentrations of 0.8 – 1 mg siRNA/mL. Furthermore, the cMAP-PEG copolymer and 
mPEG-cMAP-PEGm triblock polymers were able to formulate stable NPs directly in PBS, 
eliminating the need to first formulate stable particles in a low salt buffer followed by 
addition of PBS (required by the cMAP). 
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Formulation % 5-nPBA-PEGm 
bound to NP 
% cationic polymer bound 
to NP 
cMAP N/A 33.0 ± 0.2 
cMAP + 5-nPBA-PEG5km 34.2 ± 8.7 N/A 
cMAP-PEG5k copolymer N/A 46.1 ± 1.3 
cMAP-PEG5k copolymer  
+ 5-nPBA-PEG5km 
21.5 ± 1.7 N/A 
mPEG5k-cMAP-PEG5km N/A 34.4 ± 0.8  
mPEG5k-cMAP-PEG5km  
+ 5-nPBA-PEG5km 
18.4 ± 4.5 N/A 
Table II.2. Nanoparticle composition for NPs formulated at a charge ratio of 3+/-. Mean 
+/- S.E.M. of 3 runs (for PEG) or 2 runs (for polymer). 
 
Formulation Hydrodynamic 
Diameter by 
DLS (nm) 
Diameter 
by 
CryoTEM 
(nm) 
Zeta potential 
(mV) in 10 
mM 
phosphate 
buffer, pH 7.4 
Zeta 
potential 
(mV) in 1 
mM KCl, 
pH 5.5 
cMAP  
+ 5-nPBA-PEG5km 
40.9 ± 8.9 29.3 ± 12.8 -3.14 ± 0.56 0.76 ± 0.37 
cMAP-PEG5k 
copolymer 
25.1 ± 5.6 27.0 ± 7.9 0.69 ± 0.71 1.77 ± 0.76 
cMAP-PEG5k 
copolymer  
+ 5-nPBA-PEG5km 
38.1 ± 15.3 34.4 ± 19.7 -2.25 ± 0.64 0.70 ± 0.74 
mPEG5k-cMAP-
PEG5km 
36.8 ± 20.2 33.6 ± 16.7 0.42 ± 0.73 0.40 ± 0.64 
mPEG5k-cMAP-
PEG5km  
+ 5-nPBA-PEG5km 
29.8 ± 9.2 27.8 ± 12.9 -0.36 ± 0.64 1.44 ± 0.83 
Table II.3. Size and surface charge of formulated NPs.  
 
Nanoparticle Size. The sizes of the formulated NPs were characterized by dynamic light 
scattering (DLS) and cryo-transmission electron microscopy (CryoTEM). The diameters of 
these NPs are all ca. 30-40 nm as determined by both DLS and CryoTEM (Table II.3). The 
NPs have a spherical morphology (CryoTEM imaging, shown in Figure II.4). Additional 
images and the distributions of sizes by both DLS and CryoTEM are reported in 
Supporting Information: Figures II.S48-II.S62.  
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Nanoparticle Zeta potential. The  zeta potential of the NPs (a measure of the NP surface 
charge), was measured in two solutions of different pH: 10 mM phosphate buffered at pH 
7.4, when 5-nPBA-PEGm would be bound to the vicinal diols on cMAP; and 1 mM KCl at 
pH 5.5, when 5-nPBA-PEGm would dissociate from the diols of the mucic acid. cMAP-
siRNA NPs with 5-nPBA-PEGm have a slightly negative zeta potential at -3 mV in pH 7.4 
phosphate buffer when 5-nPBA-PEGm is present on the NP. However, when these NPs are 
placed in 1 mM KCl at pH 5.5, the zeta potential is about +1 mV. These results are 
consistent with the boronic acid binding to diols on the mucic acid to form a tetrahedral 
boronate complex at pH 7.4 that shields the positive charge on cMAP, and with the boronic 
acid dissociating from the NP at acidic pH 5.5. Similar effects are observed with the 
cMAP-PEG copolymer and mPEG-cMAP-PEGm triblock polymer with and without 5-
nPBA-PEGm (Table II.3).  
 
Figure II.4. CryoTEM images of NP formulations: cMAP + 5-nPBA-PEG5km (A), 
cMAP-PEG5k copolymer (B), cMAP-PEG5k copolymer + 5-nPBA-PEG5km (C), 
mPEG5k-cMAP-PEG5km (D), and mPEG5k-cMAP-PEG5km + 5-nPBA-PEG5km (E). 
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Nanoparticle Stoichiometry. The amount of cMAP and copolymers bound to the NPs is 
shown in Table II.2. For all three polymers (cMAP, cMAP-PEG copolymer, and mPEG-
cMAP-PEGm triblock polymer), approximately 33% of the total polymer used for 
formulation is bound for an effective NP charge ratio of 1+/-. The amount of 5-nPBA-
PEGm present on the NP formulations containing excess PEG for stabilization is also 
shown in Table II.2. The amount of 5-nPBA-PEGm bound to the cMAP + 5-nPBA-PEGm 
NP is about 34%, or one PEG per diol (Table II.2).  About 20% of the PEG was found to 
be bound to the NP for the cMAP-PEG copolymer and the mPEG-cMAP-PEGm triblock 
polymer NP formulations. Considering the excess cationic polymer present when the 
particles were formulated at a 3 +/- charge ratio and because the effective NP charge ratio 
is 1+/-, this means that a little less than 1 PEG per diol is present on the NP. Virtually all of 
the siRNA is encapsulated in the NPs, as was shown above in the data on siRNA 
encapsulation (Figure II.3).   
In vivo Pharmacokinetic Studies in Mice.  
Stable formulations of NPs were tested in vivo via tail vein injection into Balb/c 
mice. At the doses injected, no toxicities (no visible signs of distress and no deaths) were 
observed from any formulation. The pharmacokinetics (PKs) of the various NPs were 
measured, and the results are illustrated in Figure II.5.   
A NP composed of the cMAP polymer and siRNA mixed at a 3+/- charge ratio and 
stabilized with 5-nPBA-PEGm was tested, as this NP formulation is analogous to the CDP 
formulation that was used for clinical studies (CALAA-01).3-5 The cMAP-based NP has 
slightly longer circulation times than CALAA-01 (Figure II.5A). Because CALAA-01 uses 
an inclusion complex for the interaction of CDP and adamantane-PEG (AD-PEG), the AD-
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PEG can detach from the NP during circulation to cause the NP to lose stability. Han24 and 
Eriksen25 have synthesized AD2-PEG, and have shown that this compound has greater 
ability to stabilize CDP-based NPs than the AD-PEG in the original CALAA-01 
formulation. This is due to the enhanced binding of the two adamantanes per PEG (into two 
CDs) that therefore results in more steric stabilization during circulation (Figure II.5A).24,25 
With the cMAP boronic acid system, the interaction between the PEG compound and the 
polymer is through a boronic acid ester that is formed from the boronic acid and diols on 
the polymer, with ca. 30% of the PEG bound to the NP. Because only 1/3 of the cMAP 
used to formulate the NP is bound to the particle (Table II.2), this is roughly equivalent to 
one PEG present per diol. We believe that the boronic acid-diol interaction is stronger than 
the inclusion complex between adamantine and cyclodextrin, so that the 5-nPBA-PEGm is 
able to stay attached to cMAP longer than AD-PEG to CDP to result in greater steric 
stabilization and improved circulation time.  
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Figure II.5. PK of formulated siRNA NPs compared to siRNA alone. (A) Comparison of 
siRNA alone with CALAA-01, the CDP system with AD2-PEG for stabilization, and 
cMAP + 5-nPBA-PEGm, the latter of which shows greater stability than CDP with AD2-
PEG and CALAA-01. (B) Comparison of cMAP + 5-nPBA-PEGm to the copolymer and 
triblock formulations. (C) Comparison of cMAP + 5-nPBA-PEGm to the triblock 
formulation with excess components filtered away. n=3 mice. 
 
  
37
NPs formed using the cMAP-PEG copolymer can be stably formulated with siRNA 
in PBS at a 3+/- charge ratio into a NP without the use of 5-nPBA-PEGm (vide supra). The 
PEG in the cMAP-PEG copolymer is thought to form PEG loops (hypothesized by Zhong, 
et al.21 with a PEI-PEG-PEI polymer condensing pDNA) to shield the NP core. Additional 
5-nPBA-PEGm can be used for further stabilization of the NPs. The zeta potential 
switching from negative at pH 7.4 to positive at pH 5.5, in addition to the 20% PEG bound 
to the particles by measuring the amount of excess PEG filtered away, show that the 5-
nPBA-PEGm is able to interact with the cMAP-PEG copolymer in the NP formulations. 
The NPs formulated with cMAP-PEG copolymer did not provide for longer circulation 
times over the cMAP:5-nPBA-PEGm-based NPs whether or not 5-nPBA-PEGm is added 
(Figure II.5B).  
NPs formed using the mPEG-cMAP-PEGm triblock form stable NPs in PBS (vide 
supra), and should have a brush-like configuration of the PEG on the surface of the NPs. 
As shown by the data provided in Figure II.5B, injection of these NPs into mice resulted in 
an improved PK profile compared to all other cMAP-based NPs, with approximately 5-
10% of the NPs remaining in mouse circulation after 60 minutes (other formulations were 
below the limit of detection by 60 minutes). Similar results are observed with this 
formulation in nude mice (Supporting Information: Figure II.S63). These longer circulation 
times are consistent with the NPs having a greater degree of steric stabilization that is 
presumably from a PEG polymer brush configuration on the surface of the NPs.26,27  The 
addition of  5-nPBA-PEGm to the triblock polymer-siRNA NP did not provide for 
improvements in the circulation time (Figure II.5B). Furthermore, a siRNA-containing NP 
formulation with a charge ratio of 2+/- that was obtained by removing some of the 66% 
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excess triblock polymer from the 3+/- NP formulation by spin filtering the formulation with 
a 30 kD MWCO membrane did not result in a decrease in circulation time (Figure II.5C). 
Using this method of purification, it is difficult to remove all of the excess polymer. These 
results suggest that the polymer that is not contained within the NP does not alter the PK. 
Of the polymer variations investigated here, the mPEG-cMAP-PEGm NP provides 
for the longest circulation time and the circulation time does not increase with additional 
bound 5-nPBA-PEGm. Although the 5-nPBA-PEGm interaction with the diols on cMAP 
are likely stronger than the interactions between adamantane and CDP, there is still likely 
to be some amount of PEG shedding from the NP. On the other hand, the triblock polymer, 
with 2 PEGs per cMAP unit, may be able to achieve a PEG density on the NP surface 
required for a good brush layer. However, the amount of PEG covalently linked on this 
triblock polymer is less than that on the cMAP + 5-nPBA-PEGm NP. The PK data from 
these systems suggest that the PEG shedding during circulation still occurs, but is less than 
what happens with the CDP-adamantane system. Previously, Han and Davis showed with 
an antibody targeting agent bound to a mucic acid polymer based NP containing a small 
molecule drug via the same 5-nPBA-PEG linkage, that some of the targeting agent stays on 
the NP in circulation as the presence of the targeting agent on the NP led to greater 
sequestration of the NPs in the spleen (function of the humanized antibody) and altered the 
distribution of the NPs in the tumor.16 Thus, some of the 5-nPBA-PEGm must be staying 
on the NPs during the circulation.  
In order to provide further evidence that the NPs are remaining intact during 
circulation, serum collected from mice 20 minutes post-dosing was run on a gel and the 
siRNA visualized by either ethidium bromide or the fluorophore-tagged siRNA on a 
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Typhoon imager. Results from these experiments are presented in the Supporting 
Information: Figures II.S64-II.S67, and they show that the siRNA and fluorescently tagged 
siRNA remain in intact NPs while circulating in vivo.  
Summary 
A new cationic polymer that possesses repeat units based on mucic acid and dimethyl 
suberimidate was synthesized and denoted cMAP. Further modification of cMAP into a 
triblock polymer with mPEG flanking cMAP, mPEG-cMAP-PEGm, resulted in a well-
defined polymer with a molecular weight of ca. 20 kD. This triblock polymer was able to 
fully encapsulate siRNA at charge ratios of 2 +/- or greater. Stable NPs composed of this 
triblock polymer and siRNA can be formulated directly in PBS with diameters of ca. 30 nm 
(by both DLS and CryoTEM), and slightly positive surface charge of ca. 0.4 mV in both 10 
mM phosphate buffer pH 7.4 and 1 mM KCl pH 5.5. Upon injection into mice, these NPs 
formed with the mPEG-cMAP-PEGm triblock polymer showed prolonged circulation 
compared to NPs formulated with cMAP and cMAP-PEG copolymer, with 5-10% of the 
formulation remaining in the circulation after 1 hour. The circulation time remained the 
same when a portion of the excess triblock polymer is removed from the formulation. The 
absence of any excess cationic polymer will be advantageous to minimize any adverse 
effects that these entities cause in vivo. Future work with this NP formulation will involve 
in vivo anti-tumor studies in immunocompromised mice.  
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EXPERIMENTAL PROCEDURES 
General.  
Mucic acid and oxalyl chloride were purchased from Sigma-Aldrich, N-boc-
ethylenediamine from AK Scientific, dimethyl suberimidate from Thermo Fisher Scientific 
or Sigma-Aldrich, and 3-carboxyl-5-nitrophenyl boronic acid from Alfa-Aesar. 
Polyethylene glycol reagents were purchased from either Jenkem Technology USA or 
Laysan Bio, Inc.  
 Nuclear magnetic resonance (NMR) spectra were acquired on Varian 300 MHz, 
500 MHz, or 600 MHz instruments at 25 degrees Celsius, without spinning, at 500 or 600 
MHz. For most 1H proton spectra, a delay time of 1-1.5 s was used; for quantitative 
integration of the polymer, a 25 s delay was used. 13C carbon spectra were acquired at 500 
MHz with default settings. 1H-13C heteronuclear single quantum coherence (HSQC), 1H-1H 
correlation spectroscopy (COSY), and 1H-13C heteronuclear multiple-bond correlation 
spectroscopy (HMBC) spectra using default VNMRJ3.0 HSQCAD, COSY, and HMBC 
settings were acquired. Additionally, diffusion ordered spectroscopy (DOSY) spectra using 
the bipolar pulse pair stimulated echo with convection compensation (Dbppste_cc) method 
in VNMRJ3.0 with diffusion gradient length of 4.0 ms and diffusion delay of 100.0 ms was 
acquired for synthesized polymers. Acquisition parameters are listed on each spectrum in 
Supporting Information. 
Electrospray ionization masses of small molecules were acquired using a Finnigan 
LCQ ion trap mass spectrometer. Matrix-assisted laser desorption/ionization-time of flight 
(MALDI-TOF) mass spectra for polymers were acquired on an Applied Biosystems 
Voyager DE-PRO using a 10 mg/mL alpha-cyano-4-hydroxycinnamic acid matrix.  
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Synthesis of the Mucic Acid Containing Polymers. 
1. Synthesis of cationic Mucic Acid Polymer (cMAP) (Scheme II.1). Methanol (360 mL) 
was added to mucic acid (15 g, 71 mmol, 1 equiv) in a 500 mL round bottom flask 
containing a stir bar. Concentrated sulfuric acid (1.2 mL, 22.5 mmol, 0.3 equiv) was added 
to this suspension, which was then stirred overnight and refluxed at 85oC. The mixture was 
cooled to room temperature and filtered through a Buchner funnel using Whatman #5 filter 
paper. The solid was washed with 600 mL of methanol and then returned to the 500 mL 
round bottom flask. 240 mL of methanol and 1.5 mL of triethylamine were added and the 
solid was recrystallized at 85oC reflux for 1 h. The mixture was cooled to room 
temperature, filtered through a Buchner funnel, and washed with 600 mL of methanol. The 
solid was dried under vacuum at 75oC overnight to afford mucic acid dimethyl ester 
(13.72 g, 80% yield), a white solid. 1H NMR (300 MHz, DMSO-d6):  4.91 (d, 2H), 4.80 (q, 
2H), 4.29 (d, 2H), 3.76 (q, 2H), 3.62 (s, 6H).    
Methanol (220 mL) was added to mucic acid dimethyl ester (13.72 g, 57.6 mmol, 
1 equiv) in a 500 mL round bottom flask containing a stir bar. Triethylamine (20.9 mL, 150 
mmol, 2.6 equiv) was added and the mixture was stirred and refluxed at 85oC for 30 min, 
during which time a yellow suspension formed. N-boc-ethylenediamine (23.7 mL, 150 
mmol, 2.6 equiv) in methanol (55 mL) was added to the suspension and stirring and 
refluxing at 85oC was resumed overnight. The mixture was cooled to room temperature and 
filtered through a Buchner funnel using Whatman #5 filter paper. The solid was washed 
with methanol (750 mL) and recrystallized with methanol (350 mL) at 85oC for 1.5 h. The 
mixture was again cooled to room temperature, filtered through a Buchner funnel, and 
washed with methanol (750 mL). The solid was dried under vacuum at 75oC overnight to 
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afford N-boc protected mucic acid ethylenediamine (19.27 g, 68% yield), a white solid. 
1H NMR (300 MHz, DMSO-d6): 7.71 (t, 2H), 6.81 (t, 2H), 5.13 (d, 2H), 4.35 (q, 2H), 4.10 
(d, 2H), 3.77 (q, 2H), 3.13 (m, 4H), 2.97 (m, 4H), 1.36 (s, 18H). ESI 495.1 [M+H]+, 517.4 
[M+Na]+.   
N-boc protected mucic acid ethylenediamine (19.2 g) in a 500 mL round bottom 
flask with a stir bar was placed in a water bath. Methanol (260 mL), followed by 
concentrated 12 N hydrochloric acid (65 mL), was added to the flask to make 3 N HCl in 
methanol. The reaction flask was sealed with a septum and vented with a needle. The water 
bath was set to 25oC and the suspension was stirred for 6-8 h. The reaction was monitored 
by thin layer chromatography (TLC) with a mobile phase of 1% methanol in CH2Cl2 and 
the spots were visualized in an iodine tank. Reaction completion was also confirmed by 
ESI. The slurry was filtered through a glass frit with a fine grain and washed with methanol 
(750 mL) until the filtrate was close to a neutral pH. The solid was dried under vacuum at 
80oC overnight to afford mucic acid ethylenediamine (12.96 g, 91% yield) as a white 
solid. 1H NMR (500 MHz, DMSO-d6): 7.97-7.83 (m, 8H), 5.30 (d, 2H), 4.55 (d, 2H), 4.16 
(d, 2H), 3.82 (m, 2H), 2.85 (m, 4H). 13C NMR (125 MHz, DMSO-d6): 174.79, 71.39, 
70.98, 39.25, 36.76. ESI 295.1 [M+H]+, 588.93 [2M+H]+. 
Mucic acid ethylenediamine (100 mg, 0.3 mmol, 1 equiv) was added to a 4 mL 
glass vial with a stir bar. 0.5 M sodium carbonate solution in nanopure water (1 mL) was 
added to the vial and the solution was stirred for 5 min. Dimethyl suberimidate (DMS) 
(74.4 mg, 0.3 mmol, 1 equiv) was then added to the mixture and the reaction was stirred for 
16 h overnight at 25oC. The reaction was diluted with nanopure water (10 mL) and 1N HCl 
was added drop wise to adjust the pH to 4. The resulting solution was dialyzed with a 15 
  
43
mL Amicon Ultra 3 kD spin filter against nanopure water until the filtrate pH was neutral. 
The solution of polymer was concentrated to 3-4 mL, filtered through a 0.2 um PVDF 
syringe filter into a pre-weighed 20 mL glass vial, and lyophilized to dryness to afford 
cationic mucic acid polymer (29.2 mg, 16% yield) as a white solid, which was stored 
under argon at -20oC. 1H NMR (600 MHz, DMSO-d6): 9.59-8.74, 7.92, 5.40, 4.53, 4.16, 
3.82, 3.55, 3.26, 2.86-2.00, 1.60, 1.28. 13C NMR (125 MHz, DMSO-d6): 174.61, 168.12, 
71.19, 70.96, 51.67, 42.09, 36.71, 32.48, 27.84, 26.65. 
2. Synthesis of cMAP-PEG copolymer (Scheme II.2). Starting materials were equilibrated to 
room temperature for 1 h after removing them from the -20oC freezer. cMAP (50 mg, 
0.009 mmol, 2 equiv) and di-SPA-PEG-3.4kD (succinimidyl propionic acid ester, 15.7 mg, 
0.0046 mmol, 1 equiv) were weighed into an oven-dried 10 mL flask with stir bar. The 
flask was capped with a septum, the two solids were dried under vacuum for 1 h, and then 
the flask was filled with argon. Anhydrous DMSO (2 mL) was added using a needle and 
syringe to dissolve the two white solids, and the solution was stirred for 24 h. Nanopure 
water (20 mL) was added to dilute the DMSO, and the solution was dialyzed against 
nanopure water using a 10kD MWCO Amicon Ultra filter >8 times. The retentate, cMAP-
PEG3.4k copolymer, was filtered through a 0.2 um PVDF membrane and lyophilized to a 
white powder (29.6 mg, 45% yield). 1H NMR (600 MHz, DMSO-d6): 9.84-8.48, 7.90, 
5.41, 4.53, 4.15, 3.82, 3.55, 3.49 (PEG), 3.26, 2.86-2.00, 1.59, 1.27. 13C NMR (125 MHz, 
DMSO-d6): 174.66, 168.17, 71.24, 71.00, 70.24, 67.22, 51.69, 42.11, 36.75, 32.58, 27.89, 
26.66. A similar procedure was followed using 5 kD di-SVA-PEG (succinimidyl valeric 
acid ester) to synthesize cMAP-PEG5k copolymer using a 15 kD SpectraPor 7 MWCO 
membrane (Spectrum Labs) for dialysis.   
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The cMAP-PEG-cMAP Triblock Polymer was isolated from the cMAP-PEG 
copolymer by fractionation through centrifugal spin filters of various MWCO. cMAP-
PEG3.4k copolymer was dialyzed using a 20 kD MWCO centrifugal spin filter, and the 
filtrate was then dialyzed through a 10 kD MWCO spin filter to isolate cMAP-PEG3.4K-
cMAP, which was filtered through a 0.2 um PVDF membrane and lyophilized to a white 
powder (10.6 mg, 16% yield). cMAP-PEG5k-cMAP was isolated in the same way.  
3. Synthesis of mPEG-cMAP-PEGm triblock polymer (Scheme II.3). Starting materials 
were equilibrated to room temperature for 1 h after removing them from the -20oC freezer. 
cMAP (40 mg, 0.006 mmol, 2 equiv) and mPEG5k-SVA (85.7 mg, 0.017 mmol, 3 equiv) 
were weighed into an oven-dried 10 mL flask with stir bar. The flask was capped with a 
septum, the two solids were dried under vacuum for 1 h, and then the flask was filled with 
argon. Anhydrous DMSO (4 mL) was added using a needle and syringe to dissolve the two 
white solids, and the solution was stirred for 48 h. Nanopure water (40 mL) was added to 
dilute the DMSO, and the solution was dialyzed against nanopure water using a 20kD 
MWCO centrifugal spin filter >8 times. The retentate, mPEG5k-cMAP-PEG5km, was 
filtered through a 0.2 um PVDF membrane and lyophilized to a white powder (11.3 mg, 
9% yield). 1H NMR (600 MHz, DMSO-d6): 9.84-8.48, 7.90, 5.41, 4.53, 4.15, 3.82, 3.55, 
3.49 (PEG), 3.26, 3.20, 2.86-2.00, 1.59, 1.27.  
A similar procedure was followed using 2 kD mPEG-SVA to synthesize mPEG-cMAP-
PEGm with 2 kD blocks. For 2 kD PEG, a 10 kD MWCO centrifugal spin filter was used 
to isolate the triblock polymer.  
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Synthesis of 5-nitrophenylboronic acid-PEGm (5-nPBA-PEGm) (Scheme II.4).  
3-carboxyl-5-nitrophenylboronic acid (200 mg, 0.95 mmol, 1 equiv) was added to an 
oven-dried 2-necked 10 mL round bottom flask containing a dry stir bar. The flask was 
vented with argon and sealed with a rubber septum. Anhydrous tetrahydrofuran with BHT 
inhibitor (5 mL) was added to dissolve the boronic acid, followed by anhydrous DMF (14.7 
uL, 0.19 mmol, 0.2 equiv). The flask was cooled to 0oC in an ice-water bath. Oxalyl 
chloride (195.4 uL, 2.28 mmol, 2.4 equiv) was then added drop wise to the reaction 
mixture. The ice-water bath was removed after oxalyl chloride addition was complete, and 
the reaction continued stirring for 2 hours at room temperature, with an argon vent to allow 
for the escape of volatiles. Solvent and DMF was removed via rotary evaporator and then 
under vacuum for 2 days under dark to afford 3-acyl chloride-5-nitrophenyl boronic acid 
(217.5 mg, 100% yield) as a yellow solid.    
3-acyl chloride-5-nitrophenylboronic acid (27.5 mg, 0.12 mmol, 2 equiv) was added to 
an oven-dried 25 mL round bottom flask containing a dry stir bar. The flask was sealed 
with a rubber septum, vented with argon, and cooled to 0oC in an ice-water bath. 
Anhydrous dichloromethane (4 mL) was added to dissolve the boronic acid. 5 kD mPEG-
amine (300 mg, 0.06 mmol, 1 equiv) in an oven-dried 10 mL round bottom flask vented 
with argon, dissolved in anhydrous dichloromethane (5 mL) and diisopropylethylamine 
(DIPEA, 20.9 uL, 0.12 mmol, 2 equiv) dried with activated molecular sieves, was slowly 
added to the boronic acid solution. The reaction flask was left in the ice-water bath to 
slowly warm up to room temperature, and the reaction was stirred overnight under dark. 
The solvent and DIPEA was removed via rotary evaporator and then under vacuum for 2 
days under dark. The solid residue was reconstituted in 0.5 N HCl (5 mL) and stirred for 15 
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min. The resulting suspension was filtered through a 0.2 um Supor syringe filter, and the 
resulting clear solution was dialyzed with a 15 mL Amicon Ultra 3 kD spin filter against 
nanopure water until the pH was constant. The solution of polymer was concentrated to 3-4 
mL, filtered through a 0.2 um PVDF syringe filter into a pre-weighed 20 mL glass vial, and 
lyophilized to dryness to afford 5-nitrophenylboronic acid-PEGm (219.2 mg, 70% yield) 
as a fluffy white solid. 1H NMR (600 MHz, DMSO-d6): 8.89 (t, 1H), 8.72 (m, 1H), 8.68 
(m, 1H), 8.64 (m, 1H), 8.60 (s, 2H), 3.5 (s - PEG, 510H), 3.22 (s, 3H). 11B NMR (160 
MHz, 10 mM phosphate buffer, pH 7.4 in D2O): 11.26 (broad s). MALDI: 5825.5. 
Polymer Characterization 
1. Gel Permeation Chromatography. An Agilent 1100 HPLC with binary pump and 
injector was connected to a Tosoh TSKgel G3000PWXL-CP size exclusion column with 
Wyatt DAWN HELEOS light scattering and Wyatt Optilab Rex refractive index detection. 
Lyophilized polymer was dissolved at six different concentrations in 0.1 M NaNO3 and 
injected into the refractive index detector directly via a syringe pump for dn/dc 
determination. For absolute molecular weight determination by light scattering, 100 uL of 
polymer solution was injected onto the column and the detected polymer peak analyzed 
using ASTRA V software.  
2. TNBSA assay of cMAP for primary amines. The instructions provided by Thermo 
Scientific with the 2,4,6-trinitrobenzene Sulfonic Acid 5% w/v in methanol stock solution 
were followed, with modifications as described next. Briefly, cMAP and glycine were each 
dissolved in the reaction buffer and serially diluted for a concentration range of 2 to 0.0039 
mg/mL and 20 to 0.00195 mg/mL, respectively. 100 uL of each sample concentration and 
50 uL of TNBSA working solution were added to a 96-well plate in triplicates and briefly 
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shaken. The absorbance was read on a Tecan infinite M200 plate reader at a wavelength of 
335 nm, incubated at 37 degrees Celsius for 2 h, and read again. Glycine was used as a 
positive control. 
3. Polymer siRNA encapsulation assays. The ability of the cMAP polymers to encapsulate 
siRNA was analyzed using two methods: a gel retardation assay and a RiboGreen assay. 
For the gel retardation assay, increasing volumes of 0.5 mg/mL polymer was mixed with 1 
uL of 1 mg/mL siRNA at (+/-) charge ratios of 0, 0.5, 1, 1.5, 2, 2.5, 3, and 5 in water for a 
total volume of 15 uL. The mixtures were briefly vortexed, centrifuged down, and allowed 
to sit for 15 min at room temperature. 3 uL of 6X DNA loading dye was added to each 
mixture, which was then loaded onto a 1 wt% agarose gel and run at 95V for 1.5 h in 0.5x 
TBE buffer. The gel was imaged on a UVP BioDoc-It Imaging System.  
 The RiboGreen assay was performed in a similar manner to the gel retardation assay, 
except using increasing volumes of 0.1 mg/mL polymer and 1 uL of 0.1 mg/mL siRNA in 
water for a total volume of 100 uL in 96-well plate. To each of these mixtures, 100 uL of 
the Quant-iT RiboGreen RNA reagent working solution, prepared according to the kit’s 
protocol, was added. The plate was briefly shaken, incubated in the dark for 5 min at room 
temperature, and the fluorescence intensity read on a Tecan infinite M200 plate reader at an 
excitation wavelength of 480 nm and an emission wavelength of 520 nm. Measurements 
were done in triplicate. 
Nanoparticle formulation and characterization. 
1. Nanoparticle formulation. cMAP NPs were formulated by first mixing a 1:1 molar ratio 
of cMAP vicinal diols to 5-nPBA-PEGm (1 mg cMAP to 22 mg 5-nPBA-PEGm) in 10 
mM phosphate buffer pH 7.4, briefly vortexing, centrifuging down, and letting the mixture 
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sit for 15 min at room temperature. siRNA in an equivalent volume of RNAse-free water 
was then added at a 3:1 charge ratio of cMAP to siRNA, and at a concentration of up to 0.8 
mg/mL siRNA. cMAP-PEG copolymer, cMAP-PEG-cMAP triblock, and mPEG-cMAP-
PEGm triblock formulations were made in a similar fashion, though the charge ratio was 
varied from 3:1 down to a 1:1 charge ratio of polymer to siRNA, and at a concentration of 
up to 1 mg/mL siRNA. For formulations without any 5-nPBA-PEGm, the polymer and 
siRNA in equal volumes were simply mixed at an appropriate charge ratio. For injection 
into mice, 0.1 volumes of 10X phosphate buffered saline (PBS) were added to attain a 1X 
PBS solution, with a final concentration of 0.73 mg/mL siRNA. For the cMAP-PEG 
copolymer and mPEG-cMAP-PEGm NPs which were formulated in PBS, both the 
polymer and siRNA solutions were in PBS, and then mixed together; this was able to be 
directly injected into mice. For removal of excess components (i.e., polymer, PEG), the NP 
formulation was placed in a 0.5 mL 30 kD MWCO Amicon Ultra spin filter and dialyzed 
with PBS at 2,000 rpm for 10 min 5-10 times.   
2. Nanoparticle size and zeta potential. NP size was determined using two different 
methods: dynamic light scattering (DLS) and cryo-transmission electron microscopy 
(cryoTEM). DLS was performed on a Brookhaven Instruments Corporation (BIC) Zeta-
PALS with BIC Particle Sizing Software. The particles were diluted down to a 
concentration of 0.2 mg/mL siRNA or less, depending on the formulation, until a stable 
size was recorded for ten 1-minute measurements. The results of at least 10 measurements 
were averaged.  
CryoTEM imaging was performed on particles in solution that were frozen on R2/2 
Quantifoil grids in liquid ethane after blotting with filter paper using an FEI Mark IV 
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Vitrobot with a 2 s blot time (blot force 6) and a 1 s drain time. Images were collected on a 
Tecnai 120-keV transmission electron microscope equipped with a Gatan 2k x 2k 
UltraScan CCD camera and Serial EM automated software. Acquired images were 
analyzed using ImageJ software to measure NP diameter. 
 The NPs’ surface charge, or zeta potential, was measured using the same Zeta-PALS used 
for DLS, with the addition of a Brookhaven aqueous electrode assembly. 10 uL of particle 
formulation was mixed with 1.5 mL of either 10 mM phosphate buffer, pH 7.4 or 1 mM 
potassium chloride, pH 5.5 in a cuvette. The electrode was inserted into the cuvette and 
zeta potential measured using BIC PALS Zeta Potential Analyzer software with a target 
residual of 0.012. The results of at least 10 measurements were averaged. 
Nanoparticle Stoichiometry.   
1. Quantification of 5-nPBA-PEGm bound to NP. NPs were formulated with 5-nPBA-
PEGm and excess components were removed as described above. 50 uL of filtrate from the 
30 kD MWCO spin filter (containing excess components) were injected on an Agilent 1200 
HPLC with quaternary pump and autosampler connected to a Phenomenex Gemini C18 
reverse phase column and multiple wavelength detector. The absorbance at 254 nm was 
recorded and compared with a calibration curve of 5-nPBA-PEGm.   
2. Quantification of cationic polymer bound to NP. NPs were formulated in the absence of 
5-nPBA-PEGm. For cMAP, excess cationic polymer was removed from aggregated NPs as 
described above. The cationic polymer bound to the NP was directly quantitated by taking 
the retentate from the 30 kD MWCO spin filter containing the NPs, and disassembling and 
sequestering the siRNA using BcMagTM SAX (Strong Anion Exchange) magnetic beads 
(Bioclone Inc). 50 uL of the liquid containing cMAP was injected onto the GPC setup 
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described above and the amount of polymer bound to the NP was directly determined using 
the refractive index signal as compared to a cMAP calibration curve. For cMAP-PEG 
copolymer and mPEG-cMAP-PEGm, 50 uL of the formulation was injected onto the GPC 
setup described above. The refractive index signal corresponding to polymer not bound to 
the NP was recorded and compared with a calibration curve of the same cationic polymer. 
This amount was subtracted from the total amount of polymer used for the formulation to 
determine the percent of polymer bound to the NP.  
In vivo mouse pharmacokinetic (PK) studies. 
All animal studies were approved by the Institutional Animal Care and Use Committee 
at Caltech. NPs were formulated as described above, except 20% of the siRNA was 
substituted with a Cy3-fluorophore tagged siRNA. The NP formulation was injected 
intravenously via the mouse tail vein at a dose of 5 mg siRNA per kg mouse. The hind legs 
of Balb/c mice (Taconic and Jackson Labs) were shaved for blood collection from the 
saphenous vein in red top clot activator containing Sarstedt Microvette CB300 capillary 
tubes. Blood was collected at various time points starting at 2 min after NP injection, with 
up to six points per mouse. The tubes were centrifuged at 14,000xg for 15 min at 4oC and 
the serum at the top of the tube used for analysis of Cy3 fluorescence, with excitation 
wavelength 530 nm and emission wavelength 570 nm, as compared to a standard curve of 
the NP formulation in mouse serum. The fraction of Cy3-siRNA remaining in serum was 
calculated using the serum volume based on mouse weight and the amount of formulation 
injected. Data points are from 3 mice per formulation. 
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I. cMAP precursors: NMR and mass spectra 
Mucic acid dimethyl ester.  
Figure II.S1: 1H NMR Spectrum of mucic acid dimethyl ester. 
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N-boc protected mucic acid ethylenediamine.  
Figure II.S2: 1H NMR Spectrum of N-boc protected mucic acid ethylenediamine.  
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Figure II.S3: Electrospray Ionization (ESI) Mass Spectrum of N-boc protected mucic acid ethylenediamine. 
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Mucic acid ethylenediamine. 
Structure II.S1: Mucic Acid Ethylenediamine.  
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Figure II.S4: 1H NMR Spectrum of Mucic Acid Ethylenediamine in D2O. 
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Figure II.S5: 1H NMR Spectrum of Mucic Acid Ethylenediamine in DMSO.  
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Figure II.S6: 13C NMR Spectrum of Mucic Acid Ethylenediamine in DMSO. 
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Table II.S1: 1H and 13C NMR peak assignments for Mucic Acid Ethylenediamine.  
 1H in D2O Chemical 
Shift (ppm) 
1H in DMSO Chemical 
Shift (ppm) 
13C in DMSO Chemical 
Shift (ppm) 
Methylene A 3.04 2.85 36.76 
Methylene B 3.45 Covered by H2O 39.25 
Methyne A 3.90 3.82 70.98 
Methyne B 4.32 4.15 71.39 
Hydroxyl A Not observed 4.55 N/A 
Hydroxyl B Not observed 5.30 N/A 
Amide and amines Not observed 7.83, 7.97 N/A 
Amide Carbonyl 
carbon 
N/A N/A 174.78 
 
 
 
 
  
  
 
60
Figure II.S7: ESI Mass Spectrum of Mucic Acid Ethylenediamine.  
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2. Dimethyl Suberimidate (DMS) and DMS hydrolysis: NMR and mass spectra 
Dimethyl Suberimidate (DMS). 
Dimethyl suberimidate, the charged monomer with which mucic acid ethylenediamine was 
polymerized, was used as purchased from Thermo Scientific or Sigma-Aldrich. In order to assign 
peaks in the proton and carbon spectra of cMAP, NMR spectra of dimethyl suberimidate were 
acquired. Both proton and carbon NMR spectra of DMS were more complex than expected, 
suggesting that some hydrolysis was present in a freshly opened bottle. For example, the three 
protons of the methoxy peak for DMS have a chemical shift of 4.08 ppm, which completely shift to 
3.55 ppm in a sample hydrolyzed in D2O. Similarly, the methylene peak adjacent to the methoxy 
(methylene A) has a chemical shift of 2.64 ppm in DMS, which when hydrolyzed shifts more 
upfield to 2.25 ppm. 
Additionally there was the presence of dimethyl suberimidate containing one methoxy group 
which was completely hydrolyzed to a carboxylate group, as determined by both the ESI mass 
spectrum peak at m/z of 187.9 and the 1H-13C HMBC NMR spectrum. The methylene A peak in this 
case was present on 1H NMR with a chemical shift of 2.01 ppm.  
 
Table II.S2: 1H NMR peak assignments for Dimethyl Suberimidate with varying degrees of 
hydrolysis.  
 Methoxy Methylene A Methylene B Methylene C 
Dimethyl suberimidate 4.08 2.64 1.60 1.30 
Dimethyl suberimidate hydrolyzed to 
the dimethyl ester 
3.55 2.25 1.45 1.20 
Dimethyl suberimidate hydrolyzed to 
carboxylate 
None 2.01 1.46 1.20 
 
Structure II.S2: Dimethyl Suberimidate. 
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Structure II.S3: Dimethyl Suberimidate hydrolyzed to the dimethyl ester.  
 
 
Structure II.S4: Dimethyl Suberimidate with one side hydrolyzed to the carboxylate. 
 
 
 
methoxy 
methoxy 
M
et
hy
le
ne
 A 
M
et
hy
le
ne
 A 
M
et
hy
le
ne
 B 
M
et
hy
le
ne
 B 
M
et
hy
le
ne
 C 
M
et
hy
le
ne
 C 
Dimethyl Suberimidate ‐ hydrolyzed 
 
 
methoxy 
carboxylate 
M
et
hy
le
ne
 A 
M
et
hy
le
ne
 A 
M
et
hy
le
ne
 B 
M
et
hy
le
ne
 B 
M
et
hy
le
ne
 C 
M
et
hy
le
ne
 C 
Dimethyl Suberimidate – hydrolyzed to carboxylate 
  
 
63
Figure II.S8: 1H NMR Spectrum of Dimethyl Suberimidate.  
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Figure II.S9: 13C NMR Spectrum of Dimethyl Suberimidate. 
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Figure II.S10: 1H-13C HMBC Spectrum of Dimethyl Suberimidate. 
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Figure II.S11: 1H NMR Spectrum of Dimethyl Suberimidate hydrolyzed to the dimethyl ester.  
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Figure II.S12: 13C NMR Spectrum of Dimethyl Suberimidate hydrolyzed to the dimethyl ester. 
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Figure II.S13: ESI Mass Spectrum of Dimethyl Suberimidate hydrolyzed to the dimethyl ester (m/z 202.9). Dimethyl suberimidate with one 
end hydrolyzed to the carboxylate is the peak with m/z 187.9. Dimethyl suberimidate with both ends hydrolyzed to the carboxylate is the 
peak with m/z 170.8.  
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3. cMAP: NMR spectra 
cationic Mucic Acid Polymer (cMAP). 
Structure II.S5: cMAP. 
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Figure II.S14: 1H NMR Spectrum of cMAP.  
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Table II.S3: 1H NMR peak assignments for cMAP. 
 
 
 Originating Monomer 1H in DMSO Chemical Shift 
(ppm) 
Amidine Mucic acid and dimethyl 
suberimidate 
9.65 
Amidine Mucic acid and dimethyl 
suberimidate 
9.28 
Amidine Mucic acid and dimethyl 
suberimidate 
8.78 
Amide Mucic acid and dimethyl 
suberimidate 
7.92 
Hydroxyl B Mucic acid 5.42 
Hydroxyl A Mucic acid 4.56 
Methyne B Mucic acid 4.18 
Methyne A Mucic acid 3.84 
Methoxy (end group) Dimethyl suberimidate 3.58 
Methylene B Mucic acid 3.40 
Methylene A Mucic acid 3.29 
Methylene A (end group) Mucic acid 2.87 
Methylene A Dimethyl suberimidate 2.42 
Methylene A (end group) Dimethyl suberimidate 2.30 
Methylene A (end group) Dimethyl suberimidate – hydrolyzed 
to carboxylate 
2.03 
Methylene B Dimethyl suberimidate 1.63 
Methylene B (end group) Dimethyl suberimidate 1.52 
Methylene C Dimethyl suberimidate 1.30 
  
 
72
Figure II.S15: 13C NMR Spectrum of cMAP. 
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Table II.S4: 13C NMR peak assignments for cMAP. 
 Originating Monomer 13C in DMSO Chemical Shift 
(ppm) 
Amide Carbonyl Mucic acid  174.29 
Methoxy Carbonyl (end 
group) 
Dimethyl suberimidate 173.47 
Amide Carbonyl (end group) Mucic acid 171.03 
Amidine Carbonyl Dimethyl suberimidate 167.79 
  166.82 
Methyne B Mucic acid 70.83 
Methyne A Mucic acid 70.61 
Methoxy (end group) Dimethyl suberimidate 51.31 
Methylene A Mucic acid 41.73 
Methylene B Mucic acid 36.37 
Methylene A Dimethyl suberimidate 32.15 
Methylene C Dimethyl suberimidate 27.48 
Methylene B Dimethyl suberimidate 26.31 
   
Methylene A (end group) Dimethyl suberimidate – 
hydrolyzed to carboxylate 
35.06 
Methylene A (end group) Dimethyl suberimidate 33.22 
Methylene B (end group) Dimethyl suberimidate 24.23 
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Figure II.S16: 1H-13C HSQC Spectrum of cMAP used to correlate proton and carbon chemical shifts. 
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Table II.S5: 1H-13C HSQC NMR peak assignments for cMAP. 
 Originating Monomer 1H Chemical 
Shift (ppm) 
13C Chemical 
Shift (ppm) 
Methyne B Mucic acid  4.18 70.85 
Methyne A Mucic acid 3.84 70.60 
Methoxy (end group) Dimethyl suberimidate 3.58 51.27 
Methylene A Mucic acid 3.29 41.69 
DMSO (Solvent) 2.50 39.68 
Methylene A (end group) Mucic acid 2.87 38.90 
Methylene B Mucic acid 3.39 36.34 
Methylene A Mucic acid 3.29 36.32 
Methylene A (end group) Dimethyl suberimidate 
(hydrolyzed to carboxylate) 2.04 35.06 
Methylene A (end group) Dimethyl suberimidate 2.30 33.22 
Methylene A Dimethyl suberimidate 2.42 32.16 
Methylene C Dimethyl suberimidate 1.30 27.48 
Methylene B Dimethyl suberimidate 1.63 26.25 
Methylene B (end group) Dimethyl suberimidate 1.52 24.23 
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Figure II.S17: 1H-1H COSY Spectrum of cMAP used to correlate protons to nearby protons more than one bond away.  
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Table II.S6: 1H-1H COSY NMR peak assignments for cMAP. 
Correlation 1H Chemical Shift 
(ppm) 
1H Chemical Shift 
(ppm) 
Methyne B Hydroxyl B 4.19 5.41 
Methyne B Methyne A 3.86 4.18 
Methyne A Hydroxyl A 3.86 4.55 
Methylene B (mucic 
acid) 
Amide 3.41 7.91 
Methylene B (mucic 
acid) 
Methylene A (end group, 
mucic acid) 3.38 2.87 
Methylene A (mucic 
acid) 
Amide 3.21 7.91 
Methylene A (end 
group, mucic acid) 
Methylene B (mucic 
acid) 2.88 3.39 
Methylene B (DMS) Methylene A (DMS) 1.64 2.43 
Methylene B (DMS) Methylene C (DMS) 1.64 1.30 
Methylene B (end 
group, DMS) 
Methylene A (end group, 
DMS) 1.53 2.31 
Methylene B (end 
group, DMS) 
Methylene A (end group, 
DMS hydrolyzed to 
carboxylate) 
1.49 2.05 
Methylene C (DMS) Methylene B (DMS) 1.31 1.63 
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Figure II.S18: 1H-13C HMBC Spectrum of cMAP used to correlate protons to carbons more than one bond away.  
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Table II.S7: 1H-13C HMBC NMR peak assignments for cMAP. 
Correlation 13C Chemical 
Shift (ppm) 
1H Chemical 
Shift (ppm) 
Carbonyl Carbon (DMS hydrolyzed 
to carboxylate) 
Methylene A (end group, DMS 
hydrolyzed to carboxylate) 174.53 2.04 
Amide Carbonyl (mucic acid) Methylene B (mucic acid) 174.36 3.38 
Amide Carbonyl (mucic acid) Hydroxyl B (mucic acid) 174.35 5.41 
Amide Carbonyl (mucic acid) Amide proton (mucic acid) 174.32 7.91 
Amide Carbonyl (mucic acid) Methylene A (mucic acid) 174.31 3.28 
Amide Carbonyl (mucic acid) Methyne B (mucic acid) 174.17 4.18 
Methyl ester carbonyl (DMS) Methoxy (DMS) 173.49 3.58 
Methyl ester carbonyl (DMS) Methylene A (end group, DMS) 173.48 2.30 
Methyl ester carbonyl (DMS) Methylene B (end group, DMS) 173.44 1.52 
Amide Carbonyl (end group) Methylene B (end group, mucic 
acid) 171.09 2.38 
Amidine Carbonyl Methylene A (DMS) 167.84 2.41 
Amidine Carbonyl Methylene B (DMS) 167.84 1.63 
Methyne B (mucic acid) Methyne A (mucic acid) 70.86 3.84 
Methyne B (mucic acid) Hydroxyl B (mucic acid) 70.83 5.41 
Methyne A (mucic acid) Methyne B (mucic acid) 70.71 4.18 
Methyne A (mucic acid) Hydroxyl A (mucic acid) 70.71 4.56 
Methylene A (mucic acid) Methylene B (mucic acid) 41.80 3.39 
Methylene A (mucic acid) Methylene A (mucic acid) 41.77 3.27 
DMSO DMSO 39.71 2.50 
Methylene B (mucic acid) Methylene A (end group, mucic 
acid) 36.50 2.87 
Methylene B (mucic acid) Amide Proton (mucic acid) 36.42 7.91 
Methylene B (mucic acid) Methylene A (mucic acid) 36.42 3.30 
Methylene A (end group, DMS) Methylene B (end group, DMS) 33.33 1.53 
Methylene A (DMS) Methylene B (DMS) 32.24 1.63 
Methylene A (DMS) Methylene C (DMS) 32.24 1.30 
Methylene B (end group, DMS) Methylene A (end group, DMS 
hydrolyzed to carboxylate) 28.26 2.05 
Methylene B (end group, DMS) Methylene A (end group, DMS) 28.02 2.30 
Methylene B (end group, DMS) Methylene B (end group, DMS) 28.00 1.52 
Methylene C (DMS) Methylene C (DMS) 27.61 1.29 
Methylene C (DMS) Methylene A (DMS) 27.61 2.41 
Methylene C (DMS) Methylene B (DMS) 27.57 1.63 
Methylene B (DMS) Methylene C (DMS) 26.41 1.29 
Methylene B (DMS) Methylene A (DMS) 26.34 2.42 
Methylene C (end group, DMS 
hydrolyzed to carboxylate) 
Methylene A (end group, DMS 
hydrolyzed to carboxylate) 25.00 2.04 
Methylene B (end group, DMS) Methylene A (end group, DMS) 24.33 2.30 
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Figure II.S19: 1H stacked DOSY Spectrum of cMAP showing that all the peaks on the cMAP polymer, including the small end group peaks, 
diffuse at the same rate. H2O and DMSO diffuse much faster as shown by their quick disappearance after the first spectrum (bottom). 
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Figure II.S20: 1H transformed DOSY Spectrum of cMAP showing that all the peaks on the cMAP polymer, including the small end group 
peaks, diffuse at the same rate. H2O and DMSO diffuse much faster. 
82 
 
 
 
4. cMAP: End group ratios 
Table II.S8: Ratios of amine: methoxy: carboxylate end groups in 8 batches of cMAP by 
comparing NMR integrations.  
Batch % amine % methoxy % carboxylate 
11 52.52 33.96 13.52 
12 38.45 54.15 7.40 
13 48.58 45.89 5.53 
14 47.07 45.71 7.22 
15 47.75 51.17 1.08 
16 55.58 37.14 7.28 
17 63.22 29.92 6.86 
18 38.76 39.50 21.75 
Average 48.99 ± 2.93  42.18 ± 2.99 6.22 ± 2.20 
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5. cMAP-PEG copolymer: NMR spectra 
Figure II.S21: 1H NMR of cMAP-PEG5k copolymer. The large resonance at 3.5 ppm corresponds to the PEG block. 
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Figure II.S22: 1H-13C HSQC spectrum of cMAP-PEG5k copolymer. 
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Figure II.S23: 1H DOSY transformed spectrum of cMAP-PEG5k copolymer. 
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Figure II.S24: 1H NMR of cMAP-PEG3.4k copolymer. 
 
 
  
 
87
Figure II.S25: 13C NMR of cMAP-PEG3.4k copolymer. 
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Figure II.S26: 1H-13C HSQC spectrum of cMAP-PEG3.4k copolymer. 
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Figure II.S27: 1H DOSY transformed spectrum of cMAP-PEG3.4k copolymer. 
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6. cMAP-PEG copolymer fractionation yields 
A reaction was started with 50 mg of cMAP and 16.5 mg di-SPA-PEG3.4k. After stirring for 24 
hours, the reaction was diluted in water and filtered through sequentially smaller molecular weight 
cutoff (MWCO) Amicon centrifugal spin filters. Some material loss does occur onto the filter 
membrane and during transfer steps, but the retained material on each of these filters after 
lyophilization to dryness is shown in the table below. A significant amount of high molecular 
weight cMAP-PEG3.4k copolymer is formed in the synthesis due to the presence of diamine end 
groups on cMAP.  
Table II.S9: Retained mass on each MWCO filter after fractionating crude cMAP-PEG3.4k 
copolymer. 
MWCO (kD) Mass (mg) Comment 
100 9.5 High molecular weight cMAP-PEG copolymer 
50 3.4 High molecular weight cMAP-PEG copolymer 
30 5 High molecular weight cMAP-PEG copolymer 
20 12.3
10 10.6 Pure cMAP-PEG-cMAP triblock 
3 13.2 Unreacted cMAP, excess PEG 
Total 54
 
Similarly, a reaction was started with 50 mg of cMAP and 22.3 mg di-SVA-PEG5k. After stirring 
for 24 hours, the reaction was diluted in water and filtered through sequentially smaller molecular 
weight cutoff (MWCO) Amicon centrifugal spin filters. Some material loss does occur onto the 
filter membrane and during transfer steps, but the retained material on each of these filters after 
lyophilization to dryness is shown in the table below. A significant amount of higher molecular 
weight cMAP-PEG5k copolymer is formed in this synthesis similar to the analogous reaction 
above.  
Table II.S10: Retained mass on each MWCO filter after fractionating crude cMAP-PEG5k 
copolymer. 
MWCO (kD) Mass (mg) Comment 
30 18.3 High molecular weight cMAP-PEG copolymer 
20 20.8
10 12 Pure cMAP-PEG-cMAP triblock + cMAP-PEG diblock 
Total 51.1
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7. mPEG-cMAP-PEGm NMR spectra 
Figure II.S28: 1H NMR of mPEG5k-cMAP-PEG5km. The resonance at 3.5 ppm corresponds to the PEG blocks, and the resonance at 3.2 
ppm is that of the methoxy end group on PEGm. 
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Figure II.S29: 1H-13C HSQC of mPEG5k-cMAP-PEG5km. 
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Figure II.S30: 1H DOSY transform of mPEG5k-cMAP-PEG5km. 
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Figure II.S31: 1H NMR of mPEG2k-cMAP-PEG2km. 
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Figure II.S32: 1H-13C HSQC of mPEG2k-cMAP-PEG2km. 
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Figure II.S33: 1H DOSY transform of mPEG2k-cMAP-PEG2km. 
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8. 5-nitrophenylboronic acid-PEGm NMR and MALDI spectra 
Figure II.S34: 1H NMR of 5-nPBA-PEGm. 
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Figure II.S35: 1H DOSY of 5-nPBA-PEGm showing that the 5-nitrophenylboronic acid group is attached to PEGm by the downfield 
protons’ persistence with PEG throughout the gradient sequence (compared to DMSO and H2O, which disappear after the first gradients 
applied). 
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Figure II.S36: 1H DOSY transform of 5-nPBA-PEGm showing that the downfield 5-nitrophenylboronic acid peaks diffuse at the same rate 
as the PEG peaks. 
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Figure II.S37: 11B NMR of 5-nPBA-PEGm. 11.26 ppm is the boronic acid peak. 19.54 ppm is boric acid (impurity). 
 
Figure II.S38: MALDI mass spectrum of 5-nPBA-PEGm. 
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9. GPC: cMAP individual batch MW. 
Table II.S11: Gel Permeation Chromatography Analysis of cMAP Batches.  
Sample Mn Mw Mw/Mn (PDI) 
cMAP-DP11 5323 6068 1.14 
cMAP-DP12 5213 5839 1.12 
cMAP-DP13 5936 6365 1.07 
cMAP-DP14 5747 5940 1.03 
cMAP-DP15 5050 5568 1.10 
cMAP-DP16 6102 6357 1.04 
cMAP-DP17 7712 8235 1.07 
cMAP-DP18 7313 7524 1.03 
cMAP-DP19 8353 8984 1.08 
Values are reported as the average of 3 runs. 
 
10. GPC: other PEG length copolymer and triblock MW. 
Table II.S12: GPC Analysis of cMAP copolymers and triblocks (other than 5 kD PEG 
reported in main article text).  
Polymer dn/dc (mL/g) Mn (kD) Mw (kD) PDI (Mw/Mn) 
cMAP-PEG3.4k Copolymer 0.1660 128.30 289.25 2.27 
cMAP-PEG3.4k -cMAP 0.1660 used (not 
for pure 
triblock) 
12.89 14.20 1.10 
cMAP-PEG5k-cMAP 0.1660 used (not 
for pure 
triblock) 
24.17 26.84 1.11 
mPEG2k-cMAP-PEG2km 0.1654 9.75 9.81 1.01 
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11. siRNA encapsulation: Gel Retardation images 
Figure II.S39. cMAP gel retardation showing complete siRNA encapsulation at a charge ratio 
of 1+/-.  
 
 
Figure II.S40. cMAP-PEG3.4k copolymer gel retardation assay showing siRNA encapsulation 
at a charge ratio of 1+/- . 
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Figure II.S41. cMAP-PEG5k copolymer gel retardation assay showing siRNA encapsulation 
at a charge ratio of 2+/- . 
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12. siRNA encapsulation: RiboGreen comparing PEG lengths for copolymer and triblock 
Figure II.S42. cMAP-PEG copolymer RiboGreen assay showing siRNA encapsulation by a 
charge ratio of 3+/- for 3.4k and 5k PEG blocks. 
 
Figure II.S43. mPEG-cMAP-PEGm triblock RiboGreen assay showing siRNA encapsulation 
by a charge ratio of 3+/- for 2k and 5k PEG blocks. 
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13. cMAP siRNA NP Salt Stability 
Figure II.S44. Without PEG, the cMAP-siRNA NP is unstable once in 1X PBS, but is stable 
for 2 days when 5-nPBA-PEGm is used to stabilize the NP. 
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14. cMAP-PEG-cMAP pure triblock siRNA NP Salt Stability 
Table II.S13: NPs formed without extra 5-nPBA-PEGm using cMAP-PEG-cMAP triblock 
isolated from cMAP-PEG copolymer aggregates in 1X PBS, but is stable when at least one 
PEG per 2 diol groups is added to the formulation. The average sizes of the data presented in 
the following figures are shown.  
Formulation  10 mM phosphate buffer PBS 
Avg. size (nm) Avg. size (nm) 
3.4k triblock, 1:1, 0 PEG 176.6 ± 1.0 aggregates 
3.4k triblock, 1:1, 0.5 PEG 100.1 ± 0.8 57.9 ± 0.9
3.4k triblock, 1:1, 1 PEG 149.5 ± 1.6 56.5 ± 1.5
3.4k triblock, 1:1, 2 PEG 85.9 ± 2.0 74.5 ± 3.4
3.4k triblock, 3:1, 0 PEG 392.3 ± 5.0 aggregates 
3.4k triblock, 3:1, 0.5 PEG 42.8 ± 2.0 47.3 ± 2.0
3.4k triblock, 3:1, 1 PEG 61.3 ± 2.3 55.7 ± 1.2
3.4k triblock, 3:1, 2 PEG 115.9 ± 11.4 96.6 ± 1.6
5k triblock, 1:1, 0 PEG 165.2 ± 4.7 aggregates 
5k triblock, 1:1, 0.5 PEG 141.3 ± 5.2 99.8 ± 3.8
5k triblock, 1:1, 1 PEG 109.2 ± 3.6 97.5 ± 4.2
5k triblock, 1:1, 2 PEG 179.1 ± 19.9 143.5 ± 5.4
 
Figure II.S45. Without added 5-nPBA-PEGm, the cMAP-PEG3.4k-cMAP siRNA NP 
formulated at a 1+/- charge ratio aggregates once in 1X PBS, but is stable when at least one 5-
nPBA-PEGm per two diol groups (0.5 PEG) on cMAP is added to the formulation. 
 
 
 
 
 
 
0
100
200
300
400
500
600
700
800
900
‐10 ‐5 0 5 10
3k triblock, 1:1, 0 PEG
3k triblock, 1:1, 0.5 PEG
3k triblock, 1:1, 1 PEG
3k triblock, 1:1, 2 PEG
108 
 
 
 
Figure II.S46. Without added 5-nPBA-PEGm, the cMAP-PEG3.4k-cMAP siRNA NP 
formulated at a 3+/- charge ratio aggregates once in 1X PBS, but is stable when at least one 5-
nPBA-PEGm per two diol groups (0.5 PEG) on cMAP is added to the formulation.
 
 
Figure II.S47. Without added 5-nPBA-PEGm, the cMAP-PEG5k-cMAP siRNA NP 
formulated at a 1+/- charge ratio aggregates once in 1X PBS, but is stable when at least one 5-
nPBA-PEGm per two diol groups (0.5 PEG) on cMAP is added to the formulation.
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15. DLS Nanoparticle Size Distributions 
Figure II.S48: Lognormal size distribution by DLS for the cMAP + 5-nPBA-PEGm NP. 
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Figure II.S49: Lognormal size distribution by DLS for the cMAP-PEG copolymer NP. 
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Figure II.S50: Lognormal size distribution by DLS for the cMAP-PEG copolymer + 5-nPBA-PEGm NP. 
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Figure II.S51: Lognormal size distribution by DLS for the mPEG-cMAP-PEGm NP. 
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Figure II.S52: Lognormal size distribution by DLS for the mPEG-cMAP-PEGm + 5-nPBA-PEGm NP. 
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16. CryoTEM Nanoparticle Size Distributions and additional images 
Figure II.S53: Size distribution by CryoTEM for the cMAP + 5-nPBA-PEGm NP. 
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Figure II.S54: Additional CryoTEM images for the cMAP + 5-nPBA-PEGm NP. 
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Figure II.S55: Size distribution by CryoTEM for the cMAP-PEG copolymer NP. 
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Figure II.S56: Additional CryoTEM images for the cMAP-PEG copolymer NP. 
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Figure II.S57: Size distribution by CryoTEM for the cMAP-PEG copolymer + 5-nPBA-
PEGm NP. 
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Figure II.S58: Additional CryoTEM images for the cMAP-PEG copolymer + 5-nPBA-PEGm 
NP. 
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Figure II.S59: Size distribution by CryoTEM for the mPEG-cMAP-PEGm NP.  
 
 
Figure II.S60: Additional CryoTEM images for the mPEG-cMAP-PEGm NP.  
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Figure II.S61: Size distribution by CryoTEM for the mPEG-cMAP-PEGm + 5-nPBA-PEGm 
NP.  
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Figure II.S62: Additional CryoTEM images for the mPEG-cMAP-PEGm + 5-nPBA-PEGm 
NP.  
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17. Phamacokinetics of mPEG-cMAP-PEGm NP in Balb/c vs. nude mice 
Figure II.S63: The circulation time of the mPEG-cMAP-PEGm siRNA NP is similar in Balb/c 
and nude mice. n=3 mice. 
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18. Gel images of mPEG-cMAP-PEGm NP in mouse serum 
Figure II.S64: This gel shows mPEG-cMAP-PEGm NPs with and without 5-nPBA-PEGm in 
mouse serum. The samples are run on a 0.5% agarose gel in Tris-Borate-EDTA buffer (pH 8) 
at 90V, and are detected by the Cy3 fluorophore labeled siRNA on a Typhoon gel scanner 
with laser excitation 532 nm, emission 580 nm. Lanes are labeled as follows. This shows that 
the NPs shift further down the gel due to protein adsorption but are intact in mouse serum. 
SDS dissociates the nanoparticle allowing the siRNA to run down the gel. 
1. mPEG-cMAP-PEGm NP  
2. mPEG-cMAP-PEGm NP in mouse serum 
3. mPEG-cMAP-PEGm NP in mouse serum + SDS 
4. mPEG-cMAP-PEGm + 5-nPBA-PEGm NP 
5. mPEG-cMAP-PEGm + 5-nPBA-PEGm NP in mouse serum 
6. mPEG-cMAP-PEGm + 5-nPBA-PEGm NP in mouse serum + SDS 
7. siRNA in mouse serum 
8. siRNA in mouse serum + SDS 
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Figure II.S65: A 0.5% agarose gel (made as described in Figure II.S64) is detected by 
ethidium bromide intercalating siRNA on a Biodocit gel imager. Lanes are labeled as follows. 
SDS dissociates the NP so the siRNA runs down the gel. This shows that the mPEG-cMAP-
PEGm NP is intact in mouse serum, including in serum after 20 minutes of circulation post-
injection. 
1. Mouse Serum 
2. Mouse Serum + SDS 
3. siRNA 
4. siRNA + SDS 
5. mPEG-cMAP-PEGm NP 
6. mPEG-cMAP-PEGm NP + SDS 
7. Serum collected at 20 min after mPEG-cMAP-PEGm NP injection 
8. Serum collected at 20 min after mPEG-cMAP-PEGm NP injection + SDS 
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Figure II.S66: This is the same gel as in Figure II.S65, but detected by the Cy3 fluorophore 
labeled siRNA on a Typhoon gel scanner with laser excitation 532 nm, emission 580 nm. 
Lanes are labeled as follows. SDS dissociates the NP. The bands detected by fluorescence line 
up well with the bands detected by ethidium bromide staining. This shows that the mPEG-
cMAP-PEGm NP is intact in mouse serum, including in serum after 20 minutes of circulation 
after injection.  
1. Mouse Serum 
2. Mouse Serum + SDS 
3. siRNA 
4. siRNA + SDS 
5. mPEG-cMAP-PEGm NP 
6. mPEG-cMAP-PEGm NP + SDS 
7. Serum collected at 20 min after mPEG-cMAP-PEGm NP injection 
8. Serum collected at 20 min after mPEG-cMAP-PEGm NP injection + SDS 
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Figure II.S67: This gel is detected by the Cy3 fluorophore labeled siRNA on a Typhoon gel 
scanner with laser excitation 532 nm, emission 580 nm. Lanes are labeled as follows. SDS 
dissociates the NP. This shows that the mPEG-cMAP-PEGm NP is intact in mouse serum, 
including in serum after 20 minutes of circulation after injection.  
1. Mouse Serum 
2. mPEG-cMAP-PEGm NP 
3. mPEG-cMAP-PEGm NP in mouse serum 
4. mPEG-cMAP-PEGm NP in mouse serum + SDS 
5. Serum collected at 20 min after mPEG-cMAP-PEGm NP injection 
6. siRNA 
7. siRNA in mouse serum 
8. siRNA in mouse serum + SDS 
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C h a p t e r  3  
Lack of in vivo antibody dependent cellular cytotoxicity with 
antibody containing gold nanoparticles 
This chapter has been published as: 
Ahmed, M., Pan, D.W., and Davis, M.E. Lack of in vivo antibody dependent cellular 
cytotoxicity with antibody containing gold nanoparticles. Bioconjugate Chem. 2015, 26, 
812-816. doi : 10.1021/acs.bioconjchem.5b00139 
 
Abstract: 
Antibody-dependent cellular cytotoxicity (ADCC) is a cytolytic mechanism that can elicit 
in vivo antitumor effects, and can play a significant role in the efficacy of antibody 
treatments for cancer. Here, we prepared cetuximab, panitumumab, and rituximab 
containing gold nanoparticles, and investigated their ability to produce an ADCC effect 
in vivo. Cetuximab treatment of EGFR-expressing H1975 tumor xenografts showed 
significant tumor regression due to the ADCC activity of the antibody in vivo, while the 
control antibody, panitumumab, did not. However, all three antibody containing 
nanoparticles are not able to suppress tumor growth in the same in vivo mouse model. 
The antibody containing nanoparticles localized in the tumors and did not suppress the 
immune function of the animals, so the lack of tumor growth suppression of the 
cetuximab containing nanoparticle suggests that immobilizing antibodies onto a 
nanoparticle significantly decreases the ability of the antibody to promote an ADCC 
response. 
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Introduction 
A number of targeted nanoparticles have now been investigated in human clinical 
trials.1,2 At this time, there is no clinical example of a full antibody targeted nanoparticle. 
Since immunotherapies are finding increased importance in cancer, the use of a full 
antibody targeted nanoparticle could be interesting. This type of therapeutic could 
potentially elicit immunotherapeutic functions such as antibody-dependent cellular 
cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in addition to 
targeting the nanoparticles to cancer cell surface receptors and blocking cell signaling from 
those receptors. While antibody fragments can elicit the latter two functions, they do not 
stimulate immunotherapeutic pathways.  
Numerous preclinical studies utilize full antibody targeted nanoparticles. However, 
only one investigation has specifically explored the possibility of stimulating an ADCC 
response.3 Rituximab is an IgG1 antibody that binds to the CD20 receptor, and rituximab 
containing lipid nanoparticles were investigated both in vitro and in vivo for their ability to 
elicit ADCC. Rituximab nanoparticles exhibited ADCC cell lysis in vitro, but the observed 
in vivo therapeutic efficacy of the antibody-lipid conjugates could not be ascribed to ADCC 
function.3   
Natural killer (NK) cell based immunotherapies have shown considerable potential 
for cancer therapy in the clinic.4,5 ADCC is an immune mechanism dependent on the 
activity of CD56dim CD16+  NK cells. Transgenic mouse models deficient in the CD16 
receptor, also known as the activating Fcγ (FcγRIIIa/CD16) receptor are unable to inhibit 
tumor growth in the presence of IgG1 antibodies that primarily work by inducing an ADCC 
response.6 Various types of peripheral blood mononuclear cells (PBMCs) have been 
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studied for their anti-tumor ADCC activities in vitro, and NK cells have been found to 
induce the most potent ADCC response.7  
Cetuximab and panitumumab are two antibodies that specifically target the 
epidermal growth factor receptor I (EGFRI), and possess similar EGFR binding 
affinities.8,9 In contrast to cetuximab, panitumumab is not able to elicit an ADCC 
response.10  Here, we address the question as to whether full antibodies that are displayed 
on the surface of nanoparticles can elicit an ADCC response in vivo. In order to observe 
antitumor effects that would be specific to an ADCC response, we selected a lung cancer 
cell line (H1975) that does not show any in vitro anti-proliferative effects upon treatment 
with either cetuximab or panitumumab. Thus, any anti-tumor behavior observed in vivo can 
be ascribed to an ADCC function (positive for cetuximab and negative for panitumumab). 
Since gold nanoparticles will not have antitumor effects, antibody containing gold 
nanoparticles were prepared using cetuximab, panitumumab, and rituximab (negative 
control), and investigated in vivo with xenografts of the EGFR-expressing H1975 lung 
cancer cell line in athymic nude mice. While cetuximab alone reveals significant ADCC 
dependent anti-tumor behavior, the lack of anti-tumor function with the cetuximab 
containing gold nanoparticles shows that the ADCC function from antibody containing 
nanoparticles maybe be difficult to achieve in vivo. 
Results and Discussion 
Assembly of antibody containing gold nanoparticle: 
The assembly of the antibody containing gold nanoparticles was accomplished as follows.  
Conjugates of polyethylene glycol (PEG) and cetuximab, panitumumab, and rituximab 
were prepared by antibody reaction with NHS-PEG-OPSS (reacts with amine groups of 
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antibodies to yield antibody-PEG conjugates through amide bond formation (Scheme 
III.1)). High pressure liquid-phase chromatography (HPLC) purified antibody-PEG 
conjugates were analyzed by MALDI-TOF-MS and confirmed to be mono-PEGylated. 50 
nm gold nanoparticles (AuNPs) were then functionalized with the mono-PEGylated 
antibody-PEG conjugates and mPEG-SH (Scheme III.1), and were analyzed for their 
average hydrodynamic diameter and surface charge (Table III.1). The quantitative number 
of antibodies per nanoparticle was obtained using two different methods. The results from 
the two were consistent with each other (Supporting Information, Table III.S1), and the 
mean values obtained from the two methods are presented in Table III.1. PEGylated 
AuNPs containing ca. 15-20 antibodies per particle have negative zeta potential values and 
are stable in deionized water and saline solutions. 
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Scheme III.1: Assembly of antibody containing gold nanoparticles. A) Antibodies first 
reacted with the NHS-PEG-OPSS and then purified. B) In a second step, the antibody 
conjugates were then combined with mPEG-SH and assembled onto the surface of the gold 
nanoparticles.  
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Sample Size (nm) in PBS 
by DLSa 
Size (nm) by 
NTAb 
Zeta Potential 
(mV)c 
Number of 
Antibodies 
on surface 
Cetuximab-AuNPs 79.5±4 72.6±0.4 -18.7±1 19±6 
Panitumumab-
AuNPs 72.8±1.9 74.8±1.6 -19.2±2.1 20±5 
Rituximab-AuNPs 82.5±5.5 73.2±1.3 -20.5±1.7 17±3 
mPEG-AuNPs 64.1±9.5 72.3±0.9 -19.4±4.3 0 
Table III.1: Properties of antibody containing AuNPs. aDLS (Dynamic Light Scattering), 
measured in phosphate buffered saline (PBS). bNTA (Nanoparticle Tracking Analysis), 
measured in deionized water). cMeasured in 1 mM KCl solution in deionized water. 
 
In vitro Cytotoxicity of Antibodies and Antibody-functionalized Gold Nanoparticles: 
The H1975 cell line harbors a double mutation in the kinase domain of EGFR that 
makes these cells insensitive to treatments with tyrosine kinase inhibitors (TKIs). Also, 
EGFR specific monoclonal antibodies do not produce anti-proliferative effects with the 
H1975 cells in vitro.11 The in vivo anti-tumor effects observed with cetuximab are thought 
to be associated with the ADCC activity of the antibody. Here, the anti-proliferative effects 
of the antibodies cetuximab, panitumumab, and rituximab, and the corresponding antibody 
containing AuNPs were investigated with the EGFR-TKI resistant H1975 lung cancer cell 
line via a cell viability assay. The H1975 cells remained viable in the presence of all 
antibodies and antibody containing AuNPs (Supporting Information, Figure III.S1) 72 
hours post-treatment. The results are consistent with previous reports that show no in vitro 
cell death upon exposure of H1975 lung cancer cells to cetuximab or panitumumab,10  and 
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reveal that multiple antibodies on the surface of the AuNPS also do not produce any anti-
proliferative effects in vitro. 
Anti-Tumor Effects of Antibodies and Antibody Containing AuNPs: 
To investigate the role of ADCC in vivo, mice bearing established H1975 xenograft 
tumors were dosed twice a week for two weeks, and tumor growth was measured over a 
period of two months. Cetuximab treated mice showed significant tumor regression while 
panitumumab treated mice did not (Figure III.1). Thus, cetuximab treatments inhibit in vivo 
H1975 tumor growth, and these results are consistent with literature reports.  
 
Figure III.1: Effects of antibody treatment on H1975 xenograft tumors in nude mice. Mice 
treated with panitumumab (squares), cetuximab (diamonds) or saline (triangles) as a 
negative control. Arrows indicate the days treatment occurred. 
 
Antibody containing AuNPs were investigated for their anti-tumor activities in 
nude mice bearing H1975 tumor xenografts in order to compare to the results from 
treatments with the antibodies alone. The data illustrated in Figure III.2 show that neither 
the cetuximab nor panitumumab containing AuNPs produced an anti-tumor effect in vivo 
(compared to saline, rituximab containing AuNPs, and AuNPs with no antibody). These 
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results show that attaching the antibody to the surface of the AuNPs abolished cetuximab’s 
ADCC activity in vivo.  
 
Figure III.2: H1975 xenograft tumor growth in mice treated with antibody containing 
AuNPs. Non-antibody containing AuNPs, rituximab containing AuNPs and saline used as 
negative controls. Arrows indicate the days treatment occurred. 
 
Lack of ADCC with cetuximab containing AuNPs is not due to loss of tumor accumulation 
or presence of immune cells: 
 The strong tumor regression observed in cetuximab treated mice (Figure III.1) is 
attributed to the ADCC activity of cetuximab. As expected, no anti-tumor effects are 
observed with panitumumab, which does not elicit an ADCC effect. This difference in the 
anti-tumor effect between the two antibodies was completely abolished when they were 
attached to the AuNPs (Figure III.2). Unfortunately, we were not able to construct an in 
vitro model system for testing the ADCC activity of cetuximab or panitumumab. However, 
we were able to do so for trastuzumab using the BT474M1 cell line and immortalized NK 
cells (Supporting Information, Materials and Methods). These model data show that 
trastuzumab and trastuzumab AuNPs give an in vitro ADCC response (Supporting 
1400
1200
1000
800
600
400
200
Tu
m
or
 V
ol
um
e 
(m
m
3)
35302520151050
Days after Tumor Implantation
 Cetuximab AuNP
 Panitumumab AuNP
 Saline
 Rituximab AuNP
 mPEG AuNP
142 
 
 
Information, Figure III.S2). Since we used the same conjugation chemistry with cetuximab 
and panitumumab as with trastuzumab, we assume that at least some fraction of the 
antibodies displayed on the surfaces of the nanoparticles are able to bind to their cancer cell 
surface receptors and stimulate an ADCC response in vitro. Thus, in order to better 
understand the factors that cause the in vivo loss in antitumor effects for the cetuximab that 
is contained on the AuNPs, we must first prove that the AuNPs are in fact reaching the 
tumors and that these tumors possess immune cells. 
AuNPs in tissue can be visualized by silver staining and imaging by light 
microscopy. Images of silver stained tissues harvested from mice treated with antibody 
containing AuNPs (Supporting Information, Figure III.S3) show the presence of AuNPs in 
all treated tumor tissues, as well as in liver, spleen, and small amounts in kidney (non-
tumor organs were imaged to confirm that the AuNPs were reaching all organs expected 
with NPs). No staining was evident for tissues from mice treated with saline (negative 
control). Thus, the AuNPs are localizing to the tumors in these mice. The presence of 
immune cells within the tumor tissue was investigated by staining for CD45 (pan-
leukocyte) and CD11b (NK) immune cell markers. In comparison to saline treated tumors, 
no significant difference in the presence of immune cells in tumor sections was found for 
antibody or antibody containing AuNP treated mice (Supporting Information, Figures 
III.S4 and III.S5).  
Lack of ADCC with cetuximab containing AuNPs is due to loss of ADCC function: 
The in vivo anti-tumor data shown here reveal that an antibody that can elicit an 
ADCC effect when used alone loses this function when it is conjugated onto a nanoparticle. 
Cetuximab injected at 9.3 mg/kg showed significant tumor regression due to an ADCC 
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effect, while cetuximab containing AuNPs dosed at 0.44 mg of antibody/kg did not show 
any anti-tumor effects. It should be noted that cetuximab maintains anti-tumor activities in 
nude mice over the range of 0.4-40 mg/kg.12  
The mice dosed with 0.44 mg/kg of cetuximab containing AuNPs (0.299 nmoles of 
gold/gram of body weight) showed significant accumulation of AuNPs in dermis, spleen, 
liver, and kidney, as revealed by sharp changes in skin color and silver staining of tissues 
from treated mice. Similar deposition of targeted and non-targeted PEGylated AuNPs in 
mouse dermis and lymph nodes was previously observed when studied at a much lower 
dose of AuNPs per mouse.13 Most importantly, the AuNPs also trafficked to the tumors 
(Supporting Information, Figure III.S3). Thus, the lack of anti-tumor effects with the 
cetuximab containing AuNPs is not because the NPs did not reach the tumor.   
It has been argued that introducing NPs into animals can modify their immune 
response via secretion of anti- or pro-inflammatory cytokines, which in turn has an impact 
on immune cell surveillance in tumor tissues.14-16 Here, the presence of immune cells in 
tumor tissues was studied using antibodies against CD45 (for all leukocytes) and CD11b 
(for mouse NK cells). Immune cell surveillance in the tumors used here was not 
significantly different regardless of treatment (Supporting Information, Figures III.S4 and 
III.S5). CD45 and CD11b labeled immune cells were abundant in H1975 tumor xenografts, 
indicating that the inability of the cetuximab containing AuNPs to show an anti-tumor 
effect in vivo was not due to a suppression of the animal’s immune response.  
The results presented here lead to the conclusion that covalent immobilization of an 
antibody on a nanoparticle surface can eliminate the ADCC function of the antibody. Here, 
we conjugated the antibody to PEG via reactions with amines on the antibody. Due to the 
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presence of several amines on the antibody, the conjugation of the PEG component will 
occur at various sites on the antibody. The antibody-PEG conjugates were purified by 
HPLC to obtain a mono-PEGylated fraction for attachment to the nanoparticle surface. 
However, the orientation and distribution of antibodies on the nanoparticle surface, such as 
whether the Fc region is accessible to immune cell binding may play an important role in 
eliminating the ADCC effects in vivo. At this time, the mechanistic origin of the loss in 
ADCC with nanoparticle containing antibodies remains unknown. Results from a model in 
vitro system suggest that at least a fraction of the antibodies that are contained on the 
surfaces of the gold nanoparticles can bind to the appropriate cancer cell surface receptor 
and stimulate an in vitro ADCC response. Thus, at this time, the mechanistic origin of the 
in vivo loss in ADCC with nanoparticle containing antibodies remains unknown. The 
ability to perform site-specific conjugation to the antibody like what is presently done with 
antibody drug conjugates17 may help resolve some of these issues. 
 
145 
 
 
Supporting Information: 
Table of Contents: 
 
1. Materials and Methods ........................................................................................................ 145 
Synthesis of antibody-PEG conjugates ................................................................................ 145 
Synthesis of antibody-functionalized gold nanoparticles ..................................................... 146 
Physiochemical Characterization of AuNPs ......................................................................... 146 
Quantification of Antibodies per Particle ............................................................................ 146 
Cell Line .............................................................................................................................. 147 
Cell Viability Assay ............................................................................................................. 148 
In vitro Antibody Dependent Cell Cytotoxicity (ADCC) assay ........................................... 149 
Xenograft Experiments ........................................................................................................ 149 
Immunohistochemistry (IHC) .............................................................................................. 150 
 
2. Supplementary Data Files 
Table III.S1: Quantification of antibodies on AuNPs surface using  
two different methods ............................................................................................................................. 150 
Figure III.S1: Cell viabilities of H1975 cells 72 hours post-incubation with antibodies  
(top) and antibody-functionalized AuNPs (bottom), as determined by MTS assay ............. 151 
Figure III.S2: ADCC in the BT474M1 cell line occurs with trastuzumab and  
trastuzumab-PEG but not trastuzumab-Fab or rituximab (top); and with trastuzumab  
AuNPs but not rituximab- or mPEG-AuNPs (bottom) ........................................................ 152 
Figure III.S3: Silver enhancement of gold nanoparticles in frozen tissue sections ............. 153 
Figure III.S4: CD11b staining of NK cells in tumor tissues .............................................. 157 
Figure III.S5: CD45 staining of frozen tumor sections as an indication of total immune  
cell infiltration present in tumors ......................................................................................... 158 
Materials and Methods: 
Synthesis of antibody-PEG conjugates: 
Cetuximab, rituximab, panitumumab, and trastuzumab were obtained from Dr. Yun 
Yen at the City of Hope. Antibody-PEG-OPSS conjugates were prepared by reacting 
amine groups of antibodies with NHS-PEG-OPSS (5kDa, Nanocs) at a 5:1 PEG to 
antibody ratio in 0.1 M phosphate buffer, pH 7.4. The conjugates were purified by 
high performance liquid chromatography (HPLC) using 0.1 M phosphate buffered 
saline (PBS), pH 7.4, as the elution buffer. Collected fractions were analyzed by 
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matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-
TOF-MS). 
Synthesis of antibody-functionalized gold nanoparticles: 
50 nm gold nanoparticles (AuNPs) (Ted Pella) were surface functionalized with 
mPEG-SH (5 kDa, Nanocs) and antibody-PEG-OPSS conjugates by mixing 50:10:1 
molar ratios of Au:mPEG:antibody-PEG in deionized water. AuNPs were stirred at 
room temperature for 2 hours.  Surface  functionalized  AuNPs  were  centrifuged  at  
14,000  g  for  10  minutes,  the supernatant was removed, and AuNPs were washed 
with deionized water three times. The purified nanoparticles were re-suspended in 
deionized water or buffer solution for further characterization. The concentration of 
antibody-functionalized AuNPs was determined by nanoparticle tracking analysis 
(NTA) using a Nanosight NS500 system. 
Physiochemical Characterization of AuNPs: 
mPEG-AuNPs and antibody functionalized AuNPs  were pelleted and were re-
suspended in saline and deionized water. The hydrodynamic diameter and zeta 
potential (ζ) of mPEG-AuNPs and antibody functionalized AuNPs were measured 
using ZetaPALS (Brookhaven Instruments Corporation). Hydrodynamic diameter was 
also measured by nanoparticle tracking analysis (NTA) using a Nanosight NS500 
system. 
Quantification of Antibodies per Particle: 
Fluorescent Labeling of Antibody-PEG conjugates: Dylight-650 (Pierce) labeled 
fluorescent antibody-PEG conjugates were prepared according to the manufacturer’s 
protocol. Antibody coated gold nanoparticles were synthesized using the experimental 
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conditions described above. The amount of antibody in the supernatant of AuNPs was 
estimated by measuring the fluorescence of the labeled antibody using an Infinite 
M200 microplate reader (Tecan). The fluorescence of the antibody in the supernatant 
was subtracted from the original fluorescence values measured in the feed amount of 
antibody per sample. 
Ortho-Phthaldehyde Assay (OPA): 
Antibody-PEG conjugates bearing a base labile linker, (Bis[2- 
(succinimidooxycarbonyloxy)ethyl]sulfone) (BSCOES), were prepared by mixing 
antibody:NH2- PEG-SH:BSCOES  at  molar  ratios  of  1:10:25,  respectively,  in  0.1  
M  PBS,  pH  7.4.  The conjugates were purified by HPLC. Antibody-functionalized 
gold nanoparticles were prepared, as described above. The purified antibody-
functionalized AuNPs were dispersed in 8 mM boric acid buffer (pH 10.8) containing 
3.5% Birj-35 and were incubated at 37°C overnight. The supernatant was collected and 
was reacted with 0.06M OPA in the presence of 0.025M 2- mercaptoethanol, and 
fluorescence was measured using an excitation λ=340 nm and an emission λ=450 nm 
using an Infinite M200 microplate reader (Tecan). The amount of antibody on the 
AuNP surface was determined, using a calibration curve of antibody-PEG conjugates. 
Cell Line: 
H1975 (ATCC) was cultured in RPMI-1640 media (ATCC) containing 10% fetal 
bovine serum (FBS) in a humidified atmosphere at 37°C with 5% CO2. 
 
 
 
148 
 
 
Cell Viability Assay: 
H1975  cells  were  seeded  at  5,000  cells  per  well  in  96-well  plates  and  were  
treated  with antibodies and antibody-functionalized gold nanoparticles for 72 hours. 
H1975 cell viability was evaluated using the MTS assay (Promega). 
In vitro Antibody Dependent Cell Cytotoxicity (ADCC) assay: 
The H1975 cell line was unable to provide satisfactory cell lysis results even with the 
cetuximab antibody alone using NKL-cells (DFCI, Boston MA), an immortalized 
NK cell line, and the lactate dehydrogenase (LDH) assay to measure ADCC in vitro. 
Therefore, another model using the  BT474M1  cell  line  and  trastuzumab to  see  
whether  ADCC  occurs  with  the  antibody, antibody-PEG conjugates, and antibody-
functionalized AuNPs was developed. In addition to the Fab fragment of trastuzumab, 
which does not have the Fc region to which NK cells bind, rituximab was used as a 
negative control. 
Trastuzumab-Fab Synthesis: 
Trastuzumab IgG was incubated with a papain-modified agarose gel slurry (Pierce) at 
37°C for 8 hours. The enzyme to substrate ratio was 1:160 weight/weight. The digested 
IgG was neutralized, and free IgG and Fc segments were removed using a protein A 
column. The purified Fab was analyzed using sodium dodecyl sulfate poly acrylamide 
gel electrophoresis (SDS PAGE). 
Cell Lines: 
NKL-cells (DFCI, Boston MA) were cultured in the presence of IL-2 (Peprotech) and 
10% heat inactivated FBS (Invitrogen). BT474M1 cells (UCSF) were maintained in 
RPMI-1640 media (Invitrogen) containing 10% ultra-low IgG FBS (Invitrogen) in 
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humidified chambers at 37°C with 5% CO2. The cells were sub-cultured twice a 
week and were seeded in 96-well tissue culture plates. 
ADCC Assay: 
The cells were treated with varying concentrations of antibodies (10-0.001 μM), Fab, 
antibody- PEG  conjugates,  and  antibody-conjugated  gold  nanoparticles  at  a  10:1  
ratio  of  NKL  to BT474M1 cells. ADCC was evaluated 3 hours post-treatment using 
a lactate dehydrogenase (LDH) (Roche) assay according to the manufacturer’s protocol. 
Because the same chemistry was used for antibody-PEG coupling and AuNP synthesis, 
the same phenomenon observed with trastuzumab and trastuzumab-AuNPs on the 
BT474M1 cell line should hold true for cetuximab and cetuximab-AuNPs on the H1975 
cell line. 
Xenograft Experiments: 
All mouse experiments were approved by the California Institute of Technology 
Institutional Animal Care and Use Committee. 1x107 H1975 cells, suspended in 0.2 
mL of serum-free RPMI-1640 media, were injected subcutaneously into the left rear 
flank of each 8-week old athymic NCr nude mouse (Taconic Biosciences, Inc). 
Xenograft tumor size was monitored daily or every other day using electronic calipers 
starting 7 days post-implantation. Tumor volume was calculated using the equation V 
= W2 x L / 2, where W is the shortest tumor dimension and L is the longest tumor 
dimension. When tumors reached 200 mm3, mice were divided into groups of 
7 mice and treated via tail vein IV injection with either saline, cetuximab, or 
panitumumab at a dose of 9.34 mg/kg, or saline, cetuximab-AuNP, panitumumab-
AuNP, rituximab-AuNP, or mPEG-AuNP at a dose of 2.25 x 1012 nanoparticles/25 g 
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mouse, which corresponds to 0.4mg/kg of antibody per mouse. Treatment was 
repeated 3 times, for a total of 4 doses over 2 weeks. Mice were followed until tumors 
reached 1500 mm3 or for 2 months. 
Immunohistochemistry (IHC): 
Mice were euthanized by CO2 asphyxiation 24 hours post 2nd injection. Tumors were 
embedded in Tissue-Tek optimal cutting temperature compound (Sakura) and were 
frozen at -80oC. Tissue blocks were sectioned (14 μm), and were lightly fixed in 10% 
buffered formalin for 15 minutes. IHC  analysis  was  performed  for  immune  cell  
detection  in  tumor  sections.  CD45 (BD Biosciences), and CD11b (Biolegend) 
antibodies were used at 1:100 dilutions. Tissues were imaged using a Zeiss LSM 510 
META confocal laser scanning microscope (CLSM). Gold nanoparticles were 
visualized in tissue sections using a silver enhancement kit (Ted Pella) and imaged 
with an Olympus IX50 light microscope. 
 
Sample # of Antibodies by Fluorescent
labeling 
# of Antibodies by OPA assay
Cetuximab-AuNPs 21±7 16±4
Panitumumab-AuNPs 22±4 18±6
Rituximab-AuNPs 17±3  
Table III.S1: Quantification of antibodies on AuNPs surface using two different 
methods.
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Figure III.S1:  Cell viabilities of H1975 cells 72 hours post-incubation with antibodies 
(top) and antibody-functionalized AuNPs (bottom), as determined by MTS assay. Results 
reported in terms of average absorbance compared to untreated cells, with error bars 
denoting the standard error of 5 replicates. 
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Figure	 III.S2:	 ADCC in the BT474M1 cell line occurs with trastuzumab and 
trastuzumab-PEG but not trastuzumab-Fab or rituximab (top); and with trastuzumab 
AuNPs but not rituximab- or mPEG-AuNPs (bottom) as determined by the LDH assay. 
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Figure III.S3: Silver enhancement of gold nanoparticles in frozen tissue sections of 
tumor (pg. 153), liver (pg. 154), spleen (pg. 155), and kidney (pg. 156). The black 
patches denoted by the white arrows indicate the presence of gold nanoparticles in the 
tissue sections, which are absent from tissues of saline-treated mice. 
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Figure III.S4: CD11b staining of NK cells in tumor tissues. No difference in NK cells 
present in the tumors can be seen between the various treatment groups. 
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Figure III.S5: CD45 staining of frozen tumor sections as an indication of total immune 
cell infiltration present in tumors. Antibody (pg. 158) and antibody-functionalized gold 
nanoparticle (pg. 159) treated mice are shown. No difference can be seen between the 
various treatment groups. 
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C h a p t e r  4  
Achieving cell internalization, endosomal escape, and efficacy with 
the cMAP siRNA nanoparticle system 
ABSTRACT 
In a previous work, we discussed the creation of a cationic mucic acid polymer 
(cMAP)-based nanoparticle (NP) siRNA delivery system. An mPEG-cMAP-PEGm 
triblock polymer showed greatly enhanced circulation time in the bloodstream over a 
cMAP + 5nPBA-PEG5km NP formulation. We add a targeting agent to effect NP cellular 
internalization and incorporate histidine in the polymer (TriB-His) to achieve siRNA 
endosomal escape into the cytosol. This NP formulation was able to achieve knockdown of 
mRNA expression using (i) 2 mol% cetuximab targeting agent and siEGFR in H1975 
NSCLC cells and (ii) 4 mol% transferrin targeting agent and siRRM2 in Neuro-2A 
neuroblastoma cells. Some effects, though mixed, are seen with (i) the cMAP + 5nPBA-
PEG5km NP formulation containing siEGFR and targeted with 0.13 mol% cetuximab-
PEG5k-5nPBA in H1975 xenografts and (ii) the TriB-His NP formulation containing 
siBRAF and targeted with 0.25 mol% transferrin-PEG5k-(5nPBA)2. Further exploration of 
the appropriate amount of targeting agent to use, or whether the targeting agent should be 
directly conjugated to cMAP so that it cannot detach from the nanoparticle, is necessary for 
optimal nanoparticle delivery and internalization into cells for siRNA to function.  
INTRODUCTION 
 Small interfering RNA (siRNA) is a short ca. 21 base pair double stranded siRNA which 
acts through an RNA interference (RNAi) pathway using the RNA induced silencing 
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complex (RISC) in the cytosol of cells to cleave the complementary messenger RNA 
(mRNA). siRNA is a promising candidate as a therapeutic for silencing one or more 
overexpressed or mutated messenger RNA (mRNA) sequences encoding any type of 
protein that drives many types of malignant cells.1 However, siRNA can activate the innate 
immune system through the complement pathway and is also readily degraded by nucleases 
in the bloodstream, so a delivery system is need to protect the siRNA from nuclease 
degradation in the bloodstream as well as to prevent the presence of free siRNA from being 
injected.2 Additionally, siRNA is rapidly cleared from the bloodstream through the 
kidneys, and current siRNA delivery systems that exist only marginally prolong the 
circulation time.3-8 We created a biocompatible delivery system for siRNA that has a long 
circulation time in the bloodstream.9 These highly stable particles need a targeting agent to 
be internalized into the cells, where they end up in an endosome. For the siRNA to 
function, it needs to escape from the endosome to the cytosol of the cell. In order to achieve 
the latter endosomal escape function, we have incorporated a histidine group between the 
PEG and cMAP in the mPEG-cMAP-PEGm triblock to form mPEG-His-cMAP-His-
PEGm (TriB-His). Histidine contains an imidazole group which acts as a proton sponge to 
prevent acidification of the endosome, leading it to burst and release siRNA into the 
cytosol.  
RESULTS AND DISCUSSION 
We have previously synthesized an mPEG-cMAP-PEGm triblock polymer which 
encapsulated siRNA and formed stable 30-40 nm particles.9 These nanoparticles (NPs) had 
a long circulation time with nearly 10% of the formulation still remaining in the mouse 
bloodstream 1 h after intravenous (IV) injection. To achieve efficacy with this very stable 
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nanoparticle, a targeting component is needed so that the nanoparticle can bind to cell 
surface receptors and be endocytosed. Furthermore, the siRNA contained in the 
nanoparticle needs to escape from the endosome and reach the cytosol of the cell where the 
RNA-induced silencing complex (RISC) is located in order to cleave the complementary 
mRNA.  
Nanoparticle Targeting 
To target the nanoparticle, we utilized the vicinal diol groups present on the mucic 
acid entity in cMAP. Boronic acids have the ability to bind to diols. 3-carboxy-5-
nitrophenylboronic acid, which has a pKa of 6.8, was used because the electron 
withdrawing nitro and carboxyl groups allow it to bind to the diol at a physiologic pH of 
7.4 and dissociate in an acidic endosomal pH of 5.5, as shown in Scheme IV.1.10 We linked 
the 3-carboxy-5-nitrophenylboronic acid to a H2N-PEG-COOH through an amide bond to 
synthesize 5-nitrophenylboronic acid-PEG-COOH (5nPBA-PEG-COOH), as shown in 
scheme IV.2. The carboxylic acid group on the end of PEG can be conjugated to lysine 
groups on proteins such as transferrin (Scheme IV.3) or antibodies (which are also 
proteins) such as cetuximab (Scheme IV.4) using EDC/NHS chemistry to form an amide 
bond. We had discussed in our earlier work around nanoparticle stability the theory that 
some 5nPBA-PEG5km, used to stabilize NPs formulated with cMAP, sloughs off of NP 
during circulation in the bloodstream.9 Therefore, we sought to attach the targeting agent 
with the same pH-tunable properties but with stronger binding. The presence of the vicinal 
diols on mucic acid allows 2 boronic acids to bind to the same mucic acid. Therefore, by 
following scheme IV.5, we synthesized a diboronic acid, di(5-nitrophenylboronic acid), 
that links two 3-carboxy-5-nitrophenylboronic acid groups onto lysine using an amide bond 
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between the carboxyl group on the 3-carboxy-5-nitrophenylboronic acid and the amines on 
lysine (Supporting Information (SI) Figures IV.S1-IV.S4). This diboronic acid has an order 
of magnitude greater binding affinity using an Alizarin Red S (ARS) assay, 107 M-1, than 
the single boronic acid, 106 M-1, to cMAP, though it has the same binding constant of ca. 3 
x 104 to ARS because ARS only possesses one site for boronic acid binding (Table IV.1).  
 
Scheme IV.1: pH dependence of 5-nitrophenyl boronic acid.  
 
 
Scheme IV.2: Synthesis of 5-nitrophenylboronic acid-PEG5k-COOH. 
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Scheme IV.3: Conjugation of a protein such as transferrin to 5-nitrophenylboronic acid-
PEG-COOH. 
 
 
Scheme IV.4: Conjugation of an antibody such as cetuximab to 5-nitrophenylboronic acid-
PEG-COOH. 
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Scheme IV.5: Synthetic scheme for di(5-nitrophenylboronic acid)-PEG-COOH. 
Compound Binding Constant to Alizarin Red S (M-1) 
Binding Constant 
to cMAP (M-1) 
5-nPBA-PEG-COOH 3.17 x 104 1.04 ± 0.29 x 106 
(5-nPBA)2-PEG-COOH 3.01 x 104 1.01 ± 0.55 x 107 
Table IV.1: Binding constant of 5nPBA-PEG-COOH and (5nPBA)2-PEG-COOH to 
Alizarin Red S and to cMAP. 
 
168 
 
 
The 5nPBA-PEG-COOH and (5nPBA)2-PEG-COOH components were 
synthesized in 2 PEG lengths: 5kD (as shown in the above schema) and 10kD, because it 
was unknown whether a protein attached to a 5kD PEG would be exposed on the surface of 
the nanoparticle with a dense 5kD brush layer as is present with a NP formed with the 
triblock polymer. It was hypothesized that a 10kD PEG might allow the protein to be able 
to come out of the PEG brush layer and bind to cell surface receptors. Both the 5nPBA-
PEG-COOH and the (5nPBA)2-PEG-COOH in the 5kD and 10kD PEG lengths were 
successfully synthesized (SI Figures IV.S5-IV.S13) and conjugated to transferrin (Tf) and 
cetuximab. The amide formation occurs between an activated carboxylic acid on the PEG 
and an NH2 group from any lysine on the protein. The direct output of the conjugation 
reaction is a mixture of un-PEGylated, mono-PEGylated (desired product), di-PEGylated, 
and small amounts of higher order PEGylated protein as shown by MALDI-TOF mass 
spectra in the SI Figure IV.S14-IV.S15. A separation was done on a diol-functionalized 
silica column by binding the boronic acid PEGylated protein to the column at pH 7.4 when 
un-PEGylated protein elutes. The pH of the buffer is then dropped to 5.7 to dissociate the 
boronic acid PEGylated protein from the column to isolate mainly the mono-PEGylated 
fraction (SI Figures IV.S16-IV.S18).  
The boronic acid was able to bind to the nanoparticle containing cMAP and form 
stable 30-50 nm particles with slightly negative -3 to -5 mV surface charge in 10 mM 
phosphate buffer, pH 7.4, as shown in Table IV.2. These results are similar to those using 
the triblock polymer alone without targeting agent.  
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Formulation Hydrodynamic Diameter 
by DLS (nm) 
Zeta Potential (mV, 10 mM 
phosphate buffer, pH 7.4) 
 Mean Median S.D. Mean Median S.D. 
Triblock 40.6 41.5 3.6 -5.0 -5.2 1.7 
Triblock,  
Tf-PEG5k-5nPBA 
47.7 50 7.7 -4.9 -4.9 0.7 
Triblock,  
Tf-PEG5k-(5nPBA)2 
49.9 48.8 15.2 -3.7 -3.4 1.5 
Triblock,  
Tf-PEG10k-5nPBA 
35.7 30.6 16.5 -4.3 -3.9 1.3 
Triblock,  
Tf-PEG10k-(5nPBA)2 
30.5 29.5 5.0 -4.8 -4.1 3.1 
Table IV.2: Hydrodynamic diameter and surface charge of targeted nanoparticles formed 
using the triblock polymer with transferrin as the targeting agent. DLS (dynamic light 
scattering); S.D. (standard deviation). 
 
There is the possibility that the boronic acid can prematurely dissociate from the 
nanoparticle in an acidic tumor microenvironment before it is internalized into malignant 
cells. Therefore, the protein targeting agent was also directly conjugated to the cMAP 
polymer through a 5kD PEG linkage as shown in scheme IV.6. Because of the high amount 
of polymer needed for a protein conjugation reaction, both the diblock cMAP-PEG5k-
COOH and triblock HOOC-PEG5k-cMAP-PEG5k-COOH were accepted for protein 
conjugation (SI Figure IV.S19). With the targeting agent directly conjugated to cMAP (SI 
Figure IV.S20) and with cMAP associated with siRNA in the core of the nanoparticle, the 
targeting agent attachment will not be subject to dissociating from the nanoparticle 
regardless of the pH of the environment.  
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Scheme IV.6: Directly conjugating a protein to cMAP via a PEG linker.  
 
Endosomal Escape 
In order to achieve endosomal escape, the mPEG-cMAP-PEGm polymer was 
modified to include a histidine between the PEG and the cMAP. Histidine contains the 
requisite imidazole functional group which acts as a proton sponge that prevents the 
endosome from acidifying and eventually causes the endosome to burst.  
As shown in synthetic scheme IV.7, the histidine with an activated carboxylic acid 
NHS ester and boc-protected amine is able to react with the amines on the ends of cMAP. 
The Boc-protected amine of the histidine is then hydrolyzed with acid to allow the His-
cMAP-His (SI Figure IV.S21) to react with the activated carboxylic acid NHS ester on the 
mPEG to form the mPEG-His-cMAP-His-PEGm triblock polymer (also called TriB-His 
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for short) containing histidine (SI Figure IV.S22) after removal of smaller diblock cMAP-
His-PEGm, unreacted cMAP, and hydrolyzed mPEG-COOH.  
The absolute molecular weight by multi-angle light scattering of cMAP-His and 
mPEG-His-cMAP-His-PEGm were determined to be approximately 7.3 kD and 26.95 kD, 
respectively shown in table IV.3. The substitution of imidazole on the triblock polymer was 
determined by titration with acid and found to be 1.9 ± 0.2 mmol imidazoles per mmol of 
polymer which means that there is almost complete substitution of histidine on both ends of 
the cMAP, between the cMAP and PEGm. The titration curve can be seen in SI Figure 
IV.S23. 
 
Scheme IV.7: Synthesis of mPEG-His-cMAP-His-PEGm. 
 
Polymer Mn (kDa) Mw (kDa) PDI (Mw/Mn) 
cMAP-His 7.266 9.078 1.271 
mPEG-His-cMAP-His-PEGm 26.950 27.92 1.036 
Table IV.3: Absolute molecular weight of histidine-containing cMAP polymers as 
determined by multi-angle light scattering.  
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To demonstrate that adding the histidine to the ends of cMAP results in enhanced 
mRNA knockdown efficiency, we first tested the cMAP-His polymer without PEG 
stabilization in cell culture on Neuro-2A cells. Without PEG stabilization, the nanoparticles 
aggregate and are better able to enter cells immobilized on a tissue culture surface rather 
than floating around in solution in Brownian motion with fewer cell contacts. The cMAP-
His polymer was able to achieve better endosomal escape than cMAP alone with an RRM2 
mRNA knockdown study in Neuro2A cells (Figure IV.1), being able to knock down 
RRM2 mRNA 17% more than with cMAP alone using 50 nM of siRRM2 in both cases. 
 
Figure IV.1: mRNA knockdown of RRM2 in Neuro-2A cells using cMAP and cMAP-His 
siRNA nanoparticles without PEG stabilization. 
 
 The mPEG-His-cMAP-His-PEGm polymer, also called TriB-His, is able to form stable 
nanoparticles similar to those with the triblock polymer not containing histidine, both 
without and with a Tf-PEG5k-5nPBA targeting agent (Table IV.4).  
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Formulation Hydrodynamic 
Diameter by DLS (nm) 
Zeta Potential (mV, 10 mM 
phosphate buffer, pH 7.4) 
 Mean Median S.D. Mean Median S.D.
Triblock-His 22.4 21.9 5.8 -4.0 -3.8 1.7 
Triblock-His,  
Tf-PEG5k-5nPBA 
38.9 38.7 13.8 -6.8 -6.8 1.2 
Table IV.4: NP size and zeta potential formulated with TriB-His without and with 
transferrin targeting agent added to the formulation. DLS (dynamic light scattering); S.D. 
(standard deviation). 
 
In vitro studies 
Cell lines and targets 
 A few cell lines were used to test the efficacy of these nanoparticles. The H1975 non-
small cell lung cancer cell line that is a T790M and L858R epidermal growth factor 
receptor (EGFR) mutant has surface expression of EGFR and it is hypothesized that the 
mutant EGFR protein drives its growth.11 The antibody cetuximab was used for targeting 
the nanoparticle to these cells and a siRNA against EGFR was used to halt its proliferation. 
The M249hBRAF melanoma cell line is a BRAF V600E mutant with overexpressed 
transferrin receptor on the cell surface and with the BRAF mutant driving its growth.12 
Tranferrin protein was used for targeting the nanoparticle into these cells and a siRNA 
against BRAF was delivered in the nanoparticle. The Neuro-2A neuroblastoma cell line 
was used for testing nanoparticle targeting with the protein transferrin, and a siRNA against 
ribonucleotide reductase M2 (RRM2) was used for this cell line. The EGFR and BRAF 
siRNA sequences were validated in their respective cell lines using the Lipofectamine 
RNAiMAX transfection reagent to confirm mRNA knockdown, as shown in SI Figure 
IV.S24-IV.S25. The RRM2 siRNA has been used previously in our lab.13 The control 
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siRNA sequence, siEGFP, was chosen for its lack of immune stimulation activities in vivo 
as reported in the literature previously.14  
Targeting agent to receptor binding 
 Binding of the cetuximab and transferrin  targeting agents conjugated to the PEG-boronic 
acid components to their corresponding receptors were tested in the H1975 and Neuro-2A 
cells lines expressing EGFR and transferrin receptor, respectively. Cetuximab-PEG with 
both the 5k and 10k PEG and the single and di-boronic acid retained its binding affinity to 
EGFR on the surface of H1975 cells (SI Figure IV.S26). However, the transferrin-PEG-
boronic acids lost some of their binding affinity to transferrin receptor on the surface of 
Neuro-2A cells, though some binding still occurred (SI Figure IV.S27). The decrease in 
transferrin binding to transferrin receptor may be due to functionalization of the protein 
with PEG, the drops in pH needed to separate unPEGylated Tf from PEGylated Tf, or a 
change in iron loading of the protein despite iron reloading after purification.  
mRNA knockdown 
 The boronic acid-PEG-targeting agents were loaded onto the surface of nanoparticles 
formulated using TriB-His at a 1.5 +/- charge ratio of polymer to siRNA to minimize 
excess free components. The nanoparticles were formulated for a 25 nM concentration of 
siRNA in the final mixture of cells and nanoparticles in the well. For in vitro mRNA 
knockdown studies, nanoparticles using cMAP-His polymer was used as a comparison for 
mRNA knockdown because of its strong positive surface charge and ability to aggregate 
and enter cells which are localized to the bottom of the cell culture wells.15-16 In 
comparison, the 30-40 nm particles formed with PEG stabilization move about the entire 
solution volume by Brownian motion and may make fewer contacts with cells near the 
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bottom of the well. For that reason, the nanoparticle solution and freshly-detached cells 
were added to the wells in sequence, and the plate was placed on a shaker in the cell culture 
incubator to facilitate more contacts between nanoparticles and cells, though the cells do 
attach to the bottom surface after a few hours.  
For the H1975 cell line, the cetuximab (CTX) targeting agent was used at 2 mol% 
loading of the diol functional groups present of mucic acid in the cMAP component of the 
triblock-His polymer, which corresponded to 92 nM of cetuximab in the final solution 
mixture. siRNA against EGFR was loaded into the nanoparticles for treating these cells. 
Because of the potential for cetuximab to affect EGFR mRNA expression, the same 
concentration of cetuximab was added to the cMAP-His NP and the TriB-His; under the 
conditions used in this assay, CTX did not seem to have an effect on EGFR mRNA 
expression (Figure IV.2). The TriB-His NPs without a targeting agent attached, as 
expected, were not able to enter cells and decrease EGFR mRNA expression (Figure IV.2). 
However, the TriB-His NPs with CTX targeting agent on their surface were able to cause a 
decrease in EGFR mRNA expression similar to that of the cMAP-His NP which aggregates 
and enters the cells without the need for a targeting agent (Figure IV.2). Furthermore, 
neither the PEG length of 5k versus 10k, nor having a single versus a di-boronic acid, had 
an effect on EGFR mRNA expression (Figure IV.2). This suggests that the 5k PEG is 
sufficient for some of the targeting agent to be exposed on the cell surface or that the 10k 
PEG might loop out and wrap back into the NP’s PEG brush layer so that the targeting 
agent is equally exposed in both cases. The diboronic acid offers no benefit over the single 
boronic acid, suggesting that a single boronic acid is sufficient for targeting agent 
attachment to the nanoparticle. However, the diboronic acid may still be advantageous in 
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an in vivo system with an acidic tumor microenvironment to allow the targeting agent to 
stay on the nanoparticle long enough for attachment and entry into cells when the pH might 
cause the boronic acid to detach from the diol groups before the NP has a chance to attach 
to cells.  
Similar results were seen for the Neuro-2A cell line, using transferrin targeting 
agent at 4 mol% loading of the diol functional groups on the polymer, which corresponds 
to 218 nM of transferrin in the cell culture medium. siRNA against RRM2 was used for the 
nanoparticles made to treat these cells. The untargeted TriB-His showed some but not 
significant decrease in RRM2 mRNA expression compared to untreated cells (Figure IV.3). 
The NPs with transferrin targeting agents showed similar decreases in RRM2 mRNA 
expression comparable to that of the cMAP-His NPs. Similar to with the CTX-siEGFR 
NPs in the H1975 cell line, there was no difference between transferrin targeting agent 
PEG lengths or whether a single or di-boronic acid was used for attaching the Tf to the NP. 
This shows that despite the decreased binding affinity of transferrin to transferrin receptor, 
the avidity effects of multiple transferrins present on the surface of the NP may be enough 
to compensate to allow the NP to attach to the cell surface and be internalized.  
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Figure IV.2: EGFR mRNA knockdown with NPs formulated with TriB-His containing 
siEGFR and targeted with 2 mol% of cetuximab targeting agents. 
 
 
Figure IV.3: RRM2 mRNA knockdown with NPs formulated with TriB-His containing 
siRRM2 and targeted with 4 mol% of transferrin targeting agents. 
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In vivo studies 
 The cMAP + 5nPBA-PEGm and the TriB-His nanoparticle formulations were used for 
tumor studies. Tumors were also harvested for analysis of mRNA expression and siRNA 
delivery with the cMAP + 5nPBA-PEGm nanoparticles formulation.   
cMAP + 5nPBA-PEGm NP delivering siEGFR to H1975 cells.  
 H1975 NSCLC xenograft tumors were established in nude mice and used as the model for 
the cMAP + 5nPBA-PEGm NP formulation. The cMAP polymer was used at a 3+/- charge 
ratio of polymer to siRNA, so some free components are present in solution. The antibody 
cetuximab that targets EGFR was used as the targeting agent at 0.13 mol% of the diol 
groups on mucic acid in cMAP, corresponding to approximately 9 mg/kg of cetuximab in 
the formulation per dose. A siRNA against EGFR was used as the siRNA in this NP 
formulation and dosed at a 5 mg/kg per injection. The size and zeta potential of these 
nanoparticles are shown in Table IV.5. An assay to detect siEGFR, which was validated in 
vitro (SI Figure IV.S28), found the siRNA in these H1975 tumor xenografts with the 
cMAP + 5-nPBA-PEGm siRNA delivery system after 2 doses 3 days apart (Figure IV.4). 
This shows that the nanoparticles are reaching the tumor despite no difference in EGFR 
mRNA expression between the treatment groups. This nanoparticle formulation also did 
not have an imidazole endosomal escape mechanism, though we hypothesized that the 
boronic acid on the PEG could provide some acid buffering capacity. However, as 
mentioned previously, the boronic acid has the potential to prematurely fall off the 
nanoparticle in an acidic tumor microenvironment, before the nanoparticle is internalized. 
If this were the case, then the positively charged cMAP could facilitate siRNA entry into 
tumor cells.15-16   
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Formulation Hydrodynamic 
Diameter (nm) 
by DLS 
Zeta Potential (mV) 
in 10 mM phosphate 
buffer, pH 7.4 
Zeta Potential 
(mV) in 1 mM 
KCl, pH 5.5 
cMAP (no PEG) 180.3 ± 9.7 14.57 ± 0.56 1.20 ± 0.54 
cMAP +  
5nPBA-PEG5km 
57.3 ± 16.0 -3.14 ± 0.67 0.75 ± 0.37 
cMAP +  
5nPBA-PEG5km, 0.13 
mol% CTX-PEG5k-5nPBA 
43.2 ± 12.7 -3.62 ± 0.49 0.95 ± 0.31 
Table IV.5: Hydrodynamic diameter and zeta potential of nanoparticle formulation 
(building up from the cMAP polymer alone) of the CTX-targeted cMAP-siEGFR NPs used 
for treatment of H1975 tumor xenograft-bearing nude mice. 
 
Some effects of tumor regression are seen with the cMAP + 5nPBA-PEGm system 
with cetuximab as a targeting agent and siEGFR as the nucleic acid delivered compared to 
saline-treated mice and cetuximab-treated mice  after injecting 4 doses every 3 days (Figure 
IV.5), but it is not consistent across all mice in a treatment group (SI Figure IV.S29). When 
regressions do occur, however, they tend to be durable. Perhaps a certain threshold for 
mRNA knockdown needs to be achieved for cells to stop proliferating and die, or for the 
immune system to eliminate the tumor.  
The cetuximab-treated mice were treated at the same 9 mg/kg dose of cetuximab as 
was used for targeting the nanoparticle. Cetuximab has the potential for inducing an ADCC 
response as mentioned in our previous work, and there are free components, including free 
cetuximab-PEG-5nPBA, in the formulation injected into the nude mice which have intact 
NK cells despite their deficiency in T cells.17 Therefore, much of the anti-tumor activity of 
these nanoparticles can be ascribed to the potent ADCC effect of the cetuximab targeting 
agent rather than the siEGFR in the NP, though the NP was able to induce more durable 
responses compared to cetuximab alone (SI Figure IV.S30).    
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Figure IV.4: Detection of siEGFR as delivered by the cMAP + 5nPBA-PEGm formulation 
with 0.13 mol% CTX-PEG-5nPBA targeting agent in H1975 xenografts. 
 
 
Figure IV.5: H1975 tumor xenograft growth in nude mice treated with siEGFR as 
delivered by the cMAP + 5nPBA-PEGm formulation with 0.13 mol% CTX-PEG-5nPBA 
targeting agent, compared to cetuximab alone and saline control.  
  
To distinguish the ADCC effect of the targeting agent from that of the siRNA in the 
nanoparticle, we explored using a different antibody against EGFR, panitumumab, which is 
of the IgG2 subtype and does not cause an ADCC response. The panitumumab-PEG5k-
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5nPBA was prepared with the same procedures used to produce the cetuximab targeting 
agent (SI Figure IV.S31). While there was some effect of H1975 tumor growth delay in the 
mice treated with panitumumab-targeted siEGFR nanoparticles for 6 doses every 3 days 
compared to saline-treated mice, there was not a significant difference, especially 
compared to mice treated with nanoparticle loaded with siEGFP, a control siRNA (Figure 
IV.6). However, the siEGFP does cause a modest knockdown in EGFR mRNA expression 
(SI Figure IV.S24), which may cause some of an effect on tumor growth. Virtually no 
difference exists between the groups of mice treated with cetuximab-targeted NPs loaded 
with the active siEGFR versus the control siEGFP siRNAs, further suggesting that the 
majority of the NP’s effect arises from the ADCC activity of cetuximab, whether it is from 
the unbound components or targeting agent that has detached from the nanoparticle in an 
acidic tumor microenvironment. It is possible that knocking down EGFR is not enough to 
cause death in H1975 cells and additional mutations are driving cell growth, as cell death 
was not seen in vitro in siEGFR-treated cells.  
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Figure IV.6: H1975 tumor xenograft growth in nude mice treated with siEGFR as 
delivered by the cMAP + 5nPBA-PEGm formulation with 0.13 mol% CTX-PEG-5nPBA 
or panitumumab-PEG-5nPBA targeting agent, compared to the NP formulations containing 
control siEGFP and saline. 
 
TriB-His NP delivering siBRAF to M249shBRAF cells. 
 We turned to using an M249shBRAF melanoma cell line which contains a BRAF V600E 
mutation thought to drive the cancer’s growth. This cell line was also made to contain a 
doxycycline inducible shRNA targeting BRAF, and mice with tumor xenografts fed a 
doxycycline-containing diet show a prolonged duration of tumor regression even after 
cessation of the doxycycline-containing diet (SI Figure IV.S32). Though a siRNA delivery 
system would not reach the effect of the inducible shRNA, the durable response seen with 
the doxycycline diet serves as a target of maximal response that we could hope to see with 
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a NP which delivers a single siRNA against BRAF. We chose to use the triblock polymer 
which showed the longest circulation time, and to which we had incorporated a histidine 
group, TriB-His, for allowing siRNA endosomal escape.9 We believed that a NP with the 
longest circulation time would have the highest chance of reaching the tumor by the EPR 
effect.  Adding the imidazole group in histidine to the polymer further increases the chance 
of siRNA reaching the cytosol of the tumor cells for it to function. Because the 
M249shBRAF cell line expresses a high level of transferrin receptor on its surface, we 
chose to use transferrin as the targeting agent. The diboronic acid attachment of the 
transferrin-PEG5k to the vicinal diols on cMAP in the nanoparticle was chosen due to the 
order of magnitude greater affinity compared to using a single boronic acid attachment, 
decreasing the possibility of premature shedding of targeting agent before the NP is 
internalized.   
 Transferrin targeting agent was loaded onto the surface of the nanoparticle at 0.25 mol% 
of the diol groups present in the NP formulation with a 3+/- charge ratio of TriB-His 
polymer to siRNA. This corresponds to a dose of 9.9 mg/kg of transferrin. The NP was 
dosed such that 5 mg/kg of siBRAF was dosed per injection. Nude mice bearing 
established M249shBRAF tumor xenografts on their left front flank were dosed every 3 
days, with 4 doses total. Similar to results with the H1975 tumor xenografts, some effect 
was seen with the active nanoparticle (Figure IV.7), though results were mixed with some 
mice (n =3) responding very well and with others (n = 2) seeing virtually no effect (SI 
Figure IV.S33-IV.S34) so that statistical significance was not achieved.  
Though a pilot study of delivering siBRAF to tumors with the cyclodextrin polymer 
system which has a very short circulation time barely longer than that of siRNA showed 
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some effect (albeit with only n = 2 mice, SI Figure IV.S34), it was puzzling to see that a 
NP which circulates for much longer had less effect than the CDP siRNA delivery system.9 
There was 0.5 mol% of Tf (9.7 mg/kg) on the surface of the CDP NPs, which is a similar 
amount to that used for targeting the TriB-His NPs (9.9 mg/kg). Furthermore, the 
adamantane attachment of the Tf targeting agent to the cyclodextrin cups in CDP is less 
stable and more prone to shedding (though no pH sensitivity) compared to the boronic acid 
attachment to diol groups in cMAP. Perhaps the decreased stability of the CDP NPs 
facilitated the entry of the small amount of NP that was able to enter the tumor by the EPR 
effect, while even if more of the triB-His NPs arrived at the tumor site with longer 
circulation the PEG stabilization prevented the NPs from entering cells. Maybe the 4 mol% 
(compared to 0.25 mol%) loading of transferrin targeting agent onto the surface of 
nanoparticle (despite the nearly 40 mg/kg dose of transferrin that would be contained), or 
the Tf-PEG5k-cMAP with transferrin directly conjugated to cMAP so it would not shed 
from the NP, is necessary to achieve cellular internalization with the stability of these NPs,. 
It would also be interesting to compare siBRAF delivery with a cMAP-His + 5nPBA-
PEGm formulation to see whether just the smaller increase in circulation time but the 
greater amount of instability without PEG covalently attached to the cationic polymer 
would be the right balance to achieve optimal siRNA delivery and internalization for tumor 
regression.  
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Figure IV.7: M249shBRAF xenograft tumor growth in nude mice using TriB-His NP’s 
containing siBRAF with 0.25 mol% Tf-PEG5k-(5nPBA)2 targeting agent. 
 
Summary 
 We showed the ability to synthesize a (5-nPBA)2-PEG-COOH with an order of magnitude 
greater binding affinity than the single boronic acid entity, and to conjugate protein 
targeting agents to both 5-nPBA-PEG-COOH and the diboronic acid version in 5k and 10k 
PEG lengths. Furthermore, a histidine group was incorporated into the mPEG-cMAP-
PEGm triblock polymer for a siRNA endosomal escape mechanism to achieve enhanced 
mRNA knockdown. The addition of an imidazole group into the triblock polymer and a 
targeting agent onto the NP still preserved the desired NP size of 30-40 nm, and the zeta 
potential remained close to neutral. The NP formulation with the TriB-His polymer and 
either 2 mol% cetuximab or 4 mole% transferrin targeting agent was able to knock down 
expression of EGFR or RRM2, respectively, in cell culture with H1975 or Neuro-2A cells, 
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respectively. Some effect, though mixed, was seen in vivo with both the cMAP + 5nPBA-
PEG5km formulation delivering 5 mg/kg siEGFR to H1975 NSCLC xenografts using 0.13 
mol% cetuximab-PEG5k-5nPBA targeting and with the TriB-His formulation delivering 5 
mg/kg siBRAF to M249shBRAF melanoma xenografts using 0.25% transferrin-PEG5k-
(5nPBA)2 targeting. Further work is required to determine whether a higher amount of 
targeting agent, such as 4 mol% transferrin, or direct conjugation of targeting agent to the 
cationic polymer is required for optimal uptake of NPs into cells for siRNA to reach the 
cytosol where it can function, or whether a balance that trades the NP’s circulation time for 
more facile entry into cells needs to be achieved. Perhaps using a functional targeting agent 
that has a therapeutic effect is also beneficial.  
EXPERIMENTAL PROCEDURES 
Chemistry 
Anhydrous solvents, oxalyl chloride, and human holo-transferrin were purchased from 
Sigma-Aldrich; 3-carboxyl-5-nitrophenyl boronic acid from Alfa-Aesar; and H-Lysine-
OMe from Bachem. Polyethylene glycol (PEG) reagents were purchased from either 
Jenkem Technology USA or Laysan Bio, Inc. Cetuximab and panitumumab were obtained 
from Dr. Yun Yen at City of Hope Comprehensive Cancer Center in Duarte, CA. Reagents 
were used without further purification. 
 Nuclear magnetic resonance (NMR) spectra were acquired on Varian 300 MHz, 400 
MHz, 500 MHz, or 600 MHz instruments at 25 degrees Celsius, without spinning at 400 
and 600 MHz. For most 1H proton spectra, a delay time of 1-1.5 s was used; for more 
quantitative integration, a 10 s delay was used. 11B spectra were acquired at 128 MHz.  
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Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass 
spectra for polymers and proteins were acquired on an Applied Biosystems Voyager DE-
PRO using a 10 mg/mL alpha-cyano-4-hydroxycinnamic acid matrix for polymers or a 10 
mg/mL sinapic acid matrix for proteins.  
Gel Permeation Chromatography. An Agilent 1100 HPLC with binary pump and injector 
was connected to a Tosoh TSKgel G3000PWXL-CP size exclusion column with Wyatt 
DAWN HELEOS light scattering and Wyatt Optilab Rex refractive index detection. 
Lyophilized polymer was dissolved at various concentrations in 0.1 M NaNO3, filtered 
through a 0.2 um PVDF filter, and injected into the refractive index detector directly via a 
syringe pump for dn/dc determination. For absolute molecular weight determination by 
light scattering, 100 uL of polymer solution was injected onto the column and the detected 
polymer peak analyzed using ASTRA V software.  
Synthesis of cMAP has been previously described. previously.9 
Synthesis of His-cMAP-His. 
cMAP (195 mg, 0.0325 mmol, 1 equiv) and Boc-His(1-Boc)-OSu (147 mg, 0.325 
mmol, 10 equiv) were added to an oven-dried 50 mL round bottom flask with a stirbar. The 
flask was filled with argon. DIPEA dried over molecular sieves (11 uL, 0.065 mmol, 2 
equiv), followed by anhydrous DMSO (14 mL), were added to the reaction flask. The 
reaction was stirred at 25 degrees C for 16 h. 14 mL of 6 N HCl in MeOH was then added 
to the reaction and stirred for 1 h to remove the Boc protecting groups. The mixture was 
then diluted to 50 mL with deionized water and dialyzed against deionized water with a 3 
kD Amicon Ultra centrifugal spin filter, concentrated to 3 mL, filtered through a 0.2 um 
PVDF syringe filter, and lyophilized to a white solid (39.2 mg, 18.6% yield), His-cMAP-
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His, which was stored under argon at -20 degrees C. 1H NMR (600 MHz, D2O): 7.81, 
6.99, 4.31, 3.89, 3.57-3.23, 2.43-2.34, 1.52, 1.24. MW (GPC MALS): Mn 7266, Mw 9078, 
PDI 1.271.   
Synthesis of mPEG-His-cMAP-His-PEGm. 
His-cMAP-His (39.2 mg, 0.007 mmol, 1 equiv) and mPEG5k-SVA (105 mg, 0.021 
mmol, 3 equiv) were added to an oven-dried 25 mL round bottom flask with a stirbar. The 
flask was filled with argon. Anhydrous DMSO (3 mL) was added to the flask and the 
reaction was stirred for 48 h. The mixture was then diluted to 25 mL with deionized water 
and dialyzed against deionized water with a 20 kD Pierce centrifugal spin filter, 
concentrated to 3 mL, filtered through a 0.2 um PVDF syringe filter, and lyophilized to 
afford mPEG-His-cMAP-His-PEGm, a white solid (38.5 mg, 27.5% yield). 1H NMR 
(600 MHz, DMSO-d6): 9.58, 9.20, 8.72, 7.90, 7.50, 6.77, 5.40, 4.52, 4.15, 3.82, 3.60-3.36 
(PEG), 3.21, 2.39, 1.60, 1.52, 1.33-1.21. MW (GPC MALS): Mn 26950, Mw 27920, PDI 
1.036. 
Synthesis of COOH-PEG-cMAP-PEG-COOH and cMAP-PEG-COOH mixture. 
cMAP (140 mg, 0.025 mmol, 1 equiv) and SC-PEG5k-CM (500 mg, 0.1 mmol, 4 
equiv) were added to an oven-dried 25 mL round bottom flask with a stirbar. The flask was 
filled with argon, and anhydrous DMSO (10 mL) was added to the flask and the reaction 
was stirred for 48 h. The mixture was then diluted to 25 mL with deionized water and 
dialyzed against deionized water with a 10 kD Pierce centrifugal spin filter, concentrated to 
3 mL, filtered through a 0.2 um PVDF syringe filter, and lyophilized to a mixture of 
COOH-PEG-cMAP-PEG-COOH and cMAP-PEG-COOH, a white solid (212.6 mg, 
33.2% yield).  
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Synthesis of Tf-PEG-cMAP 
cMAP-PEG-COOH (125 mg, 0.0125 mmol, 50 equiv), EDC-HCl (24.0 mg, 0.125 
mmol, 500 equiv), and NHS (21.6 mg, 0.188 mmol, 750 equiv) were added to a 1.5 mL 
Eppendorf tube with a stirbar. 0.1 M MES buffer, pH 6.0 (200 uL) was added and the 
mixture was stirred for 45 min at room temperature. 20 mg Tf in 800 uL of 0.1 M PBS, 
0.15 M NaCL, pH 7.4 was then added and stirred for 6 h at room temperature. The mixture 
was dialyzed against PBS with a 30 kD Amicon Ultra centrifugal spin filter. Conjugation of 
Tf to cMAP-PEG-COOH to form Tf-PEG-cMAP was confirmed by MALDI-TOF.  
Transferrin was iron reloaded by buffer exchange into 0.1 M sodium bicarbonate, 
pH 8.5, addition of 2.5 mole excess of iron (III) citrate in 0.1 M sodium bicarbonate, pH 
8.5, and gentle stirring for 2.5 h. Excess iron was dialyzed away 6 times using 0.1 M 
sodium bicarbonate, pH 8.5 with a 0.5 mL 30 kD Amicon Ultra centrifugal spin filter. Iron 
reloading of transferrin was confirmed by measuring the ratio of A465/A280 using the 
UV/Vis function on a Nanodrop 2000. Protein concentration was also determined on the 
Nanodrop system using an extinction coefficient of 83 and a molecular weight of 79 kD.    
Synthesis of 5-nitrophenylboronic acid-PEG5km has been previously described.9  
Synthesis of 5-nitrophenylboronic acid-PEG5k-COOH.  
3-carboxyl-5-nitrophenylboronic acid (200 mg, 0.95 mmol, 1 equiv) was added 
to an oven-dried 2-necked 10 mL round bottom flask containing a dry stir bar. The flask 
was vented with argon and sealed with a rubber septum. Anhydrous tetrahydrofuran with 
BHT inhibitor (5 mL) was added to dissolve the boronic acid, followed by anhydrous DMF 
(14.7 uL, 0.19 mmol, 0.2 equiv). The flask was cooled to 0oC in an ice-water bath. Oxalyl 
chloride (195.4 uL, 2.28 mmol, 2.4 equiv) was then added drop wise to the reaction 
190 
 
 
mixture. The ice-water bath was removed after oxalyl chloride addition was complete, and 
the reaction continued stirring for 2 hours at room temperature, with an argon vent to allow 
for the escape of volatiles. Solvent and DMF was removed via rotary evaporator and then 
under vacuum for 2 days under dark to afford 3-acyl chloride-5-nitrophenyl boronic acid 
(217.5 mg, 100% yield) as a yellow solid.    
3-acyl chloride-5-nitrophenylboronic acid (68.8 mg, 0.3 mmol, 3 equiv) was 
added to an oven-dried 25 mL round bottom flask containing a dry stir bar. The flask was 
sealed with a rubber septum, vented with argon, and cooled to 0oC in an ice-water bath. 
Anhydrous dichloromethane (5 mL) was added to dissolve the boronic acid. 5 kD H2N-
PEG5k-COOH (500 mg, 0.1 mmol, 1 equiv) in an oven-dried 10 mL round bottom flask 
vented with argon, dissolved in anhydrous dichloromethane (10 mL) and 
diisopropylethylamine (52.3 uL, 0.3 mmol, 3 equiv) dried with activated molecular sieves, 
was slowly added to the boronic acid solution. The reaction flask was left in the ice-water 
bath to slowly warm up to room temperature, and the reaction was stirred overnight under 
dark. The solvent and DIPEA was removed via rotary evaporator and then under vacuum 
for 2 days under dark. The solid residue was reconstituted in 0.5 N HCl (15 mL) and stirred 
for 15 min. The resulting suspension was filtered through a 0.2 um Supor syringe filter, and 
the resulting clear solution was dialyzed with a 15 mL Amicon Ultra 3 kD spin filter 
against nanopure water until the pH was constant. The solution of polymer was 
concentrated to 3-4 mL, filtered through a 0.2 um PVDF syringe filter into a pre-weighed 
20 mL glass vial, and lyophilized to dryness to afford 5-nitrophenylboronic acid-PEG5k-
COOH (266.1 mg, 53% yield) as a fluffy white solid. 1H NMR (400 MHz, DMSO-d6): 
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12.54 (s, 1H, COOH), 8.90 (t, 1H), 8.73 (m, 1H), 8.68 (m, 1H), 8.65 (m, 1H), 8.62 (s, 2H), 
4.00 (s, 2H), 3.5 (s - PEG, 344H). MALDI: 5496.      
Synthesis of 5-nitrophenylboronic acid-PEG10k-COOH was accomplished in a similar 
fashion, using 10k PEG instead of 5k PEG.  
Preparation of 5-nitrophenylboronic acid-PEG5k-cetuximab.  
5-nitrophenylboronic acid-PEG5k-COOH (16.94 mg, 0.0033 mmol, 50 equiv) 
was added to a 1.7 mL Eppendorf tube with a stir bar and dissolved in 0.1 M MES buffer, 
pH 6.0 (250 uL). EDC-HCl (6.3 mg, 0.033 mmol, 500 equiv) and NHS (5.68 mg, 0.049 
mmol, 750 equiv) in 0.1 M MES buffer, pH 6.0 (250 uL) was added to the 5-nPBA-PEG-
COOH, and the reaction mixture was stirred for 30 min at room temperature. The reaction 
mixture was then added to a 0.5 mL Amicon Ultra 3 kD spin filter and spun 3X against 0.1 
M MES buffer, pH 6.0 to isolate the activated 5-nPBA-PEG-NHS ester. The activated 5-
nPBA-PEG-NHS ester was concentrated to a volume of 100-150 uL and added to a 
solution of antibody (10 mg, 0.000066 mmol, 1 equiv) in 0.1 M PBS, 0.15 M NaCl, pH 7.4 
(1400 uL) in a 1.7 mL Eppendorf tube. The reaction was stirred at 25oC for 5 h. The 
reaction solution was then spun down and concentrated with a 0.5 mL Amicon Ultra 50 kD 
spin filter against 0.1 M PBS, 0.15 M NaCl, pH 7.4 to remove excess PEG. The antibody-
PEG conjugate was purified via HPLC on 2 TSKgel G3000SWxl columns with an eluent 
of 0.1 M PBS, 0.15 M NaCl, 0.02% NaN3, pH 5.7. The mono-PEGylated antibody fraction 
was concentrated with a 15 mL Amicon Ultra 50 kD spin filter and dialyzed into 0.1 M 
PBS, 0.15 M NaCl, 0.02% NaN3, pH 7.2 to afford 5-nitrophenylboronic acid-PEG5k-
cetuximab (1.58 mg, 15% yield) in solution. MALDI: 158,000.      
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Synthesis of 5-nitrophenylboronic acid-PEG10k-cetuximab was achieved in a similar 
fashion, substituting 5-nitrophenylboronic acid-PEG10k-COOH for the 5k PEG and 
preserving the same equivalents of reagents. 
Synthesis of 5-nitrophenylboronic acid-PEG5k-panitumumab was accomplished using 
similar procedures as for the preparation of 5-nitrophenylboronic acid-PEG5k-cetuximab, 
substituting panitumumab for cetuximab.  
Synthesis of boronic acid-PEG-Tf was accomplished using similar procedures as for 
cetuximab and panitumumab, adjusting for the molecular weight of transferrin and 
preserving the same equivalents of reagents. Iron was additionally reloaded onto transferrin 
as described in the synthesis of Tf-PEG5k-cMAP. 
Synthesis of diboronic acid. 
Synthesis of di(5-nitrophenylboronic acid)-Lysine-OMe. 
3-carboxyl-5-nitrophenylboronic acid (4 g, 19 mmol, 1 equiv) was added to an 
oven-dried 2-necked 100 mL round bottom flask with stirbar. The flask was sealed and 
vented with argon. Anhydrous THF (40 mL) was added to the flask to dissolve the starting 
material. DMF (300 uL, 3.8 mmol, 0.2 equiv) was added and the reaction flask was cooled 
in an ice/water bath. Oxalyl chloride (4 mL, 46 mmol, 2.4 equiv) was added dropwise. 
Upon completion of oxalyl chloride addition, the reaction flask was removed from the ice 
bath and reacted for 2 h at room temperature under dark with argon vent to allow the 
escape of volatiles. Solvent was then removed in vacuo to afford 3-acyl chloride-5-
nitrophenyl boronic acid. 
To the flask with 3-acyl chloride-5-nitrophenylboronic acid (3.9 g, 17 mmol, 5 
equiv) and a dry stir bar, Lysine-OMe (800 mg, 3.4 mmol, 1 equiv) was added and dried 
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under vacuum for 1 h before filling the flask with argon and cooling in an ice/water bath. 
DIPEA dried over molecular sieves (3 mL, 17 mmol, 5 equiv) followed by anhydrous 
DCM (20 mL) was added to dissolve the reactants. The reaction was left in the ice bath to 
warm up to room temperature overnight under dark. Solvent was removed on rotovap and 
in vacuo. 20 mL 1 N aqueous HCl was added to the crude product, which was filtered 
through a fine grain frit and washed with 1 N HCl (3 x 10 mL). The solid retentate was 
collected by dissolving in MeOH. MeOH was removed in vacuo to afford 
di(5nitrophenylboronic acid)-Lysine-OMe (1.8 g, 19% yield), a yellow solid. 1H NMR 
(600 MHz, CD3OD): 8.75-8.25 (m, 10H), 4.63 (m, 1H), 3.74 (s, 3H), 3.41 (m, 2H), 1.90 
(multiplet of doublets, 2H), 1.68 (m, 2H), 1.55 (m, 2H). 11B NMR (128 MHz, CD3OD): 
26.56 ppm (s). 
Synthesis of di(5-nitrophenylboronic acid)-Lysine. 
di(5-nitrophenylboronic acid)-Lysine-OMe (1.8 g, 3.3 mmol, 1 equiv) was added 
to a 50 mL round bottom flask with a stirbar. LiOH (1.4 g, 33 mmol, 10 equiv) was added, 
followed by 3:1 MeOH/H2O (16 mL). The flask was sealed and the reaction was run under 
argon overnight. Solvent was removed in vacuo until dry. 6 N aqueous HCl was slowly 
added with stirring to acidify the solution. The mixture was filtered through a fine grain frit 
funnel and the solids were collected by dissolution with MeOH and then removing MeOH 
in vacuo to afford di(5-nitrophenylboronic acid)-Lysine (550 mg, 31% yield) as a brown 
solid. 1H NMR (500 MHz, CD3OD): 8.74-8.34 (m, 10H), 4.65 (m, 1H), 3.45 (m, 2H), 2.2 
(multiplet of doublets, 2H), 1.74 (m, 2H), 1.61 (m, 2H). 11B NMR (128 MHz, CD3OD): 
27.28 ppm (s). 
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Synthesis of di(5-nitrophenylboronic acid)-PEG5k-COOH. 
di(5-nitrophenylboronic acid)-Lysine (550 mg, 1 mmol, 1 equiv) was added to a 
100 mL round bottom flask with stirbar. The flask was purged with argon and anhydrous 
THF (5 mL) was added followed by anhydrous DMF (16 uL, 0.2 mmol, 0.2 equiv). The 
reaction flask was cooled in an ice/water bath and oxalyl chloride (213 uL, 2.5 mmol, 2.4 
equiv) was added dropwise. Upon completion of oxalyl chloride addition, the reaction flask 
was removed from the ice bath and the contents allowed to react at room temperature for 2 
h under dark. Solvent was then removed in vacuo.  
H2N-PEG5k-COOH (800 mg, 0.16 mmol, 1 equiv) dissolved in dry DIPEA (140 
uL, 0.8 mmol, 5 equiv) and anhydrous DCM (20 mL) was added to BA2-Lysine-acyl 
chloride (440 mg, 0.8 mmol, 5 equiv) in a 100 mL flask with dry stirbar under argon in an 
ice bath. The reaction was slowly warmed to room temperature and reacted overnight. The 
solvent was removed in vacuo. The solids were reconstituted in 0.5 N HCl (20 mL) and the 
solution was filtered through a 0.2 um syringe filter with a Supor membrane. The solution 
was dialyzed against deionized water using a 3 kD MWCO Amicon Ultra Centrifugal spin 
filter until the pH of the filtrate remained constant. The retentate was filtered through a 0.2 
um PVDF syringe filter and lyophilized to dryness to afford di(5-nitrophenylboronic 
acid)-PEG5k-COOH (379.2 mg, 43% yield) as a white solid. 1H NMR (600 MHz, 
DMSO-d6): 12.49 (s, 1H, COOH), 8.80-8.60 (m, 8H), 4.19 (t, 1H), 3.99 (s, 2H), 3.66 (t, 
2H), 3.5 (s - PEG, 704H), 1.77 (m, 4H). MALDI: 5234.      
Synthesis of di(5-nitrophenylboronic acid)-PEG10k-COOH was achieved in a similar 
fashion, except using H2N-PEG10k-COOH as the PEG reactant.  
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Synthesis of di(5-nitrophenylboronic acid)-PEG5k-Tf. 
di(5-nitrophenylboronic acid)-PEG5k-COOH (63 mg, 0.013 mmol, 50 equiv), 
EDC-HCl (24 mg, 0.13 mmol, 500 equiv), and NHS (22 mg, 0.19 mmol, 750 equiv) were 
dissolved in 0.1 M MES, pH 6.0 (250 uL) in a 1.7 mL Eppendorf tube and stirred for 30 
min. Transferrin (20 mg, 0.00025 mmol, 1 equiv) dissolved in 0.1 M phosphate buffer, 
0.15 M NaCl, pH 7.4 (1 mL) was then added to the reaction mixture and stirred for 5 h. 
Excess PEG, EDC, and NHS were removed using a 0.5 mL 30 kD MWCO Amicon Ultra 
centrifugal spin filter.  
The retentate containing transferrin with 0-3 PEG attached was filtered through a 
0.2 um syringe filter and injected onto an HPLC containing a 1.5 mL injection loop and a 
Tosoh Bioscience TSKgel G3000SW (21.5 mm ID x 60 cm) column. 50 mM phosphate 
buffer, 0.15 M NaCl, pH 7.4 buffer was used to remove unbound, unPEGylated transferrin. 
The eluent was then changed to 50 mM phosphate buffer, 0.15 M NaCl, pH 5.7 to elute 
mainly mono-PEGylated transferrin. The eluate containing Tf-PEG5k-(5nPBA)2 was 
concentrated using a 15 mL 30 kD MWCO Amicon Ultra centrifugal spin filter and 
exchanged into the pH 7.4 buffer. The PEGylated transferrin was exchanged into 0.1 M 
sodium bicarbonate buffer, pH 8.4 and iron reloaded with Iron (III) citrate (2.5 equiv) 
based on the nanodrop determined concentration of the transferrin. The mixture was stirred 
for 2.5 h, and then excess Fe was removed by dialysis against 0.1 M sodium bicarbonate 
buffer, pH 8.4. The transferrin-PEG5k-(5nPBA)2 was then exchanged back into pH 7.4 
buffer and concentration was determined using a Nanodrop 2000 with extinction 
coefficient 83 and molecular weight 79 kD to afford pure transferrin-PEG5k-(5nPBA)2 
(3.1 mg, 14.6% yield). MW (MALDI-TOF): 84000.  
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Synthesis of Tf-PEG10k-(5nPBA)2 was achieved in the same fashion, except with 
(5nPBA)2-PEG10k-COOH (126 mg, 0.013 mmol, 50 equiv). MW (MALDI-TOF): 89000. 
Nanoparticle formulation was accomplished as previously described.9  
Nanoparticle size and zeta potential. Nanoparticle size was determined using dynamic light 
scattering (DLS). DLS was performed on a Brookhaven Instruments Corporation (BIC) 
Zeta-PALS with BIC Particle Sizing Software. The particles were diluted down to a 
concentration of 0.1 mg/mL siRNA and size was recorded for ten 1-minute measurements.  
 The nanoparticles’ surface charge, or zeta potential, was measured using the same Zeta-
PALS used for DLS, with the addition of a Brookhaven aqueous electrode assembly. 10 uL 
of particle formulation was mixed with 1.5 mL of either 10 mM phosphate buffer pH 7.4 or 
1 mM potassium chloride pH 5.5 in a cuvette. The electrode was inserted into the cuvette 
and zeta potential measured using BIC PALS Zeta Potential Analyzer software with a 
target residual of 0.012.     
Boronic Acid Binding Constant Assay. 
The binding constants of the 5nPBA-PEG5k-COOH and (5nPBA)2-PEG5k-COOH 
to Alizarin Red S and cMAP were measured using an assay previously described.18 
Transferrin binding assay 
 The binding of transferrin and transferrin-PEG conjugates to transferrin receptor was 
determined by displacement of 50 nM transferrin with Alexa-Fluor 488 attached (Tf-
AF488 from Jackson ImmunoResearch Laboratories, Inc.). 100,000 Neuro-2A cells in 
serum-free OptiMEM I were added to each well of a 24-well plate and appropriate amounts 
of transferrin or transferrin-PEG conjugates were added to the wells. 50 nM of Tf-AF488 
was added to each well. The cells were incubated on a shaker at 37oC with 5% CO2 for 1 h. 
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The cells were collected into an Eppendorf tube, centrifuged at 200 rpm for 15 min, the 
media was removed, and the cells were fixed with 100 uL 4% formalin. The cells were then 
diluted with phosphate buffered saline to 1 mL and run on a BD FacsCalibur to determine 
the number of cells that were fluorescent by flow cytometry.  
Cetuximab binding assay 
 The binding of cetuximab and cetuximab-PEG conjugates to EGFR was determined by 
displacement of 50 nM cetuximab with Alexa-Fluor 488 attached (CTX-AF488) made by 
conjugation with NHS-ester activated AF488 (Life Technologies). All other procedures 
were similar to those used for the transferrin binding assay.  
In vitro work. 
Cell lines. The human non-small cell lung cancer adenocarcinoma cell line, NCI-H1975, 
was obtained from ATCC and maintained in RPMI-1640 medium with 10% fetal bovine 
serum without the use of antibiotics in a 37oC incubator with 5% CO2.  
The M249shBRAF melanoma cell line with a doxycycline-inducible BRAF shRNA 
construct (that was made by Jonathan Zuckerman from the M249 cell line obtained from 
UCLA) was maintained in RPMI-1640 medium with 10% fetal bovine serum and 10 
ug/mL puromycin. The shBRAF construct sequence is as follows: 
Top:  
5’-CCGGAGAATTGGATCTGGATCATTTCTCGAGAAATGATCCAGATCCAATTCTTTTTT-3’ 
Bottom:  
5’-AATTAAAAAAGAATTGGATCTGGATCATTTCTCGAGAAATGATCCAGATCCAATTCT-3’ 
Neuro-2A cells were obtained from ATCC and maintained in DMEM medium with 
10% fetal bovine serum without antibiotics.   
Cell culture and siRNA transfection. The night before siRNA transfection, 20,000 cells in 
500 uL were plated per well in a 24-well plate. The cells were washed and fresh media was 
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added the morning of siRNA transfection, which was performed using Lipofectamine 
RNAiMAX (Life Technologies) according to their protocol. Briefly, equal volumes of 
various siRNA concentrations and a 1:50 dilution of Lipofectamine, both in Opti-MEM 
Reduced Serum Medium, were mixed, incubated at room temperature for 15 min, and then 
100 uL of the mixture was added to each well of cells for a total volume of 600 uL in each 
well. Concentrations of siRNA reported are the final concentrations of siRNA in the well. 
The siRNA sequences are as follows.  
siEGFR:  
Anti-Sense: 5’-UAA-UUU-CCA-AAU-UCC-CAA-GGA-C-3’  
Sense: 5’-CCU-UGG-GAA-UUU-GGA-AAU-UAU-A-3’ 
 
siBRAF: 
Anti-Sense: 5’AUGAUCCAGAUCCAAUUCUUU 3’ 
Sense:  5’-AGAAUUGGAUCUGGAUCAUUU-3’  
 
siRRM2:13  
Sense: 5’-GAUUUAGCCAAGAAGUUCAGA-3’ 
Anti-Sense: 5’-UGAACUUCUUGGCUAAAUCGC-3’ 
 
siEGFP:14 
Sense: 5’-GGC-UAC-GUC-CAG-GAG-CGC-ACC-3’  
Anti-Sense: 5’-UGC-GCU-CCU-GGA-CGU-AGC-CUU-3’  
 
48 h after transfection, the cells were lysed and RNA collected using the Qiagen 
RNeasy Plus Mini Kit or the Qiagen miRNeasy Mini Kit for an mRNA knockdown or 
siRNA detection assay, respectively, according to the manufacturer’s protocol. RNA 
concentrations were determined using a NanoDrop 2000. Each condition was performed in 
triplicate.  
Treatment with NP formulations were accomplished in a similar manner except that 
100,000 cells in the appropriate cell medium were added to 100 uL of NP formulation in 
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Opti-MEM in each well of a 24-well plate. Cells were incubated on a shaker in the 
incubator to allow NPs and cells to better contact each other. The incubation period was 
shorter, 16-24 h, and RNA was isolated with the same Qiagen RNeasy Plus Mini Kit as 
described above.   
Quantitative real time polymerase chain reaction (qRT-PCR) analysis. For determination 
of mRNA knockdown, the RNA samples were diluted to 14.4 ng/uL, 9 uL or 130 ng of 
which was used, for reverse transcription using the Invitrogen High Capacity RNA to 
cDNA kit, according to the manufacturer’s protocol. The reverse transcription reaction was 
cycled in a Bio-Rad MJ Mini Personal Thermal Cycler, incubating for 60 min at 37oC, 5 
min at 95oC to stop the reaction, and then held at 4oC forever. The qRT-PCR reaction used 
the Life Technologies TaqMan probes with actin beta for normalization as follows:  
EGFR (human) - Assay ID: Hs01076078_m1  
Actin beta (human) - Assay ID: Hs01060665_g1  
BRAF (human): Hs00269944_m1 
RRM2 (mouse): Mm00485881_g1 
Actin (mouse): Mm02619580_g1 
The Life Technologies TaqMan Universal Master Mix II, no UNG, was used for 
the qPCR reactions, which were performed in duplicate for each triplicate sample in a 96-
well PCR plate, set up according to the manufacturer’s instructions. The reactions were run 
using a Bio-Rad iCycler, with polymerase activation at 95oC for 10 min and 40 cycles of 
PCR (95oC for 15 seconds and 60oC for 1 min).  Real time detection was performed with a 
MyiQ Single Color Real-Time PCR Detection System. The data was imported into 
Microsoft Excel and the cycle threshold value was used for calculations. The difference in 
200 
 
 
the cycle threshold was calculated using the equation dCt=2^-([EGFR]Ct-[Actin]Ct). The 
percent EGFR expression was calculated by comparing the dCt’s of siEGFR treated cells 
with those of untreated or control siRNA treated cells.  
For detection of the amount of siRNA in transfected cells, the RNA samples were 
diluted to 2 ng/uL, 2.5 uL or 5 ng of which was used, for reverse transcription using the 
Applied Biosystems TaqMan MicroRNA Reverse Transcription Kit, according to the 
manufacturer’s protocol. The reverse transcription primer was a Life Technologies Custom 
TaqMan Small RNA assay designed for the anti-sense sequence of siEGFR (Assay ID RT: 
CSPACSP). The reverse transcription reaction was cycled in a Bio-Rad MJ Mini Personal 
Thermal Cycler, incubating for 30 min at 16oC, 30 min at 42oC, 5 minutes at 85oC to stop 
the reaction, and then held at 4oC forever. The qRT-PCR reaction used the Life 
Technologies Custom TaqMan Small RNA assay designed for the anti-sense sequence for 
siEGFR, as above, for the real time primer (Assay ID TM: CSPACSP) and Actin (Assay 
ID: Hs01060665_g1) for normalization. The Life Technologies TaqMan Universal Master 
Mix II, no UNG, was used for the PCR reactions, which were performed in duplicate for 
each triplicate sample in a 96-well PCR plate, set up according to the manufacturer’s 
instructions. The reactions were run, data collected, and results analyzed as described for 
the mRNA qRT-PCR, for siEGFR instead of EGFR mRNA.  
In vivo studies. 
All animal studies were approved by the Institutional Animal Care and Use Committee 
at Caltech. In vivo studies of the nanoparticle formulation included H1975 and 
M249shBRAF xenograft tumor regression. Nanoparticles were formulated as described 
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above, and were injected intravenously via the mouse tail vein at a dose of 5 mg siRNA per 
kg mouse. 
Mouse Xenograft Tumor Studies. For the H1975 xenograft tumor regression study, H1975 
cells were grown in RPMI1640 containing 10% FBS until there were sufficient numbers of 
cells to implant 1 x 107 cells per mouse. On the day of implantation, media was aspirated 
and cells were detached using 0.25% trypsin-EDTA. The trypsin was neutralized with 
media containing FBS, the cells were spun down at 200xg for 5 min at room temperature, 
and the media aspirated. The cells were washed with phosphate buffered saline and then 
RPMI1640 without FBS in a similar fashion. The cells were re-suspended in fresh 
RPMI1640 without FBS at a concentration of 5 x 107 cells per mL. Sterile 1 mL syringes 
were filled with 0.2 mL of cells and a 25 gauge needle attached to implant H1975 cells 
directly into the left hind flank of 8 week old female nude mice under isoflurane anesthesia. 
M249shBRAF cells were prepared in a similar fashion to the H1975 cells but were 
implanted into the left front flank of 8 week old female nude mice under isoflurane 
anesthesia. Tumor size was monitored starting at 7 days after implantation using digital 
calipers, and tumor volume calculated with the equation V = l x w2/2 . When tumors 
reached 200 mm3 at 14 days after implantation, the mice were randomized to treatment 
groups. Treatment was a total of four to six doses: two doses per week over two to three 
weeks. Tumor size was monitored every day for the first month after dosing, and at least 
twice a week up to 80 days after tumor implantation if the mice were still alive.  
Tumor analysis 
 For tumor analysis, tumors were collected from 3 separate mice per group 24 h after 
the second dose of treatment. For the determination of siEGFR in the tumor, a small 10 mg 
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piece of tumor tissue was cut and placed in a tube with ceramic beads and QIAzol lysis 
reagent, homogenized with an MP Bio FastPrep tissue homogenizer. RNA was extracted 
and qRT-PCR was performed as described for siEGFR determination in cell culture above. 
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Figure IV.S1: 1H NMR of (5nPBA)2-Lysine-OMe. 
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Figure IV.S2: 11B NMR of (5nPBA)2-Lysine-OMe. 
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Figure IV.S3: 1H NMR of (5nPBA)2-Lysine. 
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Figure IV.S4: 11B NMR of (5nPBA)2-Lysine. 
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Figure IV.S5: 1H NMR of 5nPBA-PEG5k-COOH. 
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Figure IV.S6: 1H NMR of 5nPBA-PEG5k-COOH with enlarged downfield region. 
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Figure IV.S7: MALDI of 5nPBA-PEG5k-COOH. 
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Figure IV.S8: 1H NMR of 5nPBA-PEG10k-COOH. 
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Figure IV.S9: MALDI of 5nPBA-PEG10k-COOH. 
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Figure IV.S10: 1H NMR of (5nPBA)2-PEG5k-COOH. 
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Figure IV.S11: MALDI of (5nPBA)2-PEG5k-COOH. 
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Figure IV.S12: 1H NMR of (5nPBA)2-PEG10k-COOH. 
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Figure IV.S13: MALDI of (5nPBA)2-PEG10k-COOH. 
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Figure IV.S14: MALDI of crude 5nPBA-PEG5k-Tf showing Tf with 0, 1, 2, and 3+ PEGs conjugated. 
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Figure IV.S15: MALDI of crude 5nPBA-PEG5k-CTX showing CTX with 0, 1, 2, and 3+ PEGs conjugated. 
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Figure IV.S16: Purification of crude 5nPBA-PEG5k-CTX by HPLC. Cetuximab is eluted at pH 7.4 and then the pH is dropped to allow 
5nPBA-PEGylated cetuximab to elute. 
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Figure IV.S17: MALDI of purified 5nPBA-PEG5k-CTX, 158 kD. Cetuximab is originally 153 kD. 
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Figure IV.S18: MALDI of purified PEGylated transferrin. Tf is originally 79 kD. 
A. Tf-PEG5k-5nPBA, ~85 kD     B. Tf-PEG10k-5nPBA, ~90 kD      C. Tf-PEG5k-(5nPBA)2, ~85 kD         D. Tf-PEG10k-(5nPBA)2, ~90 kD 
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Figure IV.S19: 1H NMR of cMAP-PEG5k-COOH. 
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Figure IV.S20: MALDI of cMAP-PEG5k-Tf. 
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Figure IV.S21: 1H NMR of His-cMAP-His. 
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Figure IV.S22: 1H NMR of mPEG-His-cMAP-His-PEGm (TriB-His). 
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Figure IV.S23: Titration curve of mPEG-His-cMAP-His-PEGm (TriB-His). 
To determine how much imidazole is present in the polymer, 3.2 mg of the polymer was 
dissolved in 5 mL of deionized water and titrated with 1 N HCl. The equivalence point was 
reached around 40-50 uL of acid added. Calculating the helf-equivalence point results in 
1.7-2.1 imidazole groups per mmol of polymer.  
 
 
Figure IV.S24: Validation of the siEGFR sequence with Lipofectamine RNAiMAX 
transfection reagent. 
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Figure IV.S25: Validation of the siBRAF sequence with Lipofectamine RNAiMAX 
transfection reagent. 
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Figure IV.S26: Displacement binding of CTX-AF488 by cetuximab and cetuximab-PEGs 
to EGFR on H1975 cells.  
 
 
Figure IV.S27: Displacement binding of Tf-AF488 by transferrin and transferrin-PEGs to 
transferrin receptor on Neuro-2A cells.  
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Figure IV.S28: Validation of qRT-PCR assay probe for the siEGFR sequence by 
transfecting cells with siEGFR using Lipofectamine RNAiMAX transfection reagent. 
 
 
Figure IV.S29: Individual mice for the 0.13 mol% cetuximab-targeted cMAP + 5-nPBA-
PEGm NP formulation containing siEGFR group. The average of the saline group is 
included for comparison. Orange arrows indicate when mice were injected with doses of 
the NP formulation. 
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Figure IV.S30: Individual mice for the cetuximab alone group. The average of the saline 
group is included for comparison. Orange arrows indicate when mice were injected with 
doses of the NP formulation. 
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Figure IV.S31: MALDI of panitumumab-PEG5k-5nPBA, 153 kD. Panitumumab (Vectibix) is originally 148 kD. 
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Figure IV.S32: Mean sizes of M249shBRAF tumor xenografts in nude mice (n=6) 
comparing standard diet to doxycycline-containing diet.  
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Figure IV.S33: Individual nude mice bearing M249shBRAF tumor xenografts (n = 5) 
injected with saline control.  
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Figure IV.S34: Individual nude mice bearing M249shBRAF tumor xenografts (n = 5) 
injected with 0.25 mol% Tf-PEG5k-(5nPBA)2 targeted TriB-His NP containing siBRAF at 
5 mg/kg per dose.  
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Figure IV.S35: Mean sizes of nude mice (n = 5) bearing M249shBRAF tumor comparing 
the 0.25 mol% Tf-PEG5k-(5nPBA)2 targeted TriB-His NP containing siBRAF at 5 mg/kg 
per dose group with that of saline control showing no statistical significance.  
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Figure IV.S36: Mean sizes of nude mice (n = 2) bearing M249shBRAF tumor comparing 
the 0.5 mol% Tf-PEG5k-adamante targeted CDP NP containing siBRAF at 5 mg/kg per 
dose group with that of saline control showing some difference in effect.  
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C h a p t e r  5  
Conclusions and Outlook 
Small interfering RNA (siRNA) has a lot of promise as a very specific therapy that 
can silence virtually any gene. As a macromolecular double-stranded RNA, it has a number 
of hurdles to jump over in order to reach its location of function. It needs be protected from 
nuclease degradation using a delivery system, which also can serve to slow its quick 
clearance from circulation. Getting to the location, such as a tumor, can be tricky, and once 
there it needs to get inside cells. This usually occurs through an endocytic process which 
will localize the siRNA into the endosome, and so there needs to be a method to break out 
of the endosomal for the siRNA to reach the cytosol where it can function. Additional 
challenges include identifying the appropriate targets to stop the growth of a particular type 
of malignancy, as cancer types even arising from the same site with similar morphology 
can be genetically very distinct. With the genes in mind, designing siRNA sequences 
specific to the mRNA with minimal effect on other similar sequences that are very potent 
to cause durable protein silencing to result in cell death can be challenging.   
We addressed some of the siRNA delivery challenges by building a nanoparticle 
(NP) siRNA delivery system based on cationic-mucic acid polymer (cMAP). cMAP needs 
5nPBA-PEGm for creating a stable nanoparticle formulation, while the mPEG-cMAP-
PEGm triblock polymer can form stable nanoparticles with siRNA alone. These polymers 
form 30-45 nm particles with siRNA. The cMAP + 5nPBA-PEGm siRNA NP already 
circulates in the mouse bloodstream longer than siRNA alone and the CALAA-01 siRNA 
delivery system previously developed in our lab. The mPEG-cMAP-PEGm siRNA NP 
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showed the longest circulation time that we have seen, with 10% of the formulation 
remaining in the bloodstream of mice 1 h after intravenous injection. Targeting the 
nanoparticle can work by conjugating a protein through a PEG to a boronic acid entity 
which binds to diols on cMAP, or by covalently conjugating the protein through a PEG 
directly to cMAP. A histidine added to the cMAP provides for an endosomal escape 
mechanism for siRNA to reach the cytosol in order to function. The nanoparticles are able 
to enter cells to decrease mRNA expression of their target and to reach the tumor site. 
Some tumor regression in non-small cell lung cancer and melanoma tumor xenograft 
models in nude mice show mixed effects that demonstrate the potential for therapy. 
Furthermore, it may be advantageous to use a targeting agent which also interferes with 
cancer growth for maximal therapeutic benefit.  
Many of the parameters for siRNA delivery – such as circulation, stability, 
targeting, and knockdown – continue to be clarified. It may be that there needs to be an 
appropriate balance between some of these factors that will achieve the optimal delivery 
system that results in enough mRNA and ultimately protein knockdown to result in cell 
death. It is feasible that siRNA delivery challenges can be addressed and siRNA sequences 
can be developed to target many of the drivers of tumor growth. Because of the myriad 
number of genes and pathways that are dysregulated in malignant cells, and the mosaic of 
mutated cells present in a tumor, multiple genes may be altered. A siRNA delivery system 
has the ability to deliver multiple siRNA sequences to target multiple genes which fuel cell 
proliferation.   
With advances in blood detection of circulating tumor cells that reduce the need for 
invasive biopsies and with cancer genome sequencing, many mutations are identified. 
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What is complex is to interpret the information and figure out which genes to target as the 
problematic drivers of cell growth and proliferation. Of course, as with any targeted 
treatment we have seen that after a good response to therapy, these malignant cells 
eventually mutate to render the current therapy useless and the tumors return in full force. 
Therefore, real time detection of the mutations is needed while the tumor is still in 
regression and before progression can be seen in current imaging techniques used to 
monitor tumor response. If this type of feedback can be achieved with a well-functioning 
siRNA delivery system using potent siRNA’s which target many of the mutations that can 
evolve, there eventually will be enough information and therapies to accurately tune 
treatment “preemptively” under current clinical definitions of the tumor being in remission. 
 
 
